Compositions and methods for treating diabetes
Combining NgBR activators with GLP-1RAs addresses the limitations of GLP-1R agonists by enhancing insulin secretion and glucose uptake, effectively reducing blood glucose and weight in diabetic patients.
Patent Information
- Application Number
- PCT/US2026/027373
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
Existing GLP-1R agonists face challenges in effectively reducing blood glucose levels in patients with diabetes, particularly Type I diabetics, due to functional beta cell loss and insulin resistance, and are associated with gastrointestinal side effects.
Administering an NgBR activator, such as a nucleic acid encoding NgBR in an expression vector or a small molecule activator, in combination with a GLP-1RA like semaglutide, to enhance insulin secretion and glucose uptake, optionally using a hepatocyte-targeting carrier.
The combination therapy effectively reduces blood glucose levels and daily body weight, mitigating gastrointestinal side effects and improving glucose homeostasis in diabetic subjects.
Smart Images

Figure US2026027373_12112026_PF_FP_ABST
Abstract
Description
Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026COMPOSITIONS AND METHODS FOR TREATING DIABETES
[0001] This application is an International Application, which claims the benefit of priority from U. S. provisional patent application no. 63 / 802,035, filed on May 08, 2025, the entire contents of each which are incorporated herein by reference in their entireties.
[0002] For countries that permit incorporation by reference, all patents, patent applications and publications cited in this disclosure are hereby incorporated by reference in their entireties. In addition, any manufacturers’ instructions or catalogues for any products cited or mentioned herein are incorporated by reference. Documents incorporated by reference into this text, or any teachings therein, can be used in the practice of the present invention. Documents incorporated by reference into this text are not admitted being prior art.
[0003] This patent disclosure contains material that is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure as it appears in the U. S. Patent and Trademark Office patent file or records, but otherwise reserves any and all copyright rights.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
[0004] This invention was made with government support under DK132056 awarded by National Institutes of Health. The government has certain rights in the invention.FIELD OF THE INVENTION
[0005] The disclosed invention is in the field of diabetes and / or obesity treatment and specifically in the area of combination therapies for treating diabetes and / or obesity.BACKGROUND OF THE INVENTION
[0006] Blood glucose homeostasis is regulated by three biological functions, including insulindependent suppression of glucose production in the liver, insulin secretion from the pancreas, and glucose uptake by the skeletal muscle. The function of GLP1R agonists is to promote the insulin secretion from the pancreas. However, if patients lose functional beta cells due to long diabetes duration or have severe insulin resistance, meaning insulin does not suppress glucose production in the liver, GLP1R agonists cannot achieve a sufficient reduction of blood glucose. A major challenge with GLP-1 agonists is potential gastrointestinal side effects like nausea and vomiting. There is still a need for a method that includes reducing dosage by improving GLP-Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026 1R agonist efficacy or providing efficacy in a subject in which efficacy is questionable for example, Type I diabetics.
[0007] Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present disclosure as it existed before the priority date of each claim of this application.BRIEF SUMMARY OF THE INVENTION
[0008] Aspects of the invention are drawn towards methods of preventing one or more symptoms associated with diabetes in a subject. In embodiments, the method comprises administering to the subject an effective amount of an NgBR activator and a glucagon-like peptide- 1 receptor agonist (GLP-1RA).
[0009] In embodiments, the NgBR activator can comprise a nucleic acid encoding the NgBR in an expression vector. For example, the expression vector can comprise an adeno-associated vector (AAV).
[0010] In embodiments, the GLP-1RA can comprise exenatide, lixisenatide, liraglutide, albiglutide, dulaglutide, semaglutide, orfoglipron, etatrutide, CagriSema (semaglutide with cagrilintide), tirzepatide, and / or mazdutide. For example, the GLP-1RA is semaglutide.
[0011] In embodiments, the subject is a type I diabetic.
[0012] In embodiments, the subject is a type II diabetic, wherein the subject has beta cell dysfunction.
[0013] In embodiments, the NgBR activator can comprise a small molecule activator. For example, the small molecule activator can comprise caffeine, a statin, or a PPAR agonist. For example, the statin can comprise Atorvastatin (Lipitor), Rosuvastatin (Crestor), Simvastatin (Zocor), Lovastatin (Altoprev), Pravastatin (Pravachol), Fluvastatin (Lescol), Pitavastatin (Livalo). For example, the PPAR agonist can comprise Fibrates (Fenofibrate, Benzafibrate, Gemfibrozil), Thiazolidinediones (Pioglitazone, Rosiglitazone), GW501516, and Lanifibranor (Pan-PPAR agonists).
[0014] In embodiments, the subject does (a) have high cholesterol (LDL above 190 mg / dL); (b) have an LDL above 160 mg / dL, a family history of early coronary artery disease and are 20 to 39 years old; (c) have a history of a stroke, heart attack or peripheral artery disease (PAD); (d) have diabetes and an LDL of at least 70 mg / dL and are 40 to 75 years old; or (e)Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026 Have an LDL of at least 70 mg / dL and a high risk of getting heart disease and are 40-75 years old.
[0015] In embodiments, the composition can be administered for at least 10 days, and up to one month, optionally, daily. For example, the composition is administered at a first effective dose for at least two weeks, followed by administration of a second effective dose (the maintenance dose), wherein the maintenance dose is at least half, a third or a quarter of the first effective dose.
[0016] In embodiments, the NgBR activator and GLP-1RA can be administered for at least one month.
[0017] In embodiments, the NgBR activator can comprise a nucleic acid encoding the NgBR in a viral or non-viral carrier, wherein the carrier comprises a hepatocyte targeting moiety.
[0018] In embodiments, the blood glucose levels and optionally, the subject’s daily body weight, reduces following administration of the NgBR activator and GLP-1RA relative to untreated control.
[0019] Aspects of the invention are further drawn towards a construct comprising or consisting of a therapeutic nucleic acid sequence encoding NgBR (gene alias NUS1). IN embodiments, the therapeutic nucleic acid encodes a polypeptide comprising an amino acid sequence according to SEQ ID NO: 2, or a sequence at least 90% identical thereto.
[0020] In embodiments, the therapeutic nucleic acid sequence can comprise a sequence according to SEQ ID NO: 1, or a sequence at least 80% identical thereto.
[0021] Aspects of the invention are further drawn to a recombinant expression vector comprising the construct described herein.
[0022] In embodiments, the recombinant expression vector is a viral vector or a non-viral vector.
[0023] In embodiments, the viral vector can comprise an adeno-associated virus (AAV).
[0024] Still further, aspects of the invention are drawn to a cell comprising the construct described herein, or the recombinant expression vector described herein.
[0025] Aspects of the invention are further drawn to a pharmaceutical composition comprising the construct described here or the recombinant expression vector described herein, and an acceptable carrier or excipient.
[0026] In embodiments, the pharmaceutical composition can further comprise glucagon-like peptide-1 receptor agonist (GLP-1RA).Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026
[0027] In embodiments, the GLP-1RA is selected from the group consisting of exenatide, lixisenatide, liraglutide, albiglutide, dulaglutide, semaglutide, orfoglipron, retatrutide, CagriSema (semaglutide with cagrilintide), tirzepatide, and mazdutide.
[0028] Aspects of the invention are further drawn to a method of treating or preventing one or more symptoms associated with diabetes in a subject. In embodiments, the method can comprise administering to the subject an effective amount of the construct described herein, the recombinant expression vector described herein, the cell described herein, or the pharmaceutical composition described herein.
[0029] In embodiments, the method can further comprise administering to the subject a glucagon-like peptide-1 receptor agonist (GLP-1RA).
[0030] In embodiments, the GLP-1RA is selected from the group consisting of exenatide, lixisenatide, liraglutide, albiglutide, dulaglutide, semaglutide, orfoglipron, retatrutide, CagriSema (semaglutide with cagrilintide), tirzepatide, and mazdutide.
[0031] In embodiments, the GLP-1RA is semaglutide.
[0032] Aspects of the invention are further drawn to a method of treating, ameliorating, or preventing one or more symptoms associated with fatty liver disease in a subject. In embodiments, the method can comprise administering to the subject an effective amount of the construct described herein, the recombinant expression vector described herein, the cell described herein, or the pharmaceutical composition described herein.
[0033] In embodiments, the method can further comprise administering to the subject a glucagon-like peptide-1 receptor agonist (GLP-1RA).
[0034] In embodiments, the GLP-1RA is selected from the group consisting of exenatide, lixisenatide, liraglutide, albiglutide, dulaglutide, semaglutide, orfoglipron, retatrutide, CagriSema (semaglutide with cagrilintide), tirzepatide, and mazdutide.
[0035] In embodiments, the GLP-1RA is semaglutide.
[0036] Additional advantages of the disclosed method and compositions will be set forth in part in the description which follows, and in part will be understood from the description, or can be learned by practice of the disclosed method and compositions. The advantages of the disclosed method and compositions will be realized and attained by means of the elements and combinations pointed out in the appended claims. Both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention as claimed.Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026 BRIEF DESCRIPTION OF THE DRAWINGS
[0037] The accompanying drawings illustrate several embodiments of the disclosed method and compositions and together with the description, serve to explain the principles of the disclosed methods and compositions.
[0038] FIG. 1A is a schematic of the treatment regimen. FIG. IB shows body weight measurement in littermate control (NgBRfl / fl) mice, NgBR hepatocyte-specific knockout (hepKO) mice and NgBR hepKO mice with NgBR Adeno-associated virus (AAV) rescue (restoring hepatic NgBR) mice administered semaglutide. FIG. 1C shows blood glucose levels in control (NgBRfl / fl) mice, NgBR hepKO mice, and NgBR hepKO mice with NgBR AAV rescue (restoring hepatic NgBR) mice administered semaglutide.
[0039] FIG. 2A shows the results of the Insulin Tolerance Test (ITT). FIG. 2B shows the Area Under the Curve (AUC) that is derived from the ITT, which is used to diagnose the impaired ITT in the clinic. FIG. 2C shows the results of the Glucose Tolerance Test (GTT).FIG. 2D shows the Area Under the Curve (AUC) that is derived from the GTT, which is used to diagnose impaired GTT in the clinic.
[0040] FIG. 3 shows blood glucose levels in Streptozotocin (STZ)-induced type 1 diabetic mice ± semaglutide administration. The mice were either NgBR NgBR hepKO, NgBR fl / fl + GLP-1RA; NgBR hepKO + GLP1 and NgBR hepKO +AAV +GLP1 GLP-1RA.
[0041] FIG. 4 shows hepatic NgBR expression is decreased in obesity-associated diabetes and correlates with impaired glucose homeostasis. FIG. 4A provides human liver transcriptomic data (GEO: GSE156563) showing reduced NUS1 (NgBR) mRNA in obese individuals with T2D compared with lean or obese non-diabetic controls, whereas RTN4 (Nogo-B) shows minimal change (n=16-20 / group). FIG. 4B provides cynomolgus monkey liver RNA-seq dataset (GSE188418) demonstrating conserved reduction of NgBR transcripts in obesity-associated diabetes, with no significant alteration in Nogo-B (n=6 / group). FIG. 4C provides human liver single-cell RNA-seq analysis showing cell-type-specific reduction of NgBR (NUS1) in hepatocytes from individuals with T2D, while Nogo-B (RTN4) remains broadly expressed. FIG.4D provides representative human liver immunohistochemistry (IHC) images depicting decreased hepatocellular NgBR protein in T2D livers with steatosis compared with lean controls or obese non-diabetic individuals; quantification shown at right. FIG. 4E provides regional association plot of the chromosome 6 NUS1 (NgBR) locus showing genomewide significant T2D variants, including rs72951548 and rs72951506, exceeding the significance threshold (red line) within a non-coding regulatory region. Predicted liver DNase I hypersensitivity centered on rs72951548 (chr6: 117690560 OT) indicating strong chromatinDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 accessibility, with the alternate allele showing reduced DNase signal compared to wild-type.FIG. 4F provides diet-induced obesity (DIO) model: schematic (left) and metabolic phenotype (middle) with HFD-fed mice showing reduced hepatic NgBR mRNA and protein, while Nogo-B expression and serum soluble Nogo-B remain unchanged (n=5-7 / group). FIG. 4G provides db / db mouse model: schematic (left) and gene expression (middle), demonstrating progressive reduction of hepatic NgBR mRNA and protein from 4 to 10 weeks of age despite stable Nogo-B transcript and circulating protein. FIG. 4H-I shows longitudinal metabolic testing in NgBR fl / fl and NgBR HepKO mice fed control diet (CD; FIG. 4H) or high-fat diet (HFD; FIG. 41).NgBR HepKO mice exhibit fasting hyperglycemia, impaired glucose tolerance (GTT), reduced insulin sensitivity (ITT), and exaggerated pyruvate- (PTT) and alanine-stimulated (ATT) glucose production (n=6-8 / group). FIG. 4J provides comprehensive metabolic profiling showing increased fasting and refeeding glucose, elevated insulin, C-peptide, glucagon, higher HOMA-IR, reduced QUICKI, increased HbAlc, decreased hepatic glycogen, elevated leptin, and increased serum FFAs in NgBR HepKO mice under CD and HFD. Data are presented as mean ± SD. Statistical significance was determined by an unpaired two-tailed / -test or a two-way ANOVA with Tukey’s post hoc test.
[0042] FIG. 5 shows hepatic NgBR deficiency drives a conserved gluconeogenic transcriptional program across species. FIG. 5A provides human liver single-cell RNA-seq analysis showing elevated expression of G6PC and PCK1 in hepatocytes from individuals with T2D, alongside reduced NUS1 (NgBR), compared with healthy and obese non-diabetic subjects. FIG. 5B provides a schematic of the bulk RNA-seq experimental design in NgBR fl / fl and NgBR HepKO mice fed high-fat diet (HFD). Livers were collected at 16 weeks for transcriptomic profiling. FIG. 5C provides a heatmap of differentially expressed hepatic transcripts illustrating clear clustering and widespread transcriptional remodeling in NgBR HepKO mice (Z-score normalized). FIG. 5D provides a volcano plot displaying 4,163 downregulated (blue) and 4,117 upregulated (red) genes in NgBR HepKO mice (|log2FC| > 0.5, p < 0.05). FIG. 5E provides a focused heatmap of gluconeogenic and metabolic regulators showing marked upregulation of G6pc, Pckl, Fbpl, Foxol, and Ppargcla in NgBR HepKO livers. FIG.5F provides KEGG pathway enrichment revealing activation of insulin resistance, glucagon signaling, glycolysis / gluconeogenesis, pyruvate metabolism, AMPK signaling, PPAR signaling, and PI3K-Akt pathways in the absence of NgBR. FIG. 5G provides qPCR validation showing significantly increased expression of G6pc, Pckl, Fbpl, Pcx, Ppargcla, and modest elevation of Ldha, Insr, Srebfl, and Gck in NgBR HepKO livers (n=6 / group). FIG.5H provides data showing primary human hepatocytes transfected with si-NgBR showingDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 increased G6PC and PCK1 mRNA, confirming conservation of the NgBR-gluconeogenesis relationship in human cells. FIG. 51 provides representative H& E staining demonstrating hepatocellular ballooning and microvesicular lipid accumulation in NgBR HepKO livers. Immunohistochemistry for G6PC and PCK1 shows elevated protein abundance in NgBR HepKO mice; quantification below (n=5-6 / group). FIG. 5J provides functional assays demonstrating significantly elevated hepatic glucose production, increased PCK1 enzymatic activity, and elevated G6PC activity in NgBR HepKO mice compared with NgBR fl / fl controls under both CD and HFD conditions (n=6-8 / group). FIG. 5K provides cynomolgus monkey liver RNA-seq dataset (GSE188418) showing increased expression of GCK, PCK1, FOXO1, and G6PC and reduced IN SR and PPARGC1 A in livers of obese monkeys with T2D, mirroring the mouse phenotype. Data are presented as mean ± SD. Statistical significance was assessed using an unpaired two-tailed t-test or a two-way ANOVA with Tukey’s post hoc test.
[0043] FIG. 6 shows adiponectin treatment enhances glycemic control in NgBR fl / fl mice but has no effect in NgBR HepKO mice. FIG.6A provides a schematic of the adiponectin agonist (AdipoRon) intervention study in NgBR fl / fl and NgBR HepKO mice under control diet (CD). Mice were treated for 4 weeks followed by metabolic testing and tissue collection.FIG. 6B provides longitudinal fasting glucose measurements showing sustained glucose lowering in NgBR fl / fl mice treated with AdipoRon, with no improvement in NgBR HepKO mice. FIG.6C-D provide qPCR analysis demonstrating absence of NgBR expression in NgBR HepKO livers and unchanged Nogo-B mRNA following AdipoRon treatment. FIG. 6E provides circulating soluble Nogo-B levels showing no difference between genotypes or treatment groups. FIG. 6F provides data showing dynamic metabolic testing under CD. AdipoRon significantly improved glucose tolerance (GTT), insulin sensitivity (ITT), pyruvate tolerance (PTT), and alanine tolerance (ATT) in NgBR fl / fl but not NgBR HepKO mice. Insets show AUC quantification. FIG. 6G provides metabolic profiling under CD. NgBR fl / fl mice showed reduced HOMA-IR, HbAlc, fasting insulin, C-peptide, and FFAs, with increased insulin sensitivity index (QUICKI) and hepatic glycogen after AdipoRon treatment. NgBR HepKO mice displayed no improvement in any parameter and retained elevated glucagon and leptin levels. FIG. 6H provides experimental design of the adiponectin intervention under high-fat diet (HFD). FIG. 61 provides fasting glucose curves showing progressive hyperglycemia in NgBR HepKO mice despite AdipoRon treatment, with a robust glucose-lowering response only in NgBR fl / fl controls. FIG. J-K provide data showing hepatic mRNA expression confirming persistent absence of NgBR in knockout livers and unchanged Nogo-B expression in both genotypes following treatment. FIG. 6L provides serum soluble Nogo-BDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 concentrations showing no treatment effect. FIG. 6M provides data showing dynamic metabolic testing under HFD. AdipoRon improved GTT, ITT, ATT, and PTT responses only in NgBR fl / fl mice, whereas NgBR HepKO mice remained insulin-resistant with exaggerated substrate-driven glucose production. Insets show AUC quantification. FIG. 6N provides metabolic profiling under HFD showing improved HbAlc, insulin, C-peptide, FFAs, glucagon, leptin, and hepatic glycogen in AdipoRon-treated NgBR fl / fl mice. In contrast, NgBR HepKO mice exhibited no improvement across metabolic markers. Data are presented as mean ± SD. Statistical significance was determined by unpaired two-tailed t-test or two-way ANOVA with Tukey’s post hoc test.
[0044] FIG. 7 shows NgBR deficiency disrupts adiponectin-mediated repression of hepatic gluconeogenesis. FIG. 7A provides human liver single-cell transcriptomic analysis showing high hepatocyte expression of ADIPOR1, ADIPOR2, and KAT7, with selective reduction of NUS1 (NgBR) in obesity and T2D. FIG. 7B provides a schematic of the bulk RNA-seq workflow in NgBR fl / fl and NgBR HepKO mice following 4 weeks of AdipoRon treatment under high-fat diet. FIG.7C provides a heatmap of global transcriptomic remodeling induced by AdipoRon in NgBR fl / fl livers, with markedly attenuated or absent responses in NgBR HepKO mice. FIG.7D provides differential expression of key metabolic genes showing appropriate suppression of gluconeogenic regulators (G6pc, Pckl, Fbpl, Pcx, Foxol) and lipid regulators (Srebfl) in AdipoRon-treated NgBR fl / fl mice, but not in NgBR HepKO livers. FIG.7E provides a volcano plot showing widespread AdipoRon-induced gene suppression (1,536 downregulated) in NgBR fl / fl livers, contrasted with a blunted transcriptional profile in NgBR HepKO mice (1,481 upregulated). FIG. 7F provides pathway enrichment showing that AdipoRon downregulates gluconeogenesis, pyruvate metabolism, fatty-acid degradation, NF-KB signaling, and PPAR signaling only in NgBR fl / fl livers; these pathways remain persistently active in NgBR HepKO mice. FIG. 7G provides qPCR validation confirming that AdipoRon suppresses G6pc, Pckl, Fbpl, Pcx, and Ppargcla exclusively in NgBR fl / fl mice; NgBR HepKO livers fail to respond and maintain elevated expression of these genes. FIG. 7H provides data showing primary human hepatocytes recapitulate the phenotype: NgBR silencing blocks AdipoRon-mediated suppression of G6PC and PCK1. FIG. 71 provides enzymatic assays showing that AdipoRon reduces G6PC and PCK1 activity in NgBR fl / fl mice under both control diet and HFD, whereas NgBR HepKO mice remain refractory. FIG. 7J provides histology (H& E) and immunostaining demonstrating improved hepatic morphology and reduced G6PC / PCK1 expression in AdipoRon-treated NgBR fl / fl mice but persistent steatosis and high gluconeogenic protein abundance in NgBR HepKO livers. FIG. 7K providesDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 immunoblotting confirming that AdipoRon suppresses PCK1 and G6PC proteins only inNgBR fl / fl mice; no suppression occurs in NgBR HepKO livers. FIG. 7L provides a heatmap of adiponectin signaling components showing failure of AdipoRon to induce AdipoRl, AdipoR2, KAT7, and InsR in NgBR HepKO mice. FIG. 7N provides qPCR validation demonstrating blunted transcription of NUS1, AdipoRl, AdipoR2, KAT7, and Insr in NgBR HepKO livers regardless of AdipoRon treatment, indicating collapse of the receptor-chromatin regulatory axis. FIG.70 provides western blot analysis showing that AdipoRon robustly activates AMPK phosphorylation in NgBR fl / fl livers but fails to do so in NgBR HepKO mice, despite identical treatment. Data are presented as mean ± SD. Statistical significance was assessed using an unpaired two-tailed t-test or two-way ANOVA with Tukey’s post hoc test.
[0045] FIG. 8 shows KAT7 mediates adiponectin-NgBR crosstalk to control histone acetylation, AdipoRl / AdipoR2 transcription, and AMPK-dependent suppression of hepatic gluconeogenesis. FIG.8A provides qPCR analysis showing that KAT7 knockdown (si-KAT7) markedly blunts AdipoRon-induced upregulation of AdipoRl, AdipoR2, and KAT7 itself, while INSR expression remains unchanged. FIG.8B provides immunoblotting confirming that si-KAT7 prevents AdipoRon-mediated induction of AdipoRl, AdipoR2, and INSR proteins.FIG. 8C-D provides data showing NgBR HepKO livers exhibit broad reductions in activating histone H3 (H3K27ac, H3K18ac, H3K9ac, H3K14ac) and H4 (H4K12ac, H4K5ac, H4K8ac, H4K16ac) acetylation marks, while total H3 / H4 remain unchanged, indicating impaired chromatin activation in the absence of NgBR. FIG. 8E-F show si-KAT7 hepatocytes recapitulate this global hypoacetylation phenotype, confirming KAT7 dependency of these histone modifications. FIG. 8G-H provide ChlP-qPCR analysis demonstrating that both NgBR deficiency and KAT7 silencing significantly reduce H3K9ac / H3K14ac occupancy at the promoter regions of AdipoRl (-921 to -809) and AdipoR2 (-1035 to -920). Reduced acetylation corresponds to decreased chromatin accessibility for receptor transcription. FIG.81 provides qPCR data showing that KAT7 knockdown abolishes AdipoRon-mediated repression of G6PC and PCK1, indicating that KAT7 is required for adiponectin-dependent suppression of gluconeogenic gene expression. FIG. 8J provides immunoblotting demonstrating that si-KAT7 prevents AdipoRon-induced reduction of G6PC and PCK1 protein levels. FIG. 8K provides data showing si-KAT7 abolishes AdipoRon-stimulated AMPK phosphorylation without affecting total AMPK levels, confirming KAT7 as an essential upstream node linking adiponectin signaling to AMPK activation. FIG. 8L provides qPCR data showing that KAT7 overexpression restores AdipoRl, AdipoR2, NgBR, and KAT7 expression in NgBR HepKO hepatocytes. FIG. 8M provides immunoblots confirming thatDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 KAT7 overexpression rescues AdipoRl / AdipoR2 protein levels and partially restores NgBR-associated chromatin activity. FIG.8N provides data showing combined KAT7 overexpression and AdipoRon treatment reinstates AMPK phosphorylation and suppresses PCK1 and G6PC protein expression in NgBR HepKO hepatocytes. FIG. 80 provides corresponding qPCR validation showing rescued transcriptional repression of G6PC, PCK1, and restoration of the NgBR-KAT7-AdipoR axis. Data are presented as mean ± SD. Statistical significance was assessed using an unpaired two-tailed t-test or a two-way ANOVA with Tukey’s post hoc test.
[0046] FIG. 9 shows a figure where hepatic lipidomics reveal that adiponectin reduces ceramides in NgBR fl / fl mice, whereas NgBR HepKO mice fail to clear ceramides and maintain or worsen ceramide accumulation. FIG. 9A provides human plasma lipidomics from the All of Us cohort showing elevated circulating ceramide 16:0 and ceramide 22:0 levels in individuals with T2D compared with metabolically normal controls. FIG. 9B provides a schematic of the NgBR HepKO metabolic study design, including high-fat diet feeding, AdipoRon intervention, hepatic lipid extraction, and mass spectrometry-based lipidomics.FIG. 9C-D provide heatmaps of untargeted hepatic lipidomics demonstrating broad ceramide and sphingolipid accumulation in NgBR HepKO livers at baseline. Representative species include SM(dl8: 1 / 17:0), HexCer(t22:2 / 15:l[2OH]), SM(dl 8: 1 / 23:0), and Cer(d29:2 / 30:2[2OH]). FIG. 9E provides a volcano plot comparing NgBR HepKO vs NgBR fl / fl livers showing 93 lipids significantly decreased (blue) and 31 increased (red), with strong enrichment in Cer-NS, HexCer-AP, and SM subclasses. FIG. 9F provides a heatmap showing robust AdipoRon-induced remodeling of hepatic lipid profiles in NgBR fl / fl mice, including marked reductions across multiple ceramide subclasses (Cer-AS, Cer-NP, Cer-NS), hexosylceramides, and sphingomyelins. FIG. 9G-H show NgBR HepKO mice exhibit minimal or paradoxical increases in ceramide species following AdipoRon. Volcano plot highlights 442 decreased and 307 increased lipids, reflecting absent ceramide clearance and dysregulated lipid remodeling. FIG. 91 provides a focused heatmap of long-chain ceramides (Cl 6:0, Cl 8:0, C20:0, C22:0, C24:0) showing profound reduction after AdipoRon in NgBR fl / fl mice, whereas NgBR HepKO mice maintain elevated levels or show further increases.FIG. 9 J-K provide qPCR data in primary hepatocytes demonstrating that C2-ceramide induces exaggerated G6PC and PCK1 expression in NgBR-deficient cells. Co-treatment with the PP2A inhibitor LB- 100 blunts the ceramide-driven induction but does not fully normalize gene expression in NgBR HepKO hepatocytes. FIG.9L provides immunoblotting showing that C2-ceramide suppresses AMPK phosphorylation and increases G6PC and PCK1 protein levels, with effects amplified in NgBR HepKO hepatocytes. LB- 100 partially restores AMPKDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 activation and attenuates gluconeogenic protein expression. Data are presented as mean ± SD. Statistical analyses were performed using unpaired two-tailed t-tests or two-way ANOVA with Tukey’s post hoc correction.
[0047] FIG. 10 shows AAV-mediated hepatic NgBR restoration reinstates adiponectin sensitivity and normalizes glucose homeostasis in NgBR-deficient mice. FIG. 10A provides an experimental scheme illustrating AAV8-mediated hepatic NgBR overexpression in NgBR HepKO mice followed by four weeks of AdipoRon administration under control diet conditions. FIG. 10B provides longitudinal fasting glucose measurements showing persistent hyperglycemia in AAV-Control-treated NgBR HepKO mice and a progressive normalization of fasting glucose following AAV-NUS1 re-expression. FIG. 10C provides qPCR analysis from liver tissue demonstrating robust restoration of NgBR expression and recovery of KAT7, AdipoRl, AdipoR2, and Insr transcripts in AAV-NUS1 -treated mice, along with suppression of G6pc and Pckl. FIG. 10D provides dynamic metabolic testing under control diet (GTT, ITT, PTT, ATT) showing complete correction of glucose intolerance, insulin resistance, and exaggerated substrate-driven gluconeogenesis after NgBR restoration. Corresponding AUC values are shown in insets. FIG. 10E-G show metabolic profile under control diet. AAV-NUS1 significantly reduces HbAlc, fasting insulin, C-peptide, HOMA-IR, soluble Nogo-B, and leptin, while improving QUICKI and increasing hepatic glycogen content. Glucagon levels decrease and adiponectin levels normalize, indicating restoration of hormonal homeostasis.FIG. 10H provides a study design for AAV-AdipoRon co-treatment under high-fat diet (HFD). FIG. 101 provides longitudinal glucose curves under HFD showing persistent hyperglycemia in AAV-Control-treated NgBR HepKO mice and complete normalization of fasting glucose after AAV-NUS1 administration. FIG. 10J provides hepatic gene expression under HFD demonstrating restored NgBR, KAT7, AdipoRl, AdipoR2, and Insr levels with parallel suppression of G6pc and Pckl, confirming rescue of the adiponectin signaling module.FIG. 10K shows GTT, ITT, PTT, and ATT curves under HFD showing full restoration of glucose tolerance, insulin responsiveness, and suppression of gluconeogenesis with AAV-NUS1 treatment. AUC values shown in insets. FIG. 10L-O provides metabolic and hormonal parameters under HFD. AAV-NUS1 markedly lowers HbAlc, insulin, C-peptide, HOMA-IR, glucagon, leptin, and serum soluble Nogo-B, while restoring adiponectin levels and hepatic glycogen. Enzymatic assays show normalized G6PC and PCK1 activity. FIG. 10P provides immunoblot analysis confirming that hepatic NgBR re-expression restores AMPK activation in response to AdipoRon, suppresses PCK1 and G6PC protein abundance, and normalizes AdipoRl, AdipoR2, and KAT7 protein levels in NgBR HepKO mice. Data are presented asDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 mean ± SD. Statistical significance was assessed using an unpaired two-tailed t-test or two-way ANOVA with Tukey’s post hoc test.
[0048] FIG. 11 shows hepatic NgBR deficiency disrupts systemic metabolic, liver, kidney, and pancreatic function in metabolic disease. FIG. 11A provides metabolic hormone and insulin sensitivity profile in wild-type (WT), early-stage diabetic (db / db 4 wk), and advanced diabetic (db / db 10 wk) mice. Progressive diabetes is associated with declining insulin sensitivity (QUICKI), elevated fasting insulin, increased HOMA-IR, rising leptin, reduced adiponectin, and elevated glucagon levels. FIG. 11B-C show food intake and body weight of NgBR fl / fl and NgBR HepKO mice under control diet (FIG. 11B) or high-fat diet (FIG. 11C).NgBR deficiency does not alter caloric intake or body weight across diet conditions. FIG. 11D provides a lipid panel showing marked increases in hepatic triglycerides, serum triglycerides, hepatic cholesterol, and serum cholesterol in NgBR HepKO mice, amplified by high-fat diet feeding. FIG. HE provides a liver function panel demonstrating elevated serum ALT, AST, ALP, and total bilirubin and reduced serum albumin in NgBR HepKO mice, indicating heightened hepatic injury and impaired liver function. FIG. HF provides a kidney function panel showing higher serum BUN and elevated creatinine in NgBR HepKO mice, consistent with early renal stress under both diet conditions. FIG. 11G provides a pancreas function panel showing increased circulating amylase and lipase in NgBR HepKO mice under control and high-fat diet, indicating pancreatic burden associated with metabolic dysfunction. Data represent mean ± SD. Statistical analyses were performed using one-way ANOVA with Tukey’s post hoc correction; p < 0.05 was considered statistically significant.
[0049] FIG. 12 provides data showing that DEXA analysis shows preserved body composition in NgBR fl / fl and NgBR HepKO mice. FIG. 12A provides dual-energy X-ray absorptiometry (DEXA) measurements of NgBR fl / fl and NgBR HepKO mice under control diet (CD). Total body weight, sample area, bone area, soft tissue mass, lean mass, bone mineral density (BMD), fat weight, fat percentage, and bone mineral content (BMC) were comparable between genotypes, with no significant differences in overall body composition. FIG. 12B provides DEXA parameters in NgBR fl / fl and NgBR HepKO mice under high-fat diet (HFD). Similar to control diet conditions, NgBR deficiency did not alter total weight, skeletal measures (bone area, BMD, BMC), soft tissue mass, lean mass, or fat mass. A modest increase in fat percentage was observed in NgBR HepKO mice under HFD, but this change did not reflect broad alterations in body composition. Data represent mean ± SD. Statistical analyses were performed using unpaired two-tailed t-test; p < 0.05 was considered significant.Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026
[0050] FIG. 13 provides data showing that CLAMS analysis shows no significant differences between NgBR fl / fl and NgBR HepKO mice. FIG. 13A provides Comprehensive Lab Animal Monitoring System (CLAMS) measurements in NgBR fl / fl and NgBR HepKO mice under control diet (CD) conditions showing comparable body weight, energy expenditure (EE), respiratory exchange ratio (RER), food intake, and locomotor activity across light and dark cycles. A minor increase in total ambulatory activity was observed in NgBR HepKO mice.FIG. 13B shows that under high-fat diet (HFD) conditions, NgBR HepKO mice exhibited higher total body weight and increased locomotor activity but similar EE, food intake, and RER compared with NgBR fl / fl controls, indicating no major alterations in whole-body energy metabolism. Data represent mean ± SD. Statistical analyses were performed using an unpaired two-tailed t-test or a two-way ANOVA with Sidak’s post hoc test; p < 0.05 was considered significant.
[0051] FIG. 14 shows KEGG adipocytokine signaling pathway mapping highlights persistent activation of the gluconeogenic program in NgBR-deficient liver. Pathview-based visualization of the KEGG Adipocytokine Signaling Pathway using bulk RNA-seq data from NgBR fl / fl and NgBR HepKO mouse livers. Differentially expressed genes are overlaid onto the canonical adiponectin signaling cascade, with red indicating upregulation and blue indicating downregulation. NgBR-deficient livers display strong induction of key gluconeogenic enzymes G6PC and PCK1, along with activation of upstream regulators including SOCS3, PPARGC1A, and IKK, consistent with enhanced hepatic gluconeogenesis and inflammation. Conversely, components of the adiponectin-APPLl-LKBl-AMPK arm — including AdipoRl / 2, APPL1, LKB1, and AMPK — are reduced or fail to respond, reflecting impaired adiponectin signaling. The pathway map illustrates a coordinated collapse of adiponectin-dependent metabolic suppression and reinforcement of insulin resistance, fattyacid-driven lipotoxicity, and unchecked gluconeogenic output in the absence of NgBR.
[0052] FIG. 15 shows loss of hepatic NgBR abolishes AdipoRon-induced improvements in glucose homeostasis and insulin sensitivity under control and high-fat diets.FIG. 15A-C shows NgBR fl / fl mice ± AdipoRon. FIG. 15A shows control diet (CD). Glucose tolerance test (GTT), insulin tolerance test (ITT), pyruvate tolerance test (PTT), and alanine tolerance test (ATT) were performed in NgBR fl / fl mice treated with vehicle or AdipoRon. Insets show corresponding area under the curve (AUC) quantification. AdipoRon significantly improved glucose clearance and insulin sensitivity under CD conditions. FIG. 15B shows high-fat diet (HFD). Under HFD, AdipoRon markedly improved GTT, ITT, PTT, and ATT responses in NgBR fl / fl mice, with significant reductions in AUC values. FIG. 15C providesDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 metabolic profiling under CD and HFD. AdipoRon enhanced insulin sensitivity (QUICKI), reduced HOMA-IR and HbAlc, increased hepatic glycogen content, and improved circulating metabolic parameters, including insulin, glucagon, adiponectin, leptin, C-peptide, and serum free fatty acids (FFA), such as under HFD conditions. FIG. 15D-F shows NgBR HepKO mice ± AdipoRon. FIG. 15D shows control diet (CD). In hepatocyte-specific NgBR knockout (NgBR HepKO) mice, AdipoRon failed to improve GTT, ITT, PTT, or ATT responses under CD, with no significant differences in AUC values between vehicle- and AdipoRon-treated groups. FIG. 15E shows high-fat diet (HFD). Under HFD, AdipoRon did not ameliorate glucose intolerance, insulin resistance, or gluconeogenic responses in NgBR HepKO mice, as shown by unchanged GTT, ITT, PTT, and ATT curves and AUC analyses. FIG. 15F shows metabolic profiling under CD and HFD. AdipoRon failed to improve insulin sensitivity (QUICKI), HOMA-IR, HbAlc, hepatic glycogen, or circulating metabolic markers in NgBR HepKO mice, indicating resistance to adiponectin receptor agonism in the absence of hepatic NgBR. Data are presented as mean ± SD. Statistical significance was assessed using two-way ANOVA with appropriate post hoc tests. Exact p-values are shown in the panels.
[0053] FIG. 16 shows adiponectin treatment improves metabolic and hepatic function in NgBR fl / fl mice but not in NgBR HepKO mice. FIG. 16A, FIG. 16F show food intake and body weight over the treatment period in NgBR fl / fl and NgBR HepKO mice administered AdipoRon under control diet (FIG. 16A) or high-fat diet (FIG. 16F) conditions. Adiponectin did not alter feeding behavior or weight trajectories in either genotype. FIG. 16B, FIG. 16G show kidney function panels. Under control diet (FIG. 16B), AdipoRon increased serum albumin and reduced BUN only in NgBR fl / fl mice, with no improvement in NgBR HepKO mice. Under high-fat diet (FIG. 16G), adiponectin decreased creatinine and BUN and improved albumin levels in NgBR fl / fl mice, whereas NgBR HepKO mice remained unresponsive. FIG. 16C, FIG. 16H show lipid panel data. AdipoRon reduced hepatic triglycerides, serum triglycerides, and serum cholesterol in NgBR fl / fl mice under both diets (FIG. 16C, FIG. 16H). NgBR HepKO mice showed no improvement in any lipid parameter, maintaining elevated hepatic and circulating lipid levels. FIG. 16D, FIG. 161 show liver function panel data. Serum ALT, AST, ALP, and total bilirubin were significantly lowered by adiponectin in NgBR fl / fl mice under both control diet (FIG. 16D) and high-fat diet (FIG.161) These hepatoprotective effects were absent in NgBR HepKO mice, which retained elevated liver injury markers despite treatment. FIG. 16E, FIG. 16J show pancreas function panel data. In NgBR fl / fl mice, adiponectin reduced serum amylase and lipase, indicating decreased pancreatic stress under both diets (FIG. 16E, FIG. 16J). NgBR HepKO miceDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 showed no reduction in either enzyme, demonstrating persistent pancreatic dysfunction. Data represent mean ± SD. Statistical analyses were performed using one-way ANOVA with Tukey’s post hoc correction; p < 0.05 was considered statistically significant.
[0054] FIG. 17 provides data showing DEXA analysis shows no significant changes following adiponectin treatment in NgBR fl / fl or NgBR HepKO mice. FIG. 17A provides data for control diet. Dual-energy X-ray absorptiometry (DEXA) revealed no major changes in total body weight, bone area, soft tissue mass, lean mass, fat weight, or bone mineral content (BMC) following AdipoRon treatment in NgBR fl / fl or NgBR HepKO mice. Small differences in sample area, BMD, and fat percentage were detected in isolated parameters but did not follow a consistent genotype- or treatment-dependent pattern. FIG. 17B provides data for high-fat diet. Under HFD conditions, AdipoRon did not significantly alter total weight, lean mass, fat mass, or BMC in either genotype. Minor increases in bone area, sample area, soft mass, BMD, and fat percentage were observed in select comparisons, but these shifts were not sufficient to indicate meaningful treatment effects. Data are presented as mean ± SD. Statistical analyses were performed using an unpaired two-tailed t-test; p < 0.05 was considered statistically significant.
[0055] FIG. 18 shows CLAMS metabolic cage analysis shows no significant changes in whole-body energy expenditure following AdipoRon treatment in NgBR fl / fl or NgBR HepKO mice. FIG. 18A provides data for control diet. Comprehensive Lab Animal Monitoring System (CLAMS) measurements revealed that AdipoRon treatment did not significantly alter body weight, respiratory exchange ratio (RER), total energy expenditure (EE), ambulatory activity, or food intake in NgBR fl / fl or NgBR HepKO mice across 24-hour cycles. Light- and dark-phase analyses showed overlapping RER and EE profiles between treatment groups. Hourly EE traces demonstrated identical diurnal rhythmicity, with no evidence of treatmentdependent alterations in substrate utilization or metabolic rate. FIG. 18B provides data for high-fat diet. Under HFD conditions, AdipoRon similarly failed to modify whole-body energetics. RER, EE, activity counts, and food intake remained unchanged in both genotypes. Minor differences in activity and ambulatory counts at isolated timepoints did not translate into consistent shifts in overall energy balance. Hourly EE curves again showed completely overlapping trajectories between treated and untreated groups. Data represent mean ± SD. Statistical analyses were performed using an unpaired two-tailed t-test or a two-way ANOVA with Sidak’s post hoc correction; p < 0.05 was considered statistically significant.
[0056] FIG. 19 shows KEGG adipocytokine signaling pathway analysis reveals persistent activation of gluconeogenic nodes (G6PC and PEPCK) and impaired AMPK-LKB1Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026 signaling in NgBR HepKO liver following AdipoRon treatment. Pathview-based KEGG mapping of the adipocytokine signaling pathway61,63 using bulk RNA-seq data from AdipoRon-treated NgBR fl / fl and NgBR HepKO livers. Color scaling reflects Z-scores (blue = downregulated; red = upregulated). In NgBR fl / fl mice, AdipoRon induces activation of the APPL1-LKB1-AMPK axis and suppression of gluconeogenic targets. In contrast, NgBR HepKO livers show marked upregulation of G6PC and PCK1 (PEPCK), persistent activation of insulin-resistance nodes (IKB / NF-KB, IRS1 serine phosphorylation), and loss of AMPK signaling despite identical ligand exposure. These pathway-level defects illustrate that NgBR is required for downstream propagation of adiponectin signaling, and that its absence maintains a constitutively gluconeogenic, adiponectin-resistant transcriptional program.
[0057] FIG. 20 shows NgBR is required for adiponectin-induced AMPK activation and suppression of gluconeogenesis in HepG2 cells. FIG. 20A provides qPCR analysis of HepG2 cells showing that AdipoRon induces NUS1, ADIPOR1, ADIPOR2, KAT7, and INSR expression in control cells, whereas NgBR knockout abolishes this induction. FIG. 20B provides immunoblot analysis confirming that AdipoRon increases AdipoRl, AdipoR2, KAT7, and INSR protein abundance only in control cells, with no detectable response in NgBR KO cells. FIG. 20C shows AdipoRon suppresses G6PC and PCK1 mRNA in control HepG2 cells but fails to repress either gene in NgBR KO cells. FIG. 20D provides immunoblot validation showing loss of AdipoRon-mediated suppression of G6PC and PCK1 protein expression in NgBR-deficient cells. FIG. 20E shows AdipoRon robustly activates AMPK phosphorylation in control cells, whereas NgBR KO completely abolishes AMPK activation despite identical ligand exposure. FIG.20F shows recombinant Nogo-B fails to restore AMPK phosphorylation in si-NgBR cells, confirming that NgBR is required downstream of Nogo-B / adiponectin signaling. FIG. 20G provides dose-response analysis demonstrating that increasing concentrations of AdipoRon (0-50 pM) suppress PCK1 and G6Pase protein expression in control cells but have no effect in si-NgBR hepatocytes, despite comparable loading controls.
[0058] FIG. 21 provides data showing chromatin occupancy and histone acetylation profiling across the AdipoRl promoter reveals coordinated H3, HBO1, H3K14ac, and H3K18ac enrichment.
[0059] FIG. 22 provides data showing epigenetic profiling of the AdipoR2 promoter demonstrates coordinated enrichment of H3, HBO1, H3K14ac, and H3K18ac across regulatory regions.Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026
[0060] FIG. 23 shows adiponectin remodels hepatic lipid profiles in NgBR fl / fl mice but fails to normalize ceramide species in NgBR HepKO mice. FIG. 23A-B provide unsupervised hierarchical clustering heatmaps showing global hepatic lipidomic profiles in NgBR fl / fl mice before and after AdipoRon treatment. Adiponectin markedly shifts multiple lipid subclasses — including fatty acids (FA), glycerolipids (GL), glycerophospholipids (GP), prenol lipids (PR), sphingolipids (SP), and sterol lipids (ST) — toward a metabolically favorable pattern in NgBR fl / fl livers. FIG.23C provides a volcano plot of differentially abundant lipids in NgBR fl / fl mice treated with AdipoRon versus untreated controls. AdipoRon significantly reduces 579 lipid species and increases 216 species, with strong enrichment for decreases in ceramide subclasses (Cer-ADS, Cer-AP, Cer-AS, Cer-NDS, Cer-NP, Cer-NS), hexosylceramides (HexCer-AP, HexCer-NS), and sphingomyelins (SM). FIG.23D-E provide heatmaps of hepatic lipid species in NgBR HepKO mice before and after AdipoRon treatment. Unlike controls, lipids in NgBR HepKO mice show minimal or absent remodeling, with persistent elevations in multiple ceramide and hexosylceramide subclasses despite adiponectin exposure. FIG. 23F provides a volcano plot comparing AdipoRon-treated NgBR HepKO and NgBR fl / fl livers. In NgBR HepKO mice, 442 lipids increase and 307 decrease, indicating dysregulated lipid remodeling and failure of AdipoRon to suppress harmful sphingolipid species. FIG. 23G-H provide cell viability assays showing increased sensitivity of NgBR HepKO hepatocytes to the membrane-permeable ceramide analog C2 (FIG. 23G) and the PP2A inhibitor LB- 100 (FIG. 23H). Hepatocytes lacking NgBR exhibit significantly reduced survival at increasing concentrations of C2 or LB- 100, indicating heightened vulnerability to ceramide-induced stress and impaired capacity to buffer PP2A-driven metabolic signals. Data represent mean ± SD. Statistical analyses were performed using an unpaired two-tailed t-test or a two-way ANOVA with Sidak’s post hoc correction; p < 0.05 was considered statistically significant.
[0061] FIG. 24 shows AAV-mediated NgBR overexpression restores insulin sensitivity, glucose homeostasis, and multi-organ metabolic function in AdipoRon-treated NgBR HepKO mice. FIG. 24A-E provide data for Control Diet. Metabolic and biochemical assessment of NgBR HepKO mice treated with AAV-Control or AAV-NUS 1 during AdipoRon administration. FIG. 24A shows body weight and food intake remain unchanged between groups throughout the study. FIG. 24B provides kidney function panel showing that AAV-NUS 1 improves serum creatinine, albumin, and BUN levels, indicating reversal of renal stress.FIG. 24C provides lipid panel data demonstrating reduced hepatic triglycerides, lower circulating triglycerides and cholesterol, and significantly decreased serum free fatty acids inDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 AAV-NUS1 -treated mice. FIG. 24D provides liver function tests revealing improved ALT, AST, and ALP, with stabilization of total bilirubin following NgBR restoration. FIG. 24E provides pancreatic enzyme profile showing significant reductions in serum amylase and lipase with AAV-NUS1 treatment, indicating alleviation of pancreatic metabolic burden. FIG. 24F-J provide data for high-fat diet. Evaluation of AAV-NUS1 rescue under diet-induced metabolic stress. FIG.24F shows body weight and food intake remain comparable between groups under HFD feeding. FIG. 24G provides kidney panel showing AAV-NUS1 corrects elevated creatinine and BUN and stabilizes serum albumin levels in NgBR HepKO mice. FIG. 24H provides lipid panel data indicating robust improvement in hepatic triglycerides, circulating triglycerides, serum cholesterol, and FFAs, confirming restored lipid homeostasis in the presence of NgBR. FIG.241 provides liver function panel data showing reduced ALT and AST and normalization of bilirubin following NgBR re-expression. FIG. 24J provides pancreatic function markers showing AAV-NUS1 significantly reduces amylase and lipase levels, reversing adiponectin-unresponsive pancreatic stress in NgBR-deficient mice. Data represent mean ± SD. Statistical analyses were performed using an unpaired two-tailed t-test or two-way ANOVA with Sidak’s post hoc correction; p < 0.05 was considered statistically significant.
[0062] FIG. 25 provides data showing DEXA analysis shows improved tissue composition and body mass parameters in NgBR HepKO mice following AAV-mediated NgBR restoration. FIG. 25A provides data for control diet. DEXA-derived body composition measurements comparing NgBR HepKO mice treated with AAV-Control + AdipoRon versus AAV-NUS1 + AdipoRon. Restoration of hepatic NgBR results in modest improvements in several structural and metabolic parameters, including increased bone area, with trends toward higher lean mass, soft tissue mass, and BMD, while fat mass and fat percentage remain unchanged. Total body weight and BMC are comparable between groups. FIG. 25B provides data for high-fat diet. Under HFD challenge, NgBR re-expression further enhances structural indices. AAV-NUS1 significantly increases sample area, total weight, bone area, and BMD, with partial improvement in lean mass and soft mass. Fat-related parameters (fat mass and fat percentage) remain unaffected by AAV treatment. BMC shows no significant difference between groups.
[0063] FIG. 26 shows comprehensive CLAMS metabolic profiling following AAV-mediated NgBR restoration in NgBR HepKO mice. Continuous metabolic cage measurements were performed to assess locomotor activity and whole-body energy metabolism in NgBR HepKO mice treated with AAV-Control + AdipoRon or AAV-NUS1 + AdipoRon. FIG. 26A provides data showing Z-axis activity (vertical counts) shows comparable movement patternsDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 over the recording period between groups, indicating no major differences in exploratory or rearing behavior. FIG. 26B provides data showing respiratory exchange ratio (RER) remains stable across time in both groups, demonstrating similar substrate utilization for energy production. FIG.26C provides data showing oxygen consumption (VO2) exhibits overlapping trajectories, with no detectable enhancement of oxidative metabolism following NgBR rescue.FIG. 26D-E provides data showing Y-axis and high-resolution X-axis activity counts show similar locomotor behavior between groups during both light and dark cycles. FIG. 26F provides data showing carbon dioxide production (VCO2) mirrors VO2 patterns, further supporting unchanged metabolic fuel handling following AAV treatment.
[0064] FIG. 27 shows GLP-lRAs stimulate NgBR expression in the livers and soluble ligand Nogo-B in the serum and Nogo-B in white adipose tissues (WAT). Male mice were maintained under control diet (CD) or high-fat diet (HFD) conditions to establish baseline and metabolically impaired states. A subset of HFD-fed mice received treatment with a GLP-1 receptor agonist (GLP-1RA). At the experimental endpoint, serum, liver, and white adipose tissue (WAT) were collected for molecular and biochemical analyses.
[0065] FIG. 28 shows PPARy agonist pioglitazone treatment for 24 hours increases NgBR expression in HepG2 cells in a dose-dependent manner.
[0066] FIG. 29 shows GLP-1RA (Semaglutide, 10 nmol / kg, every other day) treatment increases the expression levels of PPARy and NgBR in the liver of littermate control mice fed with a high-fat diet for 10 weeks.
[0067] FIG. 30 shows H& E staining of liver tissues to assess morphology. FIG. 30A shows the liver of littermate control mice on a high-fat diet with fatty liver. GLP1-RA injection (FIG. 30B) mitigated the fatty liver. FIG. 30C shows that NgBR hepatocyte knockout (hepKO) mice have a severe fatty liver compared to FIG. 30A. GLP-1RA cannot achieve the reduction effects in NgBR hepKO mice (FIG.30D). However, AAV-mediated overexpression of NgBR (FIG.30E) in the hepatocyte restores the beneficial effects of GLP1-RA on reducing fatty liver to a healthy condition. The results indicate that NgBR is also essential for GLP-lRAs to reduce fatty liver.
[0068] FIG. 31 shows information related to the vector, including the vector summary, vector map, vector components, vector nucleic acid sequence, and validation.
[0069] FIG. 32 shows the amino acid sequence for AAV8-TBG-intron-3xFLAG-hNUSl-HA: WPRE.Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026 DETAILED DESCRIPTION OF THE INVENTION
[0070] The disclosed method and compositions can be understood more readily by reference to the following detailed description of embodiments and the Example included therein and to the Figures and their previous and following description.
[0071] The disclosed methods are based at least on the discovery demonstrated that NgBR expression is essential for maintaining the insulin sensitivity that is required for the pharmacological function of GLP-1R agonists. Data in the present application show that restoration of NgBR expression is an alternative approach to increasing the sensitivity of GLP-1R agonists and reducing the GLP-1R doses, which can be helpful to avoid any medication complications such as muscle loss and gastrointestinal adverse events.
[0072] The advantage of the disclosed combination treatment is to restore insulin sensitivity to reduce the demand for large amounts of insulin production. The unique features of the are 1) identifying a new target to restore insulin sensitivity; 2) reveal that the loss of NgBR in the obese liver is the predominant factor for jeopardizing the efficacy of GLP-1R agonists; 3) demonstrate the feasibility of restoring the efficacy of GLP-1R agonists by an AAV-mediated gene delivery approach; 4) Restoration of NgBR expression can reduce the dosage of GLP-1R agonists to achieve a similar purpose of glycemic control, which is critical for type 1 diabetes patients and other patients with beta cell failure.
[0073] The disclosed method and compositions are not limited to specific synthetic methods, specific analytical techniques, or to reagents unless otherwise specified, and, as such, can vary. The terminology used herein is for the purpose of describing embodiments only and is not intended to be limiting.
[0074] I. GENERAL TERMINOLOGY
[0075] The singular forms “a” and “an” are intended to include the plural forms as well, unless the context clearly indicates otherwise. Thus, for example, reference to “a pharmaceutical carrier” includes mixtures of two or more such carriers, and the like.
[0076] “Comprising” is intended to mean that the compositions, methods, etc. include the recited elements, but do not exclude others. The terms “comprising” and “including” and “having” and “involving” (and similarly “comprises”, “includes,” “has,” and “involves”) and the like are used interchangeably and have the same meaning. Specifically, each of the terms is defined consistent with the common United States patent law definition of “comprising” and is therefore interpreted to be an open term meaning “at least the following,” and is also interpreted not to exclude additional features, limitations, aspects, etc. Thus, for example, “aDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 process involving steps a, b, and c” means that the process includes at least steps a, b and c. Wherever the terms “a” or “an” are used, “one or more” is understood, unless such interpretation is nonsensical in context.
[0077] “Consisting essentially of’ when used to define compositions and methods, includes the recited elements, but excludes other elements of any essential significance to the combination. Thus, a composition consisting essentially of the elements as defined herein cannot exclude trace contaminants from the isolation and purification method and pharmaceutically acceptable carriers, such as phosphate buffered saline, preservatives, and the like. “Consisting of’ excludes more than trace elements of other ingredients and substantial method steps for administering the compositions provided and / or claimed in this disclosure. Embodiments defined by each of these transition terms are within the scope of this disclosure.
[0078] As used herein, the terms “may,” “optionally,” and “may optionally” are used interchangeably and include cases in which the condition occurs as well as cases in which the condition does not occur. Thus, for example, the statement that a formulation “may include an excipient” can include cases in which the formulation includes an excipient as well as cases in which the formulation does not include an excipient.
[0079] As used herein, the term “substantially the same” or “substantially” can refer to variability for a particular method is taken into account. The term “substantially” allows for deviations from the descriptor that do not negatively impact the intended purpose. Descriptive terms are understood to be modified by the term “substantially” even if the word “substantially” is not explicitly recited.
[0080] Use of the term “about” is intended to describe values either above or below the stated value in a range of approx. + / - 10%; in other embodiments the values may range in value either above or below the stated value in a range of approx. + / - 5%; in other embodiments the values may range in value either above or below the stated value in a range of approx. + / -2%; in other embodiments the values may range in value either above or below the stated value in a range of approx. + / - 1%. The preceding ranges are intended to be made clear by context, and no further limitation is implied. The term “about,” as used herein when referring to a measurable value such as an amount of the length of a polynucleotide or polypeptide sequence, dose, time, temperature, and the like, can encompass variations of about 20%, about 10%, about 5%, about 1%, about 0.5%, or even about 0.1% of the specified amount. Methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., "such as") provided herein, is intended merely to better illuminate the invention and does notDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.
[0081] “Optional” or “optionally” refers to that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.
[0082] Wherever any of the phrases “for example,” “such as,” “including” and the like are used herein, the phrase “and without limitation” is understood to follow unless explicitly stated otherwise. Similarly, “an example,” “exemplary” and the like are understood to be nonlimiting.
[0083] An “increase” can refer to any change that results in a greater amount of a compound, metabolite, symptom, disease, composition, condition or activity. An increase can be any individual, median, or average increase in a condition, symptom, activity, composition in a statistically significant amount. Thus, the increase can be a 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% increase so long as the increase is statistically significant.
[0084] A “decrease” can refer to any change that results in a smaller amount of a compound, metabolite, symptom, disease, composition, condition, or activity. A substance is also understood to decrease the genetic output of a gene when the genetic output of the gene product with the substance is less relative to the output of the gene product without the substance. Also, for example, a decrease can be a change in the symptoms of a disorder such that the symptoms are less than previously observed. A decrease can be any individual, median, or average decrease in a condition, symptom, activity, composition in a statistically significant amount. Thus, the decrease can be a 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% decrease so long as the decrease is statistically significant.
[0085] “Inhibit,” “inhibiting,” and “inhibition” can refer to decrease of an activity, response, condition, disease, or other biological parameter. This can include but is not limited to the complete ablation of the activity, response, condition, or disease. This can also include, for example, a 10% reduction in the activity, response, condition, or disease as compared to the native or control level. Thus, the reduction can be a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount of reduction in between as compared to native or control levels.
[0086] By “reduce” or other forms of the word, such as “reducing” or “reduction,” can refer to lowering of an event or characteristic (e.g., inflammation). This can be in relationDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 to some standard or expected value, in other words it is relative, but that it is not always necessary for the standard or relative value to be referred to. For example, “reduces inflammation” can refer to reducing inflammatory process in vitro or in vivo or reducing the incidence of at least one symptom of an inflammatory disorder relative to a standard or a control.
[0087] A “control” can refer to an alternative subject or sample used in an experiment for comparison purposes. A control can be “positive” or “negative.”
[0088] By “prevent” or other forms of the word, such as “preventing” or “prevention,” can refer to stopping an event or characteristic, to stabilizing or delaying the development or progression of an event or characteristic, or to minimizing the chances that an event or characteristic will occur. Prevent does not require comparison to a control as it is more absolute than, for example, reduce. As used herein, something can be reduced but not prevented, but something that is reduced can also be prevented. Likewise, something can be prevented but not reduced, but something that is prevented can also be reduced. Where reduce or prevent are used, unless specifically indicated otherwise, the use of the other word is also expressly disclosed.
[0089] As used herein, the term “therapeutic nucleic acid” or “therapeutic polynucleotide” can refer to a nucleic acid molecule that has a therapeutic effect when introduced into a eukaryotic organism (e.g., a mammal such as human).
[0090] As used herein, the term “combination therapy” can refer to a therapeutic regimen in which two or more distinct active agents (e.g., an NgBR activator and a GLP-1R agonist) are administered to a subject as part of a coordinated treatment strategy to achieve a therapeutic benefit. The active agents can be administered simultaneously, concurrently or sequentially, together or separately, and can be delivered in a single composition, in separate compositions, or as part of a kit or treatment protocol. The components of a combination therapy (e.g., an NgBR activator and a GLP-1R agonist) can be administered by the same or different routes, at the same or different dosing frequencies, and over overlapping or non-overlapping periods of time, provided that the therapeutic effects of the agents are intended to occur in a combined or complementary manner. A combination therapy can result in additive, synergistic, or enhanced therapeutic effects, including improved efficacy, reduced dosing requirements, improved durability of response, or reduced adverse effects, as compared to administration of any single agent alone. The term “combination therapy” expressly includes regimens in which one component enhances, potentiates, or supports the activity of anotherDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 component, regardless of whether the agents act through the same or different biological mechanisms.
[0091] As used herein, the term “construct” can refer to a recombinant genetic molecule having one or more isolated polynucleotide sequences. Genetic constructs used for transgene expression in a host organism, also referred to “expression constructs”, include in the 5 ’-3’ direction, a promoter sequence; a sequence encoding a gene of interest; and a termination sequence.
[0092] The construct can also include selectable marker gene(s) and other regulatory elements for expression.
[0093] As used herein, a “vector” can refer to a replicon, such as a plasmid, phage, or cosmid, into which another DNA segment can be inserted so as to bring about the replication of the inserted segment. The vectors described herein can be “expression vectors”. For example, an “expression vector” is a vector that includes one or more expression control sequences. For example, an “expression control sequence” is a DNA sequence that controls and regulates the transcription and / or translation of another DNA sequence.
[0094] “Operably linked” can refer to a juxtaposition wherein the components are configured so as to perform their usual function. For example, control sequences or promoters operably linked to a coding sequence can affect the expression of the coding sequence, and an organelle localization sequence operably linked to protein will direct the linked protein to be localized at the specific organelle.
[0095] As used herein, the term “promoter” can refer to a regulatory nucleic acid sequence, for example, located upstream (5’) of a gene or protein coding sequence that, in conjunction with various elements, is responsible for regulating the expression of the gene or protein coding sequence. These include constitutive promoters, inducible promoters, tissue-and cell-specific promoters and developmentally regulated promoters.
[0096] As used herein, “transformed” and “transfected” can refer to the introduction of a nucleic acid (e.g. a vector) into a cell by a number of techniques known in the art.
[0097] As used herein, the term “gene” can refer to a nucleic acid (e.g., DNA or RNA) sequence that includes coding sequences necessary for the production of a polypeptide, RNA (e.g., including, but not limited to, mRNA, tRNA and rRNA) or precursor. The polypeptide, RNA, or precursor can be encoded by a full-length coding sequence or by any portion thereof. The term also encompasses the coding region of a structural gene and the sequences located adjacent to the coding region on both the 5' and 3' ends for a distance of about 1 kb on either end such that the gene corresponds to the length of the full-length mRNA. The term “gene”Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026 encompasses both cDNA and genomic forms of a gene, which can be made of DNA, or RNA. A genomic form or clone of a gene can contain the coding region interrupted with non-coding sequences termed “introns” or “intervening regions” or “intervening sequences.” Introns are segments of a gene that are transcribed into nuclear RNA (hnRNA); introns can contain regulatory elements such as enhancers. Introns are removed or "spliced out" from the nuclear or primary transcript; introns therefore are absent in the messenger RNA (mRNA) transcript. The mRNA functions during translation.
[0098] The term “subject” (or a “host”) can refer to any individual who is the target of administration or treatment. The subject can be a vertebrate, for example, a mammal. For example, a “mammal” includes both humans and non-humans, which includes but is not limited to non-human primate, bovine, equine, porcine, murine, canine, or feline. The subject can also be laboratory animal, such as a guinea pig, rat, hamster, rabbit, mouse, or mole. Thus, the subject can be a human or veterinary patient. The term “patient” can refer to a subject under the treatment of a clinician, e.g., physician.
[0099] As used herein, a “therapeutic regimen” can refer to a structured treatment plan or strategy designed to improve and maintain health. A therapeutic regimen will be designed, prescribed, and / or administered by a licensed medical practitioner. The therapeutic regimen specifies the treatment dosage, the treatment scheduling, and the duration of the treatment. In some embodiments, the therapeutic regimen comprises one or more therapeutic compositions. In some embodiments, the therapeutic regimen comprises one or more therapeutic agents. In some embodiments, the therapeutic regimen comprises any combination of therapeutic compositions and therapeutic agents, such as for example the combination of an inhibitor and an antibody. In some embodiments, a therapeutic regimen comprises modifying, continuing, and / or initiating at least one therapeutic agent and / or therapeutic composition. In some embodiments, a therapeutic regimen comprises treating and / or preventing a disease, disorder, and / or condition.[000100] Administration of the therapeutic agents can be carried out at dosages and for periods of time effective for treatment of a subject.[000101] The term “treating” or “treatment” can refer to the medical management of a patient with the intent to cure, ameliorate, stabilize, or prevent a disease, pathological condition, disorder, or symptom associated with a specific disease, condition or disorder. This term includes active treatment, that is, treatment directed specifically toward the improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated disease, pathologicalDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 condition, or disorder. In addition, this term includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder.[000102] " Effective amount" and “therapeutically effective amount,” used interchangeably, as applied to the therapeutic agents, and pharmaceutical compositions described herein, can refer to the quantity necessary to render the desired therapeutic result. For example, an effective amount is a level effective to treat, cure, or alleviate the symptoms of a disease for which the composition and / or therapeutic agent, or pharmaceutical composition, is / are being administered.[000103] Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein.[000104] Disclosed are materials, compositions, and components that can be used for, can be used in conjunction with, can be used in preparation for, or are products of the disclosed method and compositions. These and other materials are disclosed herein; when combinations, subsets, interactions, groups, etc. of these materials are disclosed that while specific reference of each various individual and collective combinations and permutation of these compounds may not be explicitly disclosed, each is specifically encompassed and described herein. For example, if a ligand is disclosed and discussed and a number of modifications that can be made to a number of molecules including the ligand are discussed, each and every combination and permutation of ligand and the modifications that are possible are encompassed unless specifically indicated to the contrary. Thus, if a class of molecules A, B, and C are disclosed as well as a class of molecules D, E, and F and an example of a combination molecule, A-D is disclosed, then even if each is not individually recited, each is individually and collectively encompassed. Thus, in this example, each of the combinations A-E, A-F, B-D, B-E, B-F, C-D, C-E, and C-F are encompassed and should be considered disclosed from disclosure of A, B, and C; D, E, and F; and the example combination A-D. Likewise, any subset or combination of these is also encompassed and disclosed. Thus, for example, the sub-group of A-E, B-F, and C-E are encompassed and should be considered disclosed from disclosure of A, B, and C; D,Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026 E, and F; and the example combination A-D. Further, each of the materials, compositions, components, etc. encompassed and disclosed as above can also be specifically and independently included or excluded from any group, subgroup, list, set, etc. of such materials.[000105] These concepts apply to all aspects of this application including, but not limited to, steps in methods of making and using the disclosed compositions. Thus, if there are a variety of additional steps that can be performed, each of these additional steps can be performed with any specific embodiment or combination of embodiments of the disclosed methods, and that each such combination is encompassed and should be considered disclosed.[000106] Unless otherwise indicated, the disclosure encompasses conventional techniques of molecular biology, microbiology, cell biology and recombinant DNA, which are within the skill of the art. Unless otherwise noted, technical terms are used according to conventional usage, and in the art, such as in the references cited herein, each of which is specifically incorporated by reference herein in its entirety.[000107][000108] II. COMPOSITIONS[000109] The reticulon-4 (RTN4), also known as neurite outgrowth inhibitor or Nogo, includes three isoforms (Nogo- A, B, C) by alternative promoter usage and splicing. NgBR (the abbreviation for Nogo-B receptor) was initially identified as a putative receptor for binding Nogo-B in endothelial cells, and binding of Nogo-B to NgBR can lead to endothelial cell proliferation / vascular remodeling and angiogenesis during development. NgBR is a transmembrane receptor that contains a conserved hydrophobic pocket, which regulates the membrane localization of the prenylated protein. It also promotes the membrane accumulation of the liver kinase B 1 (LKB 1) and Ras by directly binding the prenylated LKB 1 and Ras at the plasma membrane, resulting in promoting insulin-stimulated Ras and AMPK-activated protein kinase (AMPK) pathways.[000110] Surprisingly, the inventors have discovered that activation of Nogo-B receptor (NgBR) signaling results in blood glucose control. Further, the inventors have discovered that activation of Nogo-B receptor (NgBR) signaling, in combination with GLP-1 receptor agonism, results in enhanced therapeutic effects compared to administration of either agent alone. Accordingly, NgBR activation improves cellular metabolic signaling, insulin sensitivity, hepatocyte and beta-cell function, and / or vascular or lipid-associated pathways, including those that synergize with GLP-1 receptor-mediated glucose regulation.[000111] Along these lines, aspects of the invention are drawn to compositions for treating, preventing, reducing, inhibiting, decreasing and / or ameliorating one or moreDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 symptoms (e.g., hyperglycemia, glycosuria, insulin resistance, impaired glucose tolerance, hypoglycemia or glycemic instability, polydipsia, polyuria, and polyphagia) associated with diabetes mellitus (e.g., Type I diabetes and / or Type II diabetes, such as diabetes characterized by beta cell dysfunction). Embodiments as described herein includes combination therapies comprising administration of an NgBR activator, together with a glucagon-like peptide-1 receptor agonist (GLP-1RA), to improve glycemic control, metabolic function, and optionally body weight regulation.[000112][000113] A. NgBR activator[000114] The term “NgBR activator” can refer to an agent that increases NgBR expression, activity, signaling, or functional downstream effects, non-limiting examples of such agents include nucleic acids, expression vectors, viral or non-viral delivery systems, and small molecule activators. In one embodiment, for example, an NgBR activator is a polynucleotide (e.g., nucleic acid) encoding the NgBR, such as an expression vector comprising a therapeutic polynucleotide (e.g., nucleic acid) encoding NgBR. In other embodiments, an NgBR activator is a small molecule activator (e.g., caffeine, a statin, and a PPAR agonist).[000115] Therapeutic polynucleotide[000116] In one aspect, provided herein are compositions comprising a polynucleotide (e.g., nucleic acid molecule) encoding a synthetic (e.g., recombinant) protein or polypeptide (e.g., NgBR; gene alias Nusl), such as, in a vector for delivery and expression in cells, such as in mammalian cells.[000117] Any polynucleotide (including, but not limited to, a recombinant virus or viral vector, or cell comprising the same) coding for the herein described synthetic (e.g., recombinant) proteins or polypeptides (e.g., NgBR) is comprised in embodiments described herein. Exemplary polynucleotides include those according to SEQ ID NO: 1.[000118] Accordingly, embodiments of the invention include a construct comprising or consisting of a polynucleotide (e.g., nucleic acid) sequence encoding synthetic (e.g., recombinant) NgBR (e.g., a sequence according to SEQ ID NO: 2, or a sequence at least 90% identical thereto). For example, the nucleic acid sequence encoding synthetic (e.g., recombinant) NgBR comprises or consists of a nucleic acid sequence according to SEQ ID NO: 1, or a sequence at least 80% identical thereto.[000119] The gene sequence for human NgBR is:Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026 ATGACGGGGCTGTACGAGCTGGTGTGGCGGGTGCTGCACGCGCTGCTCTGTCTGCACCGC ACGCTCACCTCCTGGCTCCGCGTTCGGTTCGGCACCTGGAACTGGATCTGGCGGCGCTGC TGCCGCGCCGCCTCTGCCGCGGTCCTAGCGCCGCTCGGCTTCACGCTCCGCAAGCCCCCG GCAGTCGGCAGGAACCGCCGTCACCACCGGCACCCGCGCGGGGGGTCGTGCCTGGCAGCC GCACACCACCGGATGCGCTGGCGCGCGGACGGTCGTTCCTTGGAGAAGCTGCCTGTGCAT ATGGGCCTGGTGATCACCGAGGTGGAGCAGGAACCCAGCTTCTCGGACATCGCGAGCCTC GTGGTGTGGTGTATGGCCGTGGGCATCTCCTACATTAGCGTCTACGACCACCAAGGTATT T T CAAAAGAAATAAT T CCAGAT T GAT GGAT GAAAT T T TAAAACAACAGCAAGAAC T T C T G G G C C T AGAT T G T T C AAAAT AC T GAG C AGAAT T T G GAAAT AG T AAT GAG AAAGAT GAT C AA GTTTTAAATTGCCATTTGGCAGTGAAGGTGCTGTCTCCGGAAGATGGAAAAGCAGATATT GTAAGAGCTGCTCAGGACTTTTGCCAGTTAGTAGCCCAGAAGCAAAAGAGACCCACAGAT TTGGATGTAGATACGTTAGCCAGTTTACTTAGTTCAAATGGTTGTCCTGATCCTGATTTA GTATTGAAGTTCGGTCCTGTGGACAGCACATTAGGCTTTCTTCCCTGGCACATCAGATTG ACTGAGATTGTCTCTTTGCCTTCCCACCTAAACATCAGTTATGAGGACTTTTTCTCTGCC CTTCGTCAATATGCAGCCTGTGAACAGCGTCTGGGAAAGTAG [SEQ IDNO: 1][000120] The protein sequence for human NgBR is:MTGLYELVWRVLHALLCLHRTLTSWLRVRFGTWNWIWRRCCRAASAAVLAPLGFT LRKPPAVGRNRRHHRHPRGGSCLAAAHHRMRWRADGRSLEKLPVHMGLVITEVEQ EPSFSDIASLWWCMAVGISYISVYDHQGIFKRNNSRLMDEILKQQQELLGLDCS KYSPEFANSNDKDDQVLNCHLAVKVLSPEDGKADIVRAAQDFCQLVAQKQKRPTD LDVDTLASLLSSNGCPDPDLVLKFGPVDSTLGFLPWHIRLTEIVSLPSHLNISYE DFFSALRQYAACEQRLGK [SEQ ID NO: 2][000121] Activity of the synthetic (e.g., recombinant) protein of the disclosure (e.g., NgBR, such as NgBR encoded by nucleic acids described herein) can be readily determined by the skilled person. See, for example, those described in Example 2.[000122] In addition to the specific protein and nucleotides mentioned herein, the invention also encompasses the use of variants, derivatives, analogues, homologues and fragments thereof.[000123] In the context of the invention, a variant of any given sequence is a sequence in which the specific sequence of residues (whether amino acid or nucleic acid residues) has been modified in such a manner that the polypeptide or polynucleotide in question substantially retains its function. A variant sequence can be obtained by addition, deletion, substitution, modification, replacement and / or variation of at least one residue present in the naturally occurring protein.[000124] The term "derivative" as used herein, in relation to proteins or polypeptides of the invention includes any substitution of, variation of, modification of, replacement of, deletion of and / or addition of one (or more) amino acid residues from or to the sequenceDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 providing that the resultant protein or polypeptide substantially retains at least one of its endogenous functions.[000125] The term "analogue" as used herein, in relation to polypeptides or polynucleotides includes any mimetic, that is, a chemical compound that possesses at least one of the endogenous functions of the polypeptides or polynucleotides which it mimics.[000126] Proteins used in the invention can also have deletions, insertions or substitutions (e.g., conservative substitutions) of amino acid residues which produce a silent change and result in a functionally equivalent protein. Deliberate amino acid substitutions can be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity and / or the amphipathic nature of the residues as long as the endogenous function is retained. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include asparagine, glutamine, serine, threonine and tyrosine.[000127] The term "homologue" as used herein refers to an entity having a certain homology with the reference (e.g., wildtype) amino acid sequence and / or the reference (e.g., wildtype) nucleotide sequence. The term "homology" can be equated with "identity". A homologous sequence can include an amino acid sequence which can be at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85% or 90% identical, such as at least 95% or 97% or 99% identical to the subject sequence. The homologues will comprise the same active sites etc. as the subject amino acid sequence. Although homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties / functions), in the context of the invention, homology can be expressed in terms of sequence identity.[000128] A homologous sequence can include a nucleotide sequence which can be at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85% or 90% identical, such as at least 95% or 97% or 99% identical to the subject sequence. Although homology can also be considered in terms of similarity, in the context of the invention, homology can be expressed in terms of sequence identity.[000129] In embodiments, reference to a sequence which has a percent identity to any one of the SEQ ID NOs detailed herein refers to a sequence which has the stated percent identity over the entire length of the SEQ ID NO referred to.[000130] Homology comparisons can be conducted by eye or, with the aid of readily available sequence comparison programs. These commercially available computer programs can calculate percentage homology or identity between two or more sequences.Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026[000131] Percentage homology can be calculated over contiguous sequences, i.e. one sequence is aligned with the other sequence and each amino acid in one sequence is directly compared with the corresponding amino acid in the other sequence, one residue at a time. This is called an "ungapped" alignment. Such ungapped alignments are performed only over a relatively short number of residues.[000132] Although this is a very simple and consistent method, it fails to take into consideration that, for example, in an otherwise identical pair of sequences, one insertion or deletion in the nucleotide sequence can cause the following codons to be put out of alignment, thus resulting in a large reduction in percent homology when a global alignment is performed. Consequently, sequence comparison methods can also be designed to produce optimal alignments that take into consideration possible insertions and deletions without penalising unduly the overall homology score. This is achieved by inserting "gaps" in the sequence alignment to try to maximize local homology.[000133] However, these more complex methods assign "gap penalties" to each gap that occurs in the alignment so that, for the same number of identical amino acids, a sequence alignment with as few gaps as possible, reflecting higher relatedness between the two compared sequences, will achieve a higher score than one with many gaps. " Affine gap costs" are used that charge a relatively high cost for the existence of a gap and a smaller penalty for each subsequent residue in the gap. This is the most commonly used gap scoring system. High gap penalties will of course produce optimized alignments with fewer gaps. Most alignment programs allow the gap penalties to be modified. However, one can use the default values when using such software for sequence comparisons. For example, when using the GCG Wisconsin Bestfit package the default gap penalty for amino acid sequences is -12 for a gap and -4 for each extension.[000134] Calculation of maximum percentage homology therefore firstly requires the production of an optimal alignment, taking into consideration gap penalties. A suitable computer program for carrying out such an alignment is the GCG Wisconsin Bestfit package (University of Wisconsin, U. S. A.; Devereux et al. (1984) Nucleic Acids Res. 12: 387). Examples of other software that can perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel et al. (1999) ibid - Ch. 18), FASTA (Atschul et al. (1990) J. Mol. Biol. 403-410) and the GENEWORKS suite of comparison tools. Both BLAST and FASTA are available for offline and online searching (see Ausubel et al. (1999) ibid, pages 7-58 to 7-60). However, for some applications, one can use the GCG Bestfit program. Another tool, called BLAST 2 Sequences, is also available for comparing protein and nucleotideDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 sequences (see FEMS Microbial. Lett. (1999) 174: 247-50; FEMS Microbial. Lett. (1999) 177: 187-8).[000135] Although the final percent homology can be measured in terms of identity, the alignment process itself is not based on an all-or-nothing pair comparison. Instead, a scaled similarity score matrix is used that assigns scores to each pairwise comparison based on chemical similarity or evolutionary distance. An example of such a matrix used is the BLOSUM62 matrix - the default matrix for the BLAST suite of programs. GCG Wisconsin programs use either the public default values or a custom symbol comparison table if supplied (see the user manual for further details). For some applications, one can use the public default values for the GCG package, or in the case of other software, the default matrix, such as BLOSUM62.[000136] Once the software has produced an optimal alignment, one can calculate percent homology, or even percent sequence identity. The software does this as part of the sequence comparison and generates a numerical result.[000137] " Fragments" of the synthetic peptide are also variants and the term refers to a selected region of the polypeptide or polynucleotide that is of interest either functionally or, for example, in an assay. " Fragment" therefore can refer to an amino acid or nucleic acid sequence that is a portion of a full-length polypeptide or polynucleotide.[000138] Such variants can be prepared using standard recombinant DNA techniques such as site-directed mutagenesis. Where insertions are to be made, synthetic DNA encoding the insertion together with 5' and 3' flanking regions corresponding to the naturally occurring sequence either side of the insertion site can be made. The flanking regions will contain convenient restriction sites corresponding to sites in the naturally occurring sequence so that the sequence can be cut with the appropriate enzyme(s) and the synthetic DNA ligated into the cut. The DNA is then expressed in accordance with the invention to make the encoded protein. These methods are only illustrative of the numerous standard techniques known in the art for manipulation of DNA sequences and other known techniques can also be used.[000139] The skilled person will understand that they can combine all features of the invention disclosed herein without departing from the scope of the invention as disclosed.[000140] Recombinant polynucleotides, such as those described herein, can be inserted into vectors for expression in cells (e.g., hepatocytes). As used herein, a “vector” is a replicon, such as a plasmid, phage, virus or cosmid, into which another DNA segment can be inserted so as to bring about the replication of the inserted segment. In some forms, the vector comprising the nucleic acid encoding NgBR is an expression vector. In eukaryotes the termDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 “expression vector” can refer to a vector that includes one or more expression control sequences regardless of the origin of the sequence (prokaryote or eukaryote). Nucleic acids in vectors can be operably linked to one or more expression control sequences. The term “expression control sequence” can refer to a DNA sequence that controls and regulates the transcription and / or translation of another DNA sequence. Control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, a ribosome binding site, and the like. For example, the control sequence can be incorporated into a genetic construct so that expression control sequences effectively control expression of a coding sequence of interest.[000141] Suitable expression vectors include, without limitation, plasmids and viral vectors derived from, for example, bacteriophage, baculoviruses, tobacco mosaic virus, herpes viruses, cytomegalo virus, retroviruses, vaccinia viruses, adenoviruses, and adeno-associated viruses. Numerous vectors and expression systems are commercially available from such corporations as Novagen (Madison, WI), Clontech (Palo Alto, CA), Stratagene (La Jolla, CA), and Invitrogen Life Technologies (Carlsbad, CA). Recent transfection studies have investigated minicircle DNA (mcDNA), nucleic acids that are derived from pDNA by recombination that removes bacterial sequences. The recombinant nucleic acids can be introduced into host cells using mcDNA using methods known in the art (Mun et al. Biomaterials, 2016;101:310-320).[000142] Nonviral vectors for oligonucleotide delivery include inorganic material-based delivery systems, lipid based nanocarriers, polymeric vectors, for example, poly(lactide-co-glycolide) (PLGA) is a copolymer of poly lactic acid (PLA) and poly glycolic acid 3D scaffoldbased delivery systems, chitosan, dendrimer based vectors, cell derived membrane vesicles and 3D scaffold-based delivery systems (reviewed in Fu, et al., ExRNA 1, 24 (2019). https: / / doi.org / 10.1186 / s41544-019-0024-y). In some forms, the vector is further modified for targeted delivery to the liver by incorporating a hepatocyte targeting moiety. A targeting approach was developed by binding a multivalent GalNAc-cluster to the LNP (lipid nanoparticles). These nanoparticles have been shown to deliver mRNA molecules to hepatocytes with high efficiency. An interesting case of liver targeting using LNPs is Onpattro, an LNP composed of an ionizable cationic lipid, a phospholipid, cholesterol, and a polyethylene glycol (PEG)-lipid carrying nucleic acid cargo (Reviewed in Maestro, et al., JHEP Rep. 2021 Apr 30;3(4): 100300. doi: 10.1016 / j.jhepr.202L 100300). Other methods of targeting LNP to the liver are reviewed in Kularatne et al. Pharmaceuticals (Basel). 2022 Jul 20;15(7):897. doi: 10.3390 / phl5070897.Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026[000143] In embodiments, the therapeutic polynucleotide encoding NgBR is delivered using a viral vector, including but not limited to adeno-associated virus (AAV) vectors.[000144] The gene sequence for AAV8-hNUSl is:CTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCAAAGCCCGGGCGTCGGGCGACC TTTGGTCGCCCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCC ATCACTAGGGGTTCCTTCTAGACAACTTTGTATAGAAAAGTTGCTAGCAGGTTAATT TTTAAAAAGCAGTCAAAAGTCCAAGTGGCCCTTGGCAGCATTTACTCTCTCTGTTTG C T C T GG T T AAT AAT C T CAGGAGCACAAACAT T C CAGAT C CAGG T T AAT T T T T AAAAA GCAGTCAAAAGTCCAAGTGGCCCTTGGCAGCATTTACTCTCTCTGTTTGCTCTGGTT AATAATCTCAGGAGCACAAACATTCCAGATCCGGCGCGCCAGGGCTGGAAGCTACCT T T GAG AT CATTTCCTCTGC GAAT GCATGTATAATTTC T AC AGAAC C T AT T AGAAAG G ATCACCCAGCCTCTGCTTTTGTACAACTTTCCCTTAAAAAACTGCCAATTCCACTGC TGTTTGGCCCAATAGTGAGAACTTTTTCCTGCTGCCTCTTGGTGCTTTTGCCTATGG CCCCTATTCTGCCTGCTGAAGACACTCTTGCCAGCATGGACTTAAACCCCTCCAGCT CTGACAATCCTCTTTCTCTTTTGTTTTACATGAAGGGTCTGGCAGCCAAAGCAATCA CTCAAAGTTCAAACCTTATCATTTTTTGCTTTGTTCCTCTTGGCCTTGGTTTTGTAC ATCAGCTTTGAAAATACCATCCCAGGGTTAATGCTGGGGTTAATTTATAACTAAGAG T GC T C TAGT T T T GCAATACAGGACAT GC TATAAAAAT GGAAAGAT GT T GC T T T C T GA GAGACTGCAGAAGTTGGTCGTGAGGCACTGGGCAGGTAAGTATCAAGGTTACAAGAC AGGTTTAAGGAGACCAATAGAAACTGGGCTTGTCGAGACAGAGAAGACTCTTGCGTT TCTGATAGGCACCTATTGGTCTTACTGACATCCACTTTGCCTTTCTCTCCACAGGTG TCCAGGCGGCCGCCAAGTTTGTACAAAAAAGCAGGCTGCCACCATGGACTACAAAGA C C AT GAG G G T GAT T AT AAAGAT CAT GAT AT C GAT T AC AAG GAT GAC GAT GAC AAGAT GACGGGGCTGTACGAGCTGGTGTGGCGGGTGCTGCACGCGCTGCTCTGTCTGCACCG CACGCTCACCTCCTGGCTCCGCGTTCGGTTCGGCACCTGGAACTGGATCTGGCGGCG CTGCTGCCGCGCCGCCTCTGCCGCGGTCCTAGCGCCGCTCGGCTTCACGCTCCGCAA GCCCCCGGCAGTCGGCAGGAACCGCCGTCACCACCGGCACCCGCGCGGGGGGTCGTG CCTGGCAGCCGCACACCACCGGATGCGCTGGCGCGCGGACGGTCGTTCCTTGGAGAA GCTGCCTGTGCATATGGGCCTGGTGATCACCGAGGTGGAGCAGGAACCCAGCTTCTC GGACATCGCGAGCCTCGTGGTGTGGTGTATGGCCGTGGGCATCTCCTACATTAGCGT C T AC GAC C AC C AAG G T AT T T T C AAAAGAAAT AAT T C CAGAT T GAT G GAT GAAAT T T T AAAACAACAGCAAGAAC T T C T GGGCC TAGAT T GT T CAAAATAC T CACCAGAAT T T GC AAATAGTAATGACAAAGATGATCAAGTTTTAAATTGCCATTTGGCAGTGAAGGTGCT GTCTCCGGAAGATGGAAAAGCAGATATTGTAAGAGCTGCTCAGGACTTTTGCCAGTT AG T AG C C C AGAAG C AAAAGAGAC C C AC AGAT T T G GAT G TAGAT AC G T T AG C C AG T T T ACTTAGTTCAAATGGTTGTCCTGATCCTGATTTAGTATTGAAGTTCGGTCCTGTGGA CAGCACATTAGGCTTTCTTCCCTGGCACATCAGATTGACTGAGATTGTCTCTTTGCC TTCCCACCTAAACATCAGTTATGAGGACTTTTTCTCTGCCCTTCGTCAATATGCAGC C T G T GAAC AG C G T C T G G GAAAG T AC C C AT AC GAT G T T C CAGAT T AC G C T T AGAC C C A GCTTTCTTGTACAAAGTGGGAATTCCGATAATCAACCTCTGGATTACAAAATTTGTG AAAGATTGACTGGTATTCTTAACTATGTTGCTCCTTTTACGCTATGTGGATACGCTG CTTTAATGCCTTTGTATCATGCTATTGCTTCCCGTATGGCTTTCATTTTCTCCTCCT TGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTTGTGGCCCGTTGTCAGGCAAC GTGGCGTGGTGTGCACTGTGTTTGCTGACGCAACCCCCACTGGTTGGGGCATTGCCA CCACCTGTCAGCTCCTTTCCGGGACTTTCGCTTTCCCCCTCCCTATTGCCACGGCGG AACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTG ACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTTCCATGGCTGCTCGCCTGTG TTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATC CAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTC GCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCATCGGGAATDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 TCCTAGAGCTCGCTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGT TTGCCCCTCCCCCGTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTC CTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGG GGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGAGAATAGCAGGCATGC TGGGGAGGGCCGCAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCT CGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCCCGG GCGGCCTCAGTGAGCGAGCGAGCGCGCAGCTGCCTGCAGGGGCGCCTGATGCGGTAT TTTCTCCTTACGCATCTGTGCGGTATTTCACACCGCATACGTCAAAGCAACCATAGT ACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGA CCGCTACACTTGCCAGCGCCTTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTC TCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGT TCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTTGGGTGATGGTT CACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCA CGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACTCTATCTCGG GCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGTCTATTGGTTAAAAAATG AG C T GAT T T AAC AAAAAT T T AAC G C GAAT T T T AAC AAAAT AT T AAC G T T T AC AAT T T TATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGAC ACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTT ACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCAT CACCGAAACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATG TCATGATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCG GAAC C C C T AT T T G T T T AT T T T T C T AAAT AC AT T C AAAT AT G T AT C C G C T C AT GAGAC AAT AAC C C T GAT AAAT G C T T C AAT AAT AT T GAAAAAG GAAGAG TAT GAG T AT T C AAC ATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTC ACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGG GTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAG AACGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCC GTATTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACT TGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAG AATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGA CAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATG TAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGC GTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCG AACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAG TTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAAT CTGGAGCCGGTGAGCGTGGAAGCCGCGGTATCATTGCAGCACTGGGGCCAGATGGTA AGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAAC GAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAG AC C AAG TTTACTCATATATACTT T AGAT T GAT T T AAAAC TTCATTTTTAATT T AAAA G GAT C TAG G T GAAGAT C C T T T T T GAT AAT C T CAT GAC C AAAAT C C C T T AAC G T GAG T TTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATC CTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGG TGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCA GCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACT TCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGG CTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTAC CGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGG AGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCA CGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAG GAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCG GGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGADocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 GCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGC CTTTTGCTCACATGTCCTGCAGGCAG [SEQ ID NO: 3][000145] Suitable AAV serotypes include hepatotropic, pancreatic-tropic, or systemically active serotypes. Viral vectors can optionally include enhancer elements, polyadenylation sequences, and regulatory control regions. Viral vector technology is well known in the art and is described, for example, in Sambrook et al., 2012, Molecular Cloning: A Laboratory Manual, volumes 1-4, Cold Spring Harbor Press, NY), and in other virology and molecular biology manuals. Viruses, which are useful as vectors include, but are not limited to, retroviruses, adenoviruses, adeno-associated viruses, herpes viruses, and lentiviruses. A suitable vector contains an origin of replication functional in at least one organism, a promoter sequence, convenient restriction endonuclease sites, and one or more selectable markers, (e.g., WO 01 / 96584; WO 01 / 29058; and U. S. Pat. No. 6,326,193). Exemplary viral vectors include but are not limited to lentiviral vector, an Adeno-associated virus (AAV) vector, or an adenovirus vector, or a Herpes Simplex virus (HSV) vector, or a vesicular stomatitis (VSV) vector, or a human Bocavirus vector (hBoV), or a chimeric vector containing a combination of any two or more of an Adeno-associated virus (AAV) vector, Herpes Simplex virus (HSV) vector, vesicular stomatitis (VSV) vector, or a human Bocavirus vector (hBoV).[000146] Adenovirus expression vectors are based on adenoviruses, which have a low capacity for integration into genomic DNA but are highly efficient for transfecting host cells. Adenovirus expression vectors contain adenovirus sequences sufficient to: (a) support packaging of the expression vector and (b) to ultimately express the recombinant nucleic acids in the host cell. In some embodiments, the adenovirus genome is a 36 kb, linear, double stranded DNA, where a foreign DNA sequence (e.g., a nucleic acid for generating the expression system) can be inserted to substitute large pieces of adenoviral DNA in order to make the expression vector (see, e.g., Danthinne and Imperiale, Gene Therapy (2000) 7(20): 1707-1714). Adeno associated viruses take advantage of the adenovirus coupled systems. This AAV expression vector has a high frequency of integration into the host genome. It can infect non-dividing cells, thus making it useful for delivery of genes into mammalian cells, for example, in tissue cultures or in vivo. The AAV vector has a broad host range for infectivity. Details concerning the generation and use of AAV vectors are described in U. S. Pat. Nos.5,139,941 and 4,797,368, which are incorporated herein in their entireties. Adeno-associated viruses (AAVs) are widely used vectors for gene therapy due to their ability to deliver genetic material to a variety of cell types with minimal immunogenicity. AAV is a useful vehicle for transferring therapeutic genes in patients with genetic disorders. For example, ~1015intactDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 AAV particles carrying DNA cargo of therapeutic gene of interest are required for a single dose. These particles are produced using human or insect cell lines along with defective particles.[000147] As used herein, the term “adeno-associated virus” (AAV), includes but is not limited to, AAV type 1, AAV type 2, AAV type 3 (including types 3 A and 3B), AAV type 4, AAV type 5, AAV type 6, AAV type 7, AAV type 8, AAV type 9, AAV type 10, AAV type 11, AAV type 12, AAV type 13, snake AAV, avian AAV, bovine AAV, canine AAV, equine AAV, ovine AAV, goat AAV, shrimp AAV, engineered serotypes (such as AAV-DJ, AAV-DJ / 8) and any other AAV now known or later discovered. See, e.g., FIELDS et al. VIROLOGY, volume 2, chapter 69 (4th ed., Lippincott-Raven Publishers). Other AAV serotypes and clades have been identified (See, e.g., Gao etal., J. Virol. 78:6381 (2004); Moris et al., Virol. 33:375 (2004). In some forms, the AAV is AAV8 or AAV9, which exhibit strong preference for hepatocytes, for example, they are more efficient at delivering genes to these cells compared to other AAV serotypes.[000148] Retrovirus expression vectors can integrate into the host genome, delivering a large amount of foreign genetic material, infecting a broad spectrum of species and cell types and being packaged in special cell lines. The retrovirus vector is constructed by inserting a nucleic acid (e.g., the recombinant nucleic acids for generating the expression system) into the viral genome at certain locations to produce a virus that is replication defective. Though the retrovirus vectors are able to infect a broad variety of cell types, integration and stable expression of the recombinant nucleic acids requires the division of host cells.[000149] Lentivirus vectors are derived from lentiviruses, which are complex retroviruses that, in addition to the common retroviral genes gag, pol, and env, contain other genes with regulatory or structural function (see, e.g., U. S. Pat. Nos. 6,013,516 and 5,994,136). Some examples of lentiviruses include the Human Immunodeficiency Viruses (HIV-1, HIV-2) and the Simian Immunodeficiency Virus (SIV). Lentivirus vectors have been generated by multiply attenuating the HIV virulence genes, for example, the genes env, vif, vpr, vpu and nef are deleted making the vector biologically safe. Lentivirus vectors can infect non-dividing cells and can be used for both in vivo and ex vivo gene transfer and expression, e.g., of the recombinant nucleic acids (see, e.g., U. S. Pat. No. 5,994,136).[000150] An expression vector can include a selectable marker, an origin of replication, and other features that provide for replication and / or maintenance of the vector. Large numbers of suitable vectors and promoters are known to those of skill in the art; many are commercially available for generating a recombinant construct. Exemplary vectors include but are not limitedDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 pBs, phagescript, PsiX174, pBluescript SK, pBs KS, pNH8a, pNH16a, pNH18a, pNH46a (Stratagene, La Jolla, Calif., USA); pTrc99A, pKK223-3, pKK233-3, pDR540, and pRIT5 (Pharmacia, Uppsala, Sweden), pWLneo, pSV2cat, pOG44, PXR1, pSG (Stratagene) pSVK3, pBPV, pMSG and pSVL (Pharmacia).[000151] Along these lines, aspects of the invention are drawn to a cell (e.g., a mammalian cell, such as a hepatic cell) and / or a population of cells comprising a polynucleotide (e.g., nucleic acid) encoding recombinant NgBR. In embodiments, the nucleic acid(s) as disclosed herein is in a vector for delivery and expression in said cell or population of cells.[000152][000153] Small Molecule Activator of NgBR[000154] In embodiments, the NgBR activator can be a small molecule compound that can increase NgBR expression or signaling. Non-limiting examples of small molecule NgBR activators include caffeine, statins (e.g., Atorvastatin (Lipitor), Rosuvastatin (Crestor), Simvastatin (Zocor), Lovastatin (Altoprev), Pravastatin (Pravachol), Fluvastatin (Lescol), and Pitavastatin (Livalo), and PPAR agonists (e.g., Thiazolidinediones, such as Pioglitazone, Rosiglitazone).[000155] As used herein, the term “statin” can refer to a class of compounds that inhibit 3 -hydroxy-3 -methylglutaryl-coenzyme A (HMG-CoA) reductase, thereby reducing cholesterol biosynthesis. Statins include both naturally derived and synthetic HMG-CoA reductase inhibitors, as well as pharmaceutically acceptable salts, esters, prodrugs, metabolites, analogues, and derivatives thereof, that retain HMG-CoA reductase inhibitory activity or associated biological activity. Statins have been when to inhibit NAFLD (nonalcoholic fatty liver disease) mainly through activation of NgBR expression. Zhang, et al., Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 1863(2) 177-190 (2018). Exemplary statins include, but are not limited to, Atorvastatin (Lipitor), Rosuvastatin (Crestor), Simvastatin (Zocor), Lovastatin (Altoprev), Pravastatin (Pravachol), Fluvastatin (Lescol), and Pitavastatin (Livalo). Statins are a class of medications primarily used to lower cholesterol levels, such as LDL cholesterol, often referred to as "bad" cholesterol, in the blood.[000156] In embodiments, the NgBR activator can comprise a statin when the subject does (a) have high cholesterol (LDL above 190 mg / dL); (b) have an LDL above 160 mg / dL, a family history of early coronary artery disease and are 20 to 39 years old; (c) have a history of a stroke, heart attack or peripheral artery disease (PAD); (d) have diabetes and an LDL of at least 70 mg / dL and are 40 to 75 years old; or (e) Have an LDL of at least 70 mg / dL and a high risk of getting heart disease and are 40-75 years old.Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026[000157] As used herein, the term “PPAR agonist” can refer to any compound that binds to and activates a peroxisome proliferator-activated receptor (PPAR), including PPAR-a, PPAR-p / 6, and PPAR-y, thereby modulating gene expression involved in metabolic, inflammatory, lipid, or insulin-regulatory pathways. PPAR agonists include selective agonists, dual agonists, and pan-PPAR agonists, as well as partial agonists, modulators, and functional equivalents that elicit PPAR-mediated biological activity. PPAR agonists can be naturally occurring or synthetic compounds, and include pharmaceutically acceptable salts, esters, prodrugs, metabolites, analogues, and derivatives thereof that retain PPAR-activating activity. Non-limiting examples of PPAR agonists include thiazolidinediones (e.g., pioglitazone, rosiglitazone), fibrates (e.g., fenofibrate, bezafibrate, gemfibrozil), and pan-PPAR agonists (e.g., lanifibranor, GW501516). Ma et al., Frontiers in Pharmacology, 12:817784 (2022) showed that Pioglitazone and Rosiglitazone increased NgBR expression by binding the PPAR responsive elements in the promoter of NgBR.[000158][000159] B. GLP-1 receptor agonist[000160] GLP-1RA (also known as incretin mimetics, or GLP-1 analogs) represents a class of medications used to treat type 2 diabetes mellitus and, in some cases, obesity. The terms “GLP-1 receptor agonist” or “GLP-1RA” can refer to any compound that binds to and activates the glucagon-like peptide- 1 receptor, including peptide agonists, dual or multi -agonists, oral or injectable formulations, and long-acting analogs. Non-limiting examples of GLP-lRAs include exenatide, lixisenatide, liraglutide, albiglutide, dulaglutide, semaglutide, orfoglipron, retatrutide, CagriSema (semaglutide with cagrilintide), tirzepatide, and mazdutide.[000161][000162] C. NgBR Activator and GLP-1R Agonist Combination Therapy [000163] In embodiments, the disclosed NgBR activators (e.g., a polynucleotide or nucleic acid encoding NgBR, or a small molecule activator) can be administered in combination with a glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA). As used herein, the term “combination therapy” can refer to a therapeutic regimen in which two or more distinct active agents (e.g., a NgBR activator and a glucagon-like peptide-1 receptor agonist) are administered to a subject as part of a coordinated treatment strategy to achieve a therapeutic benefit (e.g., glycemic control). The active agents can be administered simultaneously or sequentially, together or separately, and can be delivered in a single composition, in separate compositions, or as part of a kit or treatment protocol.Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026[000164] The components of a combination therapy can be administered by the same or different routes, at the same or different dosing frequencies, and over overlapping or non-overlapping periods of time, provided that the therapeutic effects of the agents are intended to occur in a combined or complementary manner.[000165] A combination therapy can result in additive, synergistic, or enhanced therapeutic effects, including improved efficacy, reduced dosing requirements, improved durability of response, or reduced adverse effects, as compared to administration of any single agent alone. The term “combination therapy” expressly includes regimens in which one component enhances, potentiates, or supports the activity of another component, regardless of whether the agents act through the same or different biological mechanisms.[000166] The present invention is based, in part, on the surprising discovery that activation of Nogo-B receptor (NgBR) in combination with GLP-1 receptor agonism provides synergistic and complementary therapeutic effects in the prevention and treatment of diabetes-associated symptoms. GLP-1 receptor agonists are known to enhance glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite. However, clinical outcomes in certain diabetic populations, such as subjects with beta cell dysfunction, insulin resistance, dyslipidemia, hepatic metabolic dysregulation, or vascular complications, remain suboptimal when GLP-1RA therapy is used alone. NgBR activation addresses metabolic and cellular pathways that are distinct from, yet mechanistically complementary to, GLP-1 receptor signaling. Accordingly, the combination therapy disclosed herein improves therapeutic efficacy, durability of response, and metabolic homeostasis across multiple organ systems.[000167] In embodiments, NgBR activation enhances the cellular responsiveness to GLP-1 receptor signaling, thereby lowering the effective dose of GLP-1RA required to achieve glycemic control. In other embodiments, GLP-1RA administration potentiates the metabolic benefits of NgBR activation. The combination therapy can therefore exhibit 1) additive effects, wherein the combined benefit exceeds that of either agent alone; 2) synergistic effects, wherein the combined benefit exceeds the sum of individual effects; and / or 3) dose-sparing effects, allowing reduced dosing of one or both agents.[000168] The NgBR activator and GLP-1RA can be administered in a variety of combination formats including, but not limited to simultaneous administration, sequential administration, and / or overlapping administration. The term “simultaneous administration” can refer to administration wherein both agents are administered at substantially the same time. The term “sequential administration” can refer to administration wherein one agent isDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 administered before or after the other. The term “overlapping administration” can refer to administration wherein initiation of the second agent occurs during ongoing treatment with the first agent.[000169][000170] D. Pharmaceutical Composition[000171] In embodiments, the NgBR activator (e.g., a nucleic acid encoding NgBR or a small molecule activator) and / or the glucagon-like peptide-1 receptor agonist (GLP-1RA) can be formulated into pharmaceutical compositions. The components of the composition(s) can be formulated together in a single pharmaceutical formulation or provided as separate formulations intended for combined use. The effective amounts of the NgBR activator and the GLP-1RA are selected to provide a therapeutic effect in preventing, reducing, or ameliorating one or more symptoms associated with diabetes.[000172] These compositions can comprise, in addition to the NgBR activator (e.g., a nucleic acid encoding NgBR or a small molecule activator) and / or the glucagon-like peptide-1 receptor agonist (GLP-1RA), a pharmaceutically acceptable carrier, diluent, excipient, buffer, stabilizer or other materials well known in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material can be determined by the skilled person according to the route of administration.[000173] Conventional excipients and accessory ingredients can be used in any pharmaceutical composition, except insofar as any conventional excipient or accessory ingredient is incompatible with one or more components of a pharmaceutical composition. An excipient or accessory ingredient can be incompatible with a component of a pharmaceutical composition if its combination with the component can result in any undesirable biological effect or otherwise deleterious effect.[000174] Relative amounts of the one or more components (e.g., the therapeutic nucleic acid molecule encoding soluble Nogo-B), the one or more pharmaceutically acceptable excipients, and / or any accessory ingredients in a pharmaceutical composition in accordance with the present disclosure will vary, depending upon the identity, size, and / or condition of the subject treated and further depending upon the route by which the composition is to be administered.[000175] Pharmaceutical compositions can be prepared in a variety of forms suitable for a variety of routes and methods of administration. For example, pharmaceutical compositions can be prepared in liquid dosage forms (e.g., emulsions, microemulsions, nanoemulsions,Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026 solutions, suspensions, syrups, and elixirs), injectable forms, solid dosage forms (e.g., capsules, tablets, pills, powders, and granules), dosage forms for topical and / or transdermal administration (e.g., ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, and patches), suspensions, powders, and other forms. General guidelines for the formulation and manufacture of pharmaceutical compositions and agents are available, for example, in Remington’s The Science and Practice of Pharmacy, 21st Edition, A. R. Gennaro; Lippincott, Williams & Wilkins, Baltimore, Md., 2006.[000176] For example, the compositions can be in solid or liquid form, suitable for oral, parenteral, intravenous or intra-arterial administration. The pharmaceutical composition is in liquid form. Liquid pharmaceutical compositions include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, magnesium chloride, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol can be included. In some cases, a surfactant, such as pluronic acid (PF68) 0.001% can be used.[000177] For injection at the site of affliction, the active ingredient(s) can be in the form of an aqueous solution which is pyrogen-free, and has suitable pH, isotonicity and stability. The skilled person is well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection or Lactated Ringer's Injection. Preservatives, stabilizers, buffers, antioxidants and / or other additives can be included as required.[000178] For delayed release, the active ingredient(s) may be included in a pharmaceutical composition which is formulated for slow release, such as in microcapsules formed from biocompatible polymers or in liposomal carrier systems according to methods known in the art. Such compositions are well-known in the art, see for example Remington's Pharmaceutical Sciences; last edition, Mack Pub.[000179][000180] III. METHODS[000181] A. Method of Treating Diabetes[000182] As described herein, aspects of the invention are drawn towards methods of treating or preventing one or more symptoms (e.g., impaired insulin sensitivity, impaired glycemic control, and glucose intolerance) associated with diabetes in a subject (e.g., a type I diabetic, or a type II diabetic, or a subject that has beta cell dysfunction), such as by administering to the subject an effective amount of an NgBR activator (e.g., a nucleic acid encoding the NgBR in an expression vector, such as an AAV, or a small molecule activator,Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026 such as caffeine, a statin, or a PPAR agonist), together with a GLP-1RA (e.g., exenatide, lixisenatide, liraglutide, albiglutide, dulaglutide, semaglutide, orfoglipron, retatrutide, CagriSema (semaglutide with cagrilintide), tirzepatide, and mazdutide).[000183] In embodiments, the methods described herein are applicable to subjects in need of glycemic control, such as subjects with Type I diabetes and / or Type II diabetes, such as subjects exhibiting beta cell dysfunction, impaired insulin secretion, insulin resistance, or metabolic syndrome features.[000184] In embodiments, the methods described herein are applicable to subjects requiring long-term glycemic control, such as those with chronic diabetes.[000185] In some forms, the subject has been diagnosed with Type I diabetes, and the disclosed embodiments are effective for glycemic control in the subject. Currently approved treatment options for glycemic control in T1DM include insulin, which combats insulin deficiency but does not effectively target disease progression or alpha cell dysfunction; and pramlintide, whose use requires multiple daily doses and involves a high likelihood of gastrointestinal side effects.[000186] In some forms, the subject has been diagnosed with Type II diabetes, such as with beta cell dysfunction, and the disclosed embodiments are effective for glycemic control in the subject. Beta cell dysfunction can refer to the impaired ability of pancreatic beta cells to produce and release insulin. Beta cells are specialized cells located within the pancreatic islets, which are clusters of cells within the pancreas. Their primary function is to produce and release insulin in response to rising blood glucose levels. When beta cells become dysfunctional, they can't produce enough insulin or release it effectively, leading to elevated blood glucose levels. Beta cell dysfunction is determined by assessing their ability to produce and release insulin in response to changes in blood glucose levels. This can be done through various methods, including measuring the proinsulin to insulin ratio, the homeostatic model assessment (HOMA), and functional tests like the hyperglycemic clamp test and intravenous glucose tolerance test (IVGTT).[000187] Hyperglycemic clamp test: This test involves maintaining a high blood glucose level and measuring the subsequent insulin response from the beta cells.[000188] Intravenous glucose tolerance test (IVGTT): IVGTT measures how quickly and to what extent the body's glucose levels rise and fall after an injection of glucose.[000189] Oral glucose tolerance test (OGTT): OGTT assesses the body's response to glucose intake, similar to IVGTT but with glucose taken orally.Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026[000190] Mixed meal tolerance test (MMTT): MMTT evaluates the insulin response to a mixed meal, mimicking a dietary intake.[000191] Glucose-potentiated arginine stimulation test: This test combines glucose and arginine to further stimulate insulin release and assess beta cell function.[000192] Proinsulin to Insulin Ratio (PI / I) Ratio: This ratio reflects the efficiency of the beta cells in converting proinsulin to insulin, a key indicator of beta cell function.[000193] Nucleic Homeostatic Model Assessment (HOMA): HOMA uses fasting glucose and insulin levels to calculate a measure of insulin sensitivity and beta cell function.[000194][000195] B. Methods of Treating Obesity[000196] Aspects of the invention are also drawn towards methods of treating or preventing obesity in a subject (including but not limited to subjects afflicted with Type I diabetes, or type II diabetes, or a subject that has beta cell dysfunction), such as by administering to the subject an effective amount of an NgBR activator (e.g., a nucleic acid encoding the NgBR in an expression vector, such as an AAV, or a small molecule activator, such as caffeine, a statin, or a PPAR agonist), together with a GLP-1RA (e.g., exenatide, lixisenatide, liraglutide, albiglutide, dulaglutide, semaglutide, orfoglipron, retatrutide, CagriSema (semaglutide with cagrilintide), tirzepatide, and mazdutide).[000197] In some form, the subject has been diagnosed with obesity. Obesity can refer to a medical condition characterized by excessive accumulation of body fat associated with adverse health effects, including a body mass index (BMI) of 30 kg / m2or greater, increased adiposity, or abnormal fat distribution, as well as related metabolic, endocrine, or inflammatory dysfunctions. The term “obesity” encompasses clinical obesity, morbid obesity, central or visceral obesity, and other conditions of excess body weight or adipose tissue recognized as contributing to metabolic disease.[000198] As described herein, aspects of the invention are drawn towards methods of treating or preventing one or more symptoms (e.g., impaired insulin sensitivity, impaired glycemic control, and glucose intolerance) associated with diabetes and / or obesity in a subject. In embodiments, for example, the subject’s blood glucose levels, daily body weight, or both blood glucose levels and daily body weight reduces following administration of an NgBR activator (e.g., a nucleic acid encoding the NgBR in an expression vector, such as an AAV, or a small molecule activator, such as caffeine, a statin, or a PPAR agonist), optionally in combination with a GLP-1RA. As shown in the examples herein, when combined, GLP-1 RA and the NgBR activator (e.g., a nucleic acid encoding the NgBR in an expression vector, suchDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 as an AAV, or a small molecule activator, such as caffeine, a statin, or a PPAR agonist) produce the strongest benefit in blood glucose control (e.g., as shown in FIG. 1, absence of NgBR in hepatocytes impairs the efficacy of GLP-1RA and restoration of NgBR enhances the efficacy of GLP-lRAs on blood glucose control).[000199][000200] C. Methods of Treating Fatty Liver Disease[000201] Aspects of the invention are also drawn towards methods of treating or preventing fatty liver disease in a subject, such as by administering to the subject an effective amount of an NgBR activator (e.g., a nucleic acid encoding the NgBR in an expression vector, such as an AAV, or a small molecule activator, such as caffeine, a statin, or a PPAR agonist), together with a GLP-1RA (e.g., exenatide, lixisenatide, liraglutide, albiglutide, dulaglutide, semaglutide, orfoglipron, retatrutide, CagriSema (semaglutide with cagrilintide), tirzepatide, and mazdutide).[000202] In some form, the subject has been diagnosed with fatty liver disease. Fatty liver disease can refer to a condition characterized by excess accumulation of lipids in hepatocytes, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as fatty liver conditions associated with metabolic dysfunction, obesity, insulin resistance, diabetes, or dyslipidemia. The term encompasses both simple hepatic steatosis and progressive forms involving inflammation, fibrosis, cirrhosis, or liver dysfunction, regardless of etiology.[000203] As described herein, aspects of the invention are drawn towards methods of treating or preventing one or more symptoms associated with fatty liver disease in a subject. In embodiments, for example, NgBR overexpression in the liver can reduce fatty liver in a subject caused by high-fat diet feeding (e.g., as shown in FIG. 30, AAV-mediated overexpression of NgBR (FIG. 30E) in the hepatocyte restores the beneficial effects of GLP1-RA on reducing fatty liver to a healthy condition, indicating that NgBR is essential for GLP-lRAs to reduce fatty liver).[000204][000205] D. Methods of Administration[000206] A variety of administration routes and techniques can be utilized to administer to a subject the polynucleotide or vector of the invention, among them parenteral techniques such as intravenous, intracardiac and intra-arterial injections, catheterization and the like. Average quantities of the polynucleotide or vector of the invention can vary and in particular should be based upon the recommendations and prescription of a qualified physician.Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026[000207] The polynucleotide or vector of the invention can be administered systemically (for example by peripheral vein infusion) or can be administered locally or regionally.[000208] In embodiments, the polynucleotide or vector of the invention is administered by parenteral route, such as intravenous, intraarterial or intramyocardial route.[000209] The administration, regime, dosage and posology will be determined by the physician according to his experience, the disease to be treated and the patient's conditions.[000210] In embodiments, the NgBR activator and / or the GLP-1RA are administered at therapeutically effective dosages. In some embodiments, the NgBR activator and / or the GLP-1RA are administered 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, or more times until no longer indicated as being needed. In some embodiments, the NgBR activator and / or the GLP-1RA are administered 1, 2, or 3 times a day until no longer indicated as being needed. In some embodiments, the NgBR activator and / or the GLP-1RA are administered daily. In some embodiments, the NgBR activator and / or the GLP-1RA are administered every day, every 2 days, every 3 days, every 4 days, every 5 days, every 6 days, every 7 days, every 8 days, every 9 days, every 10 days, or more. In some embodiments, the NgBR activator and / or the GLP-1RA are administered every week, every 2 weeks, every 3 weeks, every 4 weeks, or more. In some embodiments, the NgBR activator and / or the GLP-1RA are administered every month, every 2 months, every 3 months, every 4 months, every 5 months, every 6 months, every 7 months, every 8 months, every 9 months, every 10 months, every 11 months, every 12 months, or more. In some embodiments, the NgBR activator and / or the GLP-1RA are administered every year, every 2 years, every 3 years, every 4 years, every 5 years, or more. In some embodiments, the NgBR activator and / or the GLP-1RA are administered for at least 10 days, and up to one month, optionally, daily. In some embodiments, the NgBR activator and / or the GLP-1RA are administered at a first effective dose for at least two weeks, followed by administration of a second effective dose (the maintenance dose), wherein the maintenance dose is at least half, a third or a quarter of the first effective dose. In some embodiments, the NgBR activator and / or the GLP-1RA are administered for at least one month.[000211] In some embodiments, administration of the NgBR activator and / or the GLP-1RA can be sequential, concurrent, or alternating.Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026[000212] In some forms, the effective amount of the GLP-1RA when administered in combination with NgBR activator is less than the effective amount of the GLP-1RA is administered without the NgBR activator.[000213] In some forms, the effective amount of GLP-1RA when administered in combination with an NgBR activator is less than the effective amount of the GLP-1RA is administered without the NgBR activator.[000214] In some forms, the NgBR activator is a nucleic acid encoding the NgBR in an expression vector.[000215] In some forms, the NgBR activator is a small molecule such as caffeine or a statin. Providers prescribe statins for people who: (a) have high cholesterol (LDL above 190 mg / dL) and can’t reduce it by changing their eating and physical activity habits; (b) have an LDL above 160 mg / dL, a family history of early coronary artery disease and are 20 to 39 years old; (c) have a history of a stroke, heart attack or peripheral artery disease (PAD); (d) have diabetes and an LDL of at least 70 mg / dL and are 40 to 75 years old; or (e) have an LDL of at least 70 mg / dL and a high risk of getting heart disease and are 40 to 75 years old.[000216] In some forms, when the NgBR activator is caffeine, the subject being treated does not have any the co-morbidities for which statin is prescribed, for example, the conditions listed in (a)- (e) herein.[000217] The disclosed compositions and methods can be further understood through the following examples.[000218][000219] IV. Other Embodiments[000220] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of chemistry, biochemistry, molecular biology, microbiology and immunology, which are within the capabilities of a person of ordinary skill in the art. Such techniques are explained in the literature. See, for example, Sambrook, J., Fritsch, E. F. and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press; Ausubel, F. M. et al. (1995 and periodic supplements) Current Protocols in Molecular Biology, Ch. 9, 13 and 16, John Wiley & Sons; Roe, B., Crabtree, J. and Kahn, A. (1996) DNA Isolation and Sequencing: Essential Techniques, John Wiley & Sons; Polak, J. M. and McGee, J. O'D. (1990) In Situ Hybridization: Principles and Practice, Oxford University Press; Gait, M. J. (1984) Oligonucleotide Synthesis: A Practical Approach, IRL Press; and Lilley, D. M. and Dahlberg, J. E. (1992) Methods in Enzymology: DNADocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 Structures Part A: Synthesis and Physical Analysis of DNA, Academic Press. Each of these general texts is herein incorporated by reference.[000221] While the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.[000222] The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.EXAMPLES[000223] Example 1[000224] Materials and Methods[000225] Animal studies[000226] C57BL / 6 mice (male, 6-week-old) were purchased from the Jackson Laboratory and received scheduled treatment as indicated in FIG. 1A. NGBRfl / flmice were crossbred with albumin-specific Cre mice [Alb-Cre, B6. CgTg(Alb-cre)21Mgn / J] (The Jackson Laboratory) on a C57BL / 6J background. Alb-Cre efficiently induces hepatocyte-specific recombination of floxed genes to generate NGBRhepKOmice. The protocols for animal studies were approved by the Institutional Animal Care and Use Committee of NYU Langone Health. Animals were housed in a temperature-controlled environment with a 12 / 12 h light / dark cycles. Mice had free access to water and standard rodent chow. The studies were performed in compliance with the Guide for the Care and Use of Laboratory Animals published by the NIH.[000227] At 12 weeks of age, mice began a high-fat diet (HFD). After 12 weeks on the HFD, GLP-1RA (semaglutide) was administered at a dose of 35 pg / kg body weight for 14 weeks (FIG. 1A). After 14 weeks of GLP-1RA injection, insulin tolerance tests (ITT) and glucose tolerance tests (GTT) were performed. For the NgBR AAV rescue groups, mice were i.v. injected once with AAV8-NgBR (named as T2D+NgBR group) at a dose of 1 x 1012viral genomes (vg) per mouse.[000228] Twelve-week-old male C57BL / 6 mice were used for the experiments to determine the effect of GLP-1RA on type 1 diabetes. A single intraperitoneal injection of streptozotocin (STZ) at a dose of 200 mg / kg body weight was administered to induce type 1 diabetes, which was confirmed two weeks later. GLP-1RA (semaglutide) treatment began immediately following the STZ injection at a dose of 70 pg / kg body weight for two weeks. Bodyweight, and 12-h fasting glucose levels were monitored weekly. At the end of experiment,Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026 mice were anesthetized and euthanized in a CO2 chamber, followed by collection of blood and tissue samples.[000229] GTT and ITT[000230] GTT and ITT were carried out after 14 days of GLP-1RA injection. For GTT, mice were orally intraperitoneally administered with glucose (0.52 g / kg bodyweight) after 12-h fasting, followed by determination of blood glucose levels at the indicated time points. To conduct ITT in the nondiabetic (NgBRfl / fland NgBRhepKO) mice, the animals were preadministrated glucose (0.5 g / kg bodyweight) for 2 h after 12-h intraperitoneally administered a fasting, then continued insulin (0.01U) injection and a blood glucose test as described herein.[000231] Results[000232] Hepatic NgBR is essential for the glycemic control of GLP-1R agonists in obesity-caused T2D[000233] FIG. 1A and FIG. IB show that hepatic NgBR is essential for the glycemic control of GLP-1R agonists in obesity-induced T2D mice. Body weight measurements and blood glucose levels of mice were observed. At 12 weeks of age, the mice began a high-fat diet (HFD). After 12 weeks on the HFD, GLP-1RA (semaglutide) was administered at a dose of 35 pg / kg body weight for 14 weeks.[000234] No significant difference in body weight was observed among the groups (FIG. IB). However, NgBR hepKO mice with NgBR AAV rescue (restoring hepatic NgBR) showed significantly decreased blood glucose levels. The littermate control (NgBR fl / fl) group maintained lower blood glucose levels, whereas NgBR hepKO mice exhibited persistently high blood glucose levels despite the GLP-1RA treatment (FIG. 1C). These results indicate that the absence of NgBR in hepatocytes impairs the efficacy of GLP-1RA, while restoration of NgBR enhances the efficacy of GLP-lRAs on blood glucose control.[000235] Hepatic NgBR is essential for the glycemic control of GLP -1R agonists by improving insulin sensitivity[000236] After 14 weeks of GLP-1RA injection, insulin tolerance tests (ITT) and glucose tolerance tests (GTT) were performed. (FIG. 2A and 2B). The ITT results indicate that the AAV-mediated restoration of NgBR expression in the NgBR hepKO liver enhances insulin sensitivity compared to both NgBR fl / fl mice and NgBR hepKO mice. The insulin resistance observed in NgBR fl / fl mice is attributed to NgBR loss following 12 weeks of HFD feeding.(FIG. 2C and 2D) The subsequent week saw the GTT being conducted, revealing higher glucose levels in NgBR hepKO mice compared to the other groups. These findings indicate that the absence of NgBR in hepatocytes diminishes the efficacy of GLP- IRA, resulting inDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 impaired insulin sensitivity and glucose tolerance; however, restoration of NgBR can enhance insulin sensitivity.[000237] GLP1R agonists cannot achieve the complete response on glycemic control in Type 1 diabetes, and hepatic NgBR restoration improves the efficacy of GLP1R agonist [000238] Blood glucose levels in type 1 diabetic mice were assessed. Twelve-week-old male mice were used for the experiments. A single intraperitoneal injection of streptozotocin (STZ) at a dose of 200 mg / kg body weight was administered to induce type 1 diabetes, which was confirmed two weeks later. GLP-1RA (semaglutide) treatment began immediately following the STZ injection at a dose of 70 pg / kg body weight for two weeks.[000239] No significant differences in body weight were observed among the groups. The NgBR hepKO mice showed persistently elevated glucose levels despite GLP-1RA treatment. In contrast, NgBR hepKO mice receiving NgBR AAV rescue (restoring hepatic NgBR) exhibited a significant reduction in blood glucose levels (FIG.3). These findings indicate that the expression of NgBR in hepatocytes is critical for the glucose-lowering efficacy of GLP-1RA in the context of type 1 diabetes.[000240][000241] Example 2[000242] Hepatic NgBR is Essential for KAT7-Dependent Regulation of Adiponectin Receptor and Adiponectin Sensitivity[000243] Hepatic NgBR loss drives adiponectin resistance, uncoupling AdipoRl / AdipoR2 signaling from metabolic control. NgBR deficiency suppresses KAT7-dependent transcription of AdipoRl / AdipoR2, thereby sustaining gluconeogenic gene expression despite adiponectin agonism. AdipoRon improves glycemic control in controls but not in NgBR-deficient liver, defining a state of hepatic adiponectin unresponsiveness. AAV-mediated NgBR restoration re-sensitizes the liver to adiponectin and normalizes glucose homeostasis, independent of insulin resistance.[000244] Abstract[000245] Adiponectin signaling is crucial for hepatic glucose homeostasis, but the molecular mechanisms regulating adiponectin receptor responsiveness remain poorly understood. In this study, we identify the Nogo-B receptor (NgBR) as a key hepatic regulator of adiponectin sensitivity. By integrating multi-species transcriptomic datasets from humans, cynomolgus monkeys, and mice, we observed that hepatic NgBR expression is consistently reduced in obesity and type 2 diabetes. Furthermore, NgBR levels showed a strong positive correlation with AdipoRl and AdipoR2 expression and an inverse relationship with theDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 gluconeogenic genes G6PC and PCK1. Using hepatocyte-specific NgBR-deficient mice (NgBR HepKO) and adeno-associated virus (AAV)-mediated NgBR rescue models, we demonstrate that NgBR is essential for the metabolic actions of adiponectin. Loss of NgBR abolished the transcriptional and physiological responses to the adiponectin agonist AdipoRon, leading to impaired AMPK phosphorylation, sustained gluconeogenesis, and a significant accumulation of hepatic ceramides. Mechanistically, NgBR deficiency suppressed KAT7 expression and reduced histone acetylation (H3K14 and H4K5) at the AdipoRl and AdipoR2 promoters, which diminished adiponectin receptor transcription. Restoration of NgBR expression via AAV gene delivery reinstated KAT7-dependent histone acetylation at adiponectin receptor promoters and fully re-established adiponectin sensitivity and glucose homeostasis. These findings identify NgBR as a central hepatic determinant of adiponectin receptor functionality and uncover an NgBR-KAT7 regulatory module that integrates epigenetic control of adiponectin signaling with ceramide and glucose homeostasis.[000246] Introduction[000247] Obesity and type 2 diabetes (T2D) are the primary metabolic disorders of modern society, affecting over 460 million people worldwide and expected to surpass 1.31 billion by 2050. At the molecular level, both conditions involve a gradual breakdown in nutrient and hormonal signaling among fat tissue, the liver, and muscles. The hormone adiponectin, derived from fat cells, is central to this communication network. Adiponectin, which circulates almost exclusively from adipocytes, functions as a systemic hormone that enhances insulin sensitivity and regulates lipids, coordinating energy metabolism across multiple organs. Through its receptors AdipoRl and AdipoR2, adiponectin activates AMP-activated protein kinase (AMPK) and peroxisome-proliferator-activated receptor-a (PPARa) pathways to increase fatty acid oxidation, suppress hepatic gluconeogenesis, and promote glucose utilization. In lean physiology, adiponectin maintains metabolic flexibility — enabling dynamic switching between fasting and feeding states and protects against inflammation, endoplasmic reticulum stress, and atherogenesis.[000248] Despite its abundance and widespread tissue distribution, adiponectin's effects are markedly reduced in obesity and T2D, a state known as adiponectin resistance. This condition features decreased receptor expression, impaired downstream AMPK activation, and ongoing hepatic glucose overproduction despite normal or high adiponectin levels. Adiponectin resistance mirrors insulin resistance in systemic effects but remains less well understood mechanistically. While the molecular defects underlying insulin resistance — such as IRS 1 / 2 phosphorylation or PI3K-AKT pathway disruption — are well known, the primary cause ofDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 adiponectin unresponsiveness in metabolic tissues has not been fully identified. This knowledge gap hampers efforts to translate adiponectin biology into effective treatments. Although drugs like AdipoRon, an orally active adiponectin receptor agonist, can activate AdipoRl / R2 in preclinical models, their success in treating obesity or diabetes has been inconsistent. This variability indicates that receptor context, rather than ligand availability, influences the effectiveness of adiponectin-based therapies.[000249] Our previous work identified one such regulatory node: the Nogo-B receptor (NgBR, encoded by NUS1). NgBR was initially characterized as a receptor for the reticulon family member Nogo-B (encoded by RTN4), and subsequent studies have implicated it in additional cellular processes, including dolichol biosynthesis, intracellular cholesterol homeostasis, and protein N-glycosylation. Beyond these biological functions, we recently demonstrated that NgBR acts as a transcriptional modulator by stabilizing the histone acetyltransferase K(lysine) acetyltransferase 7 (KAT7 / HBO1) and maintaining histone H3 / H4 acetylation in endothelial cells. Without wishing to be bound by theory, this indicates that NgBR supports metabolic resilience by preserving epigenetic accessibility.[000250] Here, we revealed the role of NgBR in regulating the functional aspects of the adiponectin pathway in the liver. Our data showed that NgBR maintains hepatic adiponectin sensitivity by supporting KAT7-dependent histone acetylation at the AdipoRl and AdipoR2 promoters, thereby promoting receptor expression and signaling capacity. Hepatic NgBR loss in obesity-induced diabetes can therefore suppress AdipoRl / R2 transcription, decrease adiponectin-induced AMPK activation, and increase gluconeogenesis — mimicking the metabolic pattern of adiponectin resistance. NgBR deficiency reveals a previously unrecognized molecular cause of adiponectin resistance — an event that unifies epigenetic, hormonal, and lipid dysregulation into a single pathogenic framework.[000251] Results[000252] Downregulation of NgBR expression in diabetic livers is associated with glucose intolerance[000253] To determine whether NgBR is altered in human metabolic disease, we first analyzed liver microarray transcriptome data (GSE156563) from individuals with lean physiology, obesity, or obesity with type 2 diabetes (T2D). In this cohort, NUS1 mRNA levels were significantly reduced in the livers of obese subjects with T2D, whereas obese individuals without T2D showed only modest changes compared with lean healthy controls. Conversely, RTN4 (Nogo-B), the precursor of the NgBR ligand, showed only a mild downward trend across metabolic groups (FIG. 4A). Building on this human evidence and to evaluate whether theseDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 gene patterns were evolutionarily conserved, we analyzed liver RNA-seq data from cynomolgus monkeys (GSE188418), which showed a parallel decrease in NUS1 expression in animals with obesity-associated diabetes, while RTN4 transcripts remained largely unchanged (FIG. 4B) To determine whether these gene changes reflect hepatocyte-specific gene regulation, we integrated human single-cell RNA-seq data (GSE202379). This analysis revealed a parallel decline in RTN4 and NUS1 gene expression in hepatocytes from T2D_Obese individuals compared with healthy subjects (FIG. 4C), mirroring the gene expression patterns observed in bulk RNA-seq of human and monkey. These transcriptional changes were corroborated at the protein level: immunohistochemical staining of human liver sections demonstrated a -40% reduction in hepatocellular NgBR signal intensity in T2D, accompanied by prominent micro- and macrovascular steatosis (FIG. 4D). Regional association plot of the chromosome 6 NUS1 (NgBR) locus showing genome-wide significant T2D-associated variants, including rs72951548 and rs72951506, located within a non-coding regulatory region (left). Predicted liver DNase I hypersensitivity at rs72951548 (chr6: 117690560 OT) indicates that the alternate allele is associated with reduced chromatin accessibility compared to the wild-type allele (right) (FIG. 4E). Together, these findings indicate that inherited perturbations in the NgBR signaling axis contribute to altered metabolic regulation and heightened diabetes risk. Together, these multi-layered datasets identify hepatic NgBR downregulation as a conserved feature of obesity-associated diabetes, implicating NgBR as a key metabolic determinant whose loss can predispose the liver to insulin resistance.[000254] To determine whether NgBR downregulation also occurs in experimental models of metabolic disease, we examined hepatic NgBR expression in both diet induced obesity (DIO) and db / db genetic diabetes models. In DIO mice, chronic high-fat diet feeding produced a gradual rise in fasting blood glucose, accompanied by a significant reduction in hepatic Nusl transcript levels, while Rtn4 expression and serum soluble Nogo-B remained unchanged (FIG. 4F). Immunoblotting of liver lysates confirmed a robust decrease in NgBR protein abundance under high-fat diet conditions, demonstrating that nutrient excess directly suppresses hepatic NgBR expression. A similar pattern was observed in db / db mice, a genetic model of severe insulin resistance and spontaneous type 2 diabetes. Compared with wild-type controls, db / db mice exhibited marked hyperglycemia and a progressive decline in hepatic NgBR mRNA and protein levels from 4 to 10 weeks of age, paralleling disease progression (FIG. 4G). In contrast, Nogo-B expression and circulating soluble Nogo-B concentrations remained stable, indicating that the effect is specific to NgBR. These observations establish that hepatic NgBR reduction is a conserved metabolic signature across diet-induced and geneticDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 models of diabetes, occurring independently of changes in its ligand and preceding or accompanying worsening hyperglycemia.[000255] To determine the physiological consequences of hepatic NgBR loss, we performed longitudinal metabolic testing in NgBR fl / fl and NgBR hepatocyte-specific knockout (NgBR HepKO) mice fed a control diet (CD) or a high-fat diet (HFD). Under CD, NgBR HepKO mice developed progressive fasting hyperglycemia beginning at 14-16 weeks of age, despite no differences in body weight or food intake between genotypes (FIG. 11B).Dynamic metabolic testing revealed that NgBR hepKO mice exhibited marked impairments in glucose tolerance (GTT), insulin sensitivity (ITT), pyruvate-driven gluconeogenesis (PTT), and alanine-driven gluconeogenesis (ATT) compared with NgBR littermate controls (FIG.4H) These findings indicate that hepatic NgBR is required to maintain normal glycemic control even in the absence of dietary metabolic stress. When challenged with HFD, both groups showed similar increases in body weight and comparable food intake (FIG. 11C), yet the metabolic phenotype of NgBR HepKO mice was markedly exacerbated. NgBR HepKO mice exhibited accelerated fasting hyperglycemia, severe glucose intolerance, blunted insulin responsiveness, and exaggerated substrate-driven hepatic glucose production during PTT and ATT (FIG.41). The degree of metabolic deterioration was substantially greater than under CD, indicating that loss of NgBR renders the liver unable to adapt to nutrient excess.[000256] Importantly, because food intake and body weight were unchanged across both dietary conditions, the impaired glycemic control observed in NgBR HepKO mice reflects a direct hepatic defect rather than secondary effects of altered adiposity or energy intake. Together, these findings establish that hepatocyte NgBR is an important regulator of systemic glucose homeostasis, required to maintain glucose tolerance, insulin sensitivity, and suppression of gluconeogenesis under both physiological and obesogenic conditions. We next examined how hepatocyte-specific deletion of NgBR affects systemic metabolic homeostasis. Compared with NgBR fl / fl littermate controls, NgBR HepKO mice showed significantly higher blood glucose in both fasting and refeeding states under control diet (CD) and high-fat diet (HFD) conditions. This hyperglycemia was accompanied by a marked reduction in insulin sensitivity, as reflected by decreased QUICKI values, and a robust increase in HOMA-IR, indicating severe insulin resistance across dietary conditions.[000257] Consistent with impaired insulin action, circulating HbAlc levels were significantly elevated in NgBR HepKO mice, such as under HFD. Despite significant hyperglycemia, NgBR HepKO mice exhibited elevated circulating insulin and C-peptide levels under both CD and HFD, indicating compensatory [3-cell insulin secretion. The persistence ofDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 hyperglycemia in the setting of hyperinsulinemia supports profound hepatic insulin resistance rather than insulin deficiency. Circulating glucagon levels were significantly reduced in NgBR HepKO mice under both CD and HFD, consistent with compensatory suppression by hyperinsulinemia. Circulating adiponectin levels were modestly increased in NgBR HepKO mice, particularly under HFD, indicating preserved or compensatory adipokine secretion. However, this increase failed to confer metabolic benefit, consistent with impaired hepatic adiponectin signaling. In contrast, serum leptin levels were markedly elevated, reflecting adipose expansion and leptin resistance. Together, these findings indicate adipokine dysregulation characterized by preserved hormone production but defective hepatic responsiveness. In addition, serum free fatty acid (FFA) levels were significantly elevated, consistent with enhanced lipolysis and insulin-resistant lipid flux (FIG. 4J).[000258] To determine whether this pattern mirrored other diabetic states, we analyzed metabolic markers in wild-type, 4-week db / db, and 10-week db / db mice. Progressive diabetes in db / db mice was characterized by a stepwise decline in insulin sensitivity and a corresponding rise in insulin, HOMA-IR, and leptin, closely resembling the phenotype of NgBR HepKO mice. Notably, adiponectin decreased with disease progression, while glucagon remained mildly elevated (FIG. HA) These parallels indicate that hepatic NgBR loss phenocopies key metabolic features of diabetic progression.[000259] Hepatic NgBR deficiency also caused widespread metabolic organ dysfunction. NgBR HepKO mice exhibited hypertriglyceridemia, increased hepatic triglyceride deposition, and elevated serum cholesterol, particularly under HFD feeding. Markers of hepatocellular injury — including ALT, AST, ALP, and total bilirubin — were elevated, indicating increased susceptibility to diet-induced liver stress (FIG. HE). Kidney function was compromised, with increased creatinine and BUN (FIG. HF), and pancreatic enzymes amylase and lipase were significantly elevated (FIG. HG), indicating metabolic injury extending beyond the liver. Importantly, these systemic abnormalities occurred without differences in body weight, adiposity, bone composition, or lean mass, as shown by comprehensive dual-energy X-ray absorptiometry (DEXA) analysis. Under both CD and HFD, total fat mass, fat percentage, bone mineral density (BMD), bone mineral content (BMC), lean mass, and soft tissue mass were indistinguishable between genotypes (FIG. 12A-B). Thus, NgBR deficiency does not alter fundamental body composition parameters that can otherwise explain the metabolic phenotype.[000260] We next asked whether defects in energy expenditure or locomotor behavior can account for the metabolic dysfunction. Comprehensive Lab Animal Monitoring System (CLAMS) metabolic cage analysis showed that NgBR HepKO mice had normal energyDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 expenditure (EE), normal food intake, comparable 24-hour locomotor activity, and an unchanged respiratory exchange ratio (RER) under CD (FIG. 13A). Under HFD, spontaneous activity was higher in NgBR HepKO mice, yet this did not improve EE or substrate utilization, nor did it ameliorate any aspect of metabolic dysfunction (FIG. 13B). Together, these results show that alterations in movement or energy balance do not contribute to the severe metabolic defects caused by hepatic NgBR loss.[000261] Collectively, these data demonstrate that NgBR is a conserved metabolic regulator in the liver, and its loss is consistently observed in humans, primates, and diabetic mouse models. NgBR downregulation is tightly linked to insulin resistance, impaired adiponectin signaling, increased gluconeogenesis, and widespread lipid abnormalities. The NgBR HepKO mouse fully recapitulates the metabolic features of obesity-associated diabetes — despite normal body composition and energy expenditure — thereby identifying hepatic NgBR loss as a primary driver of adiponectin resistance and metabolic dysfunction. These results establish NgBR as a key node in hepatic insulin sensitivity and provide a basis for deeper mechanistic analyses.[000262] NgBR deficiency triggers the liver to increase gluconeogenesis and undergo metabolic reprogramming[000263] The previous single-cell analysis of human liver data revealed marked upregulation of key gluconeogenic genes, PCK1 and G6PC, in Obese and T2D_Obese individuals, along with significant downregulation of NUS1 compared with healthy subjects (FIG. 5A). These observations encourage us to enumerate the transcriptional and molecular consequences of hepatic NgBR loss. To this end, we designed an experiment using hepatocytespecific NgBR knockout and NgBR fl / fl control mice, which were maintained on a 16-week high-fat diet (HFD) (FIG. 5B). Subsequently, we performed bulk RNA sequencing on liver tissue from NgBR fl / fl and NgBR HepKO mice after HFD feeding to delineate transcriptional alterations associated with hepatic loss of NgBR. Differential expression analysis showed global transcriptional changes among these groups, with clear gene expression differences as depicted in the hierarchical heatmap (FIG. 5C). In total, 8,280 genes were identified as significant and differentially expressed (DEGs), including 4,117 upregulated and 4,163 downregulated genes with |log2FC| > 0.5; p < 0.05 (FIG. 5D). Among the top DEGs, key gluconeogenic regulators, including G6pc, Pckl, Fbpl, Pcx, and Foxol, were highly upregulated, whereas critical metabolic and insulin signaling genes such as Ppargcla, Srebf2, Ldha, Insr, and Gck were significantly downregulated (FIG. 5E). In accordance with these gene-level alterations, pathway enrichment analyses revealed significant activation of variousDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 metabolic and signaling pathways, including insulin resistance, glucagon signaling, glycolysis / gluconeogenesis, pyruvate metabolism, were upregulated, whereas AMPK signaling, PPAR signaling, and PI3K-Akt signaling were downregulated (FIG. 5F).Collectively, these findings demonstrate that hepatic NgBR deficiency promotes increased gluconeogenic activity and metabolic reprogramming, highlighting NgBR as a vital regulator of hepatic metabolic homeostasis in obesogenic environments.[000264] Quantitative PCR validation confirmed the RNA-seq findings: NgBR HepKO mice displayed marked increases in G6pc, Pckl, Fbpl, Pcx, and Ppargcla, with modest elevation of Ldha, Gck, Insr, and Srebfl (FIG. 5G). To determine whether this phenotype was hepatocyte-intrinsic, we knocked down NgBR in primary human hepatocytes. NgBR silencing significantly increased G6PC and PCK1 mRNA expression, replicating the mouse phenotype and confirming conservation across species (FIG.5H). Histological and immunohistochemical analyses further supported these transcriptional changes. H& E staining of NgBR HepKO livers showed hepatocellular ballooning and micro vesicular lipid accumulation, while immunostaining revealed significantly higher G6PC and PCK1 protein levels (FIG. 51).Similarly, hepatic glucose production and gluconeogenic enzyme activity (PCK1 and G6PC) were markedly increased in NgBR HepKO mice under both control and high-fat diet conditions (FIG. 5J). To assess the evolutionary conservation of the NgBR-gluconeogenesis regulatory axis, we then reviewed liver transcriptome data from cynomolgus monkeys previously analyzed in this study. In accordance with our mouse findings, obese and T2D monkeys showed a coordinated elevation in the gluconeogenic genes G6PC, PCK1, and FOXO1 compared with lean or non-diabetic obese counterparts, alongside reduced expression of INSR and PPARGC1A (FIG. 5K). Together, our cross-species results show that hepatic NgBR deficiency is associated with conserved activation of gluconeogenic pathways, further underscoring its central role in metabolic regulation across mammals.[000265] KEGG pathway mapping of the Adipocytokine Signaling Pathway (FIG. 14) revealed that hepatic NgBR deficiency disrupts multiple metabolic regulatory nodes converging on gluconeogenesis. The pathway visualization highlighted strong induction of the key gluconeogenic enzymes G6PC and PEPCK, placing them at the center of the transcriptional response in NgBR HepKO liver. Several components of the AdipoRl / AdipoR2-APPLl-AMPK signaling axis, which normally promote fatty acid oxidation and suppress gluconeogenesis, showed altered expression, while downstream metabolic regulators — including PPARa, CPT1, and ACC2 — were significantly affected.Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026 Concurrent activation of stress and inflammatory mediators, such as SOCS3 and NF-KB, further indicated a shift toward insulin-resistant signaling.[000266] Together, these results show that hepatic NgBR loss directly activates a conserved gluconeogenic program, strongly inducing G6PC, PCK1, and related metabolic regulators across mice, primates, and human hepatocytes. Transcriptomic and pathway analyses reveal broad disruption of insulin- and adiponectin-linked AMPK signaling, along with activation of inflammatory nodes, establishing NgBR as a key suppressor of hepatic glucose production and metabolic dysregulation.[000267] Adiponectin-mediated glycemic control is impaired in NgBR hepKO mice [000268] Adiponectin agonists are widely regarded as metabolic modulators that suppress hepatic glucose production through adiponectin receptor-dependent signaling. To directly assess whether hepatic NgBR is required for adiponectin responsiveness in vivo, we treated littermate control (NgBR fl / fl) and hepatocyte-specific NgBR-deficient (NgBR hepKO) mice with the adiponectin receptor agonist AdipoRon under both control diet (CD) and high-fat diet (HFD) conditions. This approach allowed us to functionally define hepatic adiponectin sensitivity and resistance using metabolic and hepatic endpoints (FIG. 6A, FIG. 6H). Over four weeks of treatment, littermate control mice showed sustained reductions in fasting glucose and improved glucose tolerance, whereas NgBR hepKO mice exhibited no significant changes (FIG. 6B, FIG.61). Quantitative PCR confirmed that hepatic Nusl expression remained absent in knockout mice and was unaffected by AdipoRon (FIG. 6C, FIG. 6J). Serum Nogo-B levels remained unchanged, indicating that systemic Nogo-B did not influence the adiponectin response (FIG. 6E, FIG. 6L). Hepatic Nogo-B mRNA levels also showed no significant changes with AdipoRon treatment (FIG. 6D, FIG. 6K).[000269] Under both control diet (CD) and high-fat diet (HFD), littermate control mice treated with AdipoRon showed improved glucose clearance in glucose (GTT), insulin (ITT), pyruvate (PTT), and alanine (ATT) tolerance tests. However, there was no improvement in the NgBR HepKO group (FIG.6F, FIG. 6M). AdipoRon treatment markedly improved metabolic homeostasis in littermate control mice, as evidenced by reduced HOMA-IR, a significant increase in the insulin sensitivity index (QUICKI), and reduced HbAlc (FIG. 6G, FIG. 6N).These improvements were observed under CD and were further amplified under HFD. AdipoRon also improved circulating insulin and C-peptide levels, metabolic indices, and hepatic glycogen stores, indicating effective suppression of hepatic glucose output (FIG. 6G, FIG. 6N). In contrast, NgBR HepKO mice were refractory to AdipoRon under both dietary conditions, demonstrating a failure of adiponectin responsiveness despite equivalent systemicDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 exposure. Operationally, hepatic adiponectin resistance is defined here as the inability of AdipoRon to suppress hepatic glucose production and restore hepatic glycogen content, despite elevated circulating adiponectin. Consistent with this definition, NgBR HepKO mice exhibited paradoxically elevated serum adiponectin, impaired hepatic glycogen accumulation, sustained hyperinsulinemia with increased C-peptide, elevated HbAlc, and increased circulating free fatty acids (FFAs), reflecting defective adiponectin-mediated control of hepatic glucose and lipid metabolism rather than primary insulin resistance (FIG. 6G, FIG. 6N).[000270] To determine whether hepatic NgBR is required for adiponectin receptor-mediated metabolic improvement, we treated NgBR fl / fl and NgBR HepKO mice with the adiponectin receptor agonist AdipoRon under both control diet (CD) and high-fat diet (HFD) conditions, followed by comprehensive metabolic phenotyping. Under both CD and HFD, NgBR fl / fl mice treated with AdipoRon exhibited significantly improved glucose clearance during glucose (GTT), insulin (ITT), pyruvate (PTT), and alanine (ATT) tolerance tests (FIG.15A-B) These improvements were reflected by reduced glucose excursions and lower AUC values, such as under HFD where metabolic dysfunction was more pronounced. In contrast, NgBR HepKO mice showed no improvement in GTT, ITT, PTT, or ATT following AdipoRon treatment under either dietary condition (FIG. 15D-E), indicating loss of adiponectin responsiveness.[000271] AdipoRon markedly improved systemic metabolic homeostasis in NgBR fl / fl mice, as evidenced by reduced HOMA-IR, increased insulin sensitivity index (QUICKI), and decreased HbAlc levels (FIG. 15C). These effects were present under CD and further amplified under HFD. AdipoRon also improved circulating insulin and C-peptide levels, reduced glucagon and leptin, lowered serum free fatty acids (FFAs), and restored hepatic glycogen stores, consistent with effective suppression of hepatic glucose output. In contrast, NgBR HepKO mice were refractory to AdipoRon under both dietary conditions (FIG. 15F).Indices of insulin resistance remained elevated, including persistent hyperinsulinemia, increased C-peptide, elevated HbAlc, and increased circulating FFAs. Hepatic glycogen content failed to recover despite treatment. Operationally, hepatic adiponectin resistance is defined here as the inability of AdipoRon to suppress hepatic glucose production and restore hepatic glycogen content despite systemic agonist exposure. Consistent with this definition, NgBR HepKO mice exhibited impaired metabolic correction despite pharmacologic adiponectin receptor activation, demonstrating that hepatic NgBR is essential for adiponectin-mediated regulation of hepatic glucose and lipid metabolism.Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026[000272] With food intake and body weight unchanged across groups (FIG. 16A, FIG.16F), AdipoRon improved metabolic and hepatic profiles only in littermate control mice. In these mice, AdipoRon reduced hepatic and circulating triglycerides, lowered serum cholesterol, and improved ALT / AST / ALP levels, indicating restored hepatic function. In contrast, NgBR HepKO mice were unresponsive, showing persistently elevated triglycerides, cholesterol, and liver enzymes under both diets. However, total bilirubin levels did not change (FIG. 16C-D, FIG. 16H-I). Kidney and pancreatic markers also showed clear genotype-dependent differences. There were no significant changes in kidney or pancreatic profiles under the control diet. However, under HFD, NgBR HepKO mice exhibited higher serum creatinine, lower albumin, and elevated BUN, consistent with early renal stress, and significantly increased amylase and lipase, indicating a heightened pancreatic burden (FIG. 16B, FIG. 16E, FIG. 16G, FIG. 16J). AdipoRon improved these abnormalities only in littermate control mice, whereas NgBR HepKO mice showed no biochemical correction.[000273] DEXA body composition analysis showed that AdipoRon treatment did not produce meaningful changes in total weight, fat mass, or lean mass in littermate control or NgBR HepKO mice under control diet conditions (FIG. 17A). Minor differences in bone area, BMD, and fat percentage were observed in a few parameters, but these did not follow a consistent pattern and did not distinguish treatment responses between genotypes. Under a high-fat diet, AdipoRon again failed to alter overall body composition in either group, with only small shifts detected in bone-related parameters and fat percentage (FIG. 17B).Importantly, NgBR HepKO mice showed no improvement in adiposity or lean mass with AdipoRon, confirming that the absence of NgBR renders mice unresponsive to adiponectin-driven changes in body composition. These findings indicate that the differential metabolic response to AdipoRon is not attributable to alterations in body composition.[000274] CLAMS analysis showed that AdipoRon did not alter energy expenditure, RER, locomotor activity, or food intake in NgBR fl / fl or NgBR HepKO mice under control or high-fat diet conditions (FIG. 18A-B). Hourly EE curves and activity patterns largely overlapped across groups, indicating no treatment effect on whole-body energetics. Thus, the impaired metabolic response of NgBR HepKO mice cannot be attributed to differences in energy expenditure or activity. Thus, while adiponectin agonism restores glucose homeostasis, lipid balance, and hepatic function in wild-type mice, NgBR knockout livers remain completely unresponsive, resulting in intrinsic adiponectin resistance characterized by persistent hyperglycemia, impaired insulin sensitivity, uncorrected liver injury, and unchanged whole-Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026 body energetics. This phenotype closely parallels human adiponectin resistance, positioning NgBR as an essential molecular determinant of adiponectin efficacy in vivo.[000275] NgBR knockout disrupts adiponectin— AdipoR signaling and impairs the repression of hepatic gluconeogenesis[000276] Adiponectin signaling is essential for suppressing hepatic gluconeogenic gene programs through coordinated transcriptional regulation. To determine whether NgBR is required for the hepatic response to adiponectin agonism, we performed bulk RNA sequencing of liver samples from NgBR fl / fl and NgBR HepKO mice after four weeks of AdipoRon treatment (FIG. 7A). In littermate control mice, AdipoRon induced broad transcriptional remodeling, with 1,481 genes upregulated and enrichment of pathways linked to glucose metabolism, lipid handling, and insulin signaling (FIG. 7B-D). In contrast, NgBR HepKO livers showed a blunted transcriptional response, with 1,536 genes downregulated and loss of the induction of gluconeogenic suppressors and insulin-sensitizing pathways. Heatmap (FIG.7C) highlighted that genes suppressed by adiponectin — such as G6pc, Pckl, Fbpl, Foxol, and Srebfl — responded appropriately in littermate control livers but remained unchanged or paradoxically increased in the liver of NgBR HepKO mice (FIG. 7C). Likewise, insulin-responsive genes, including Ldha and Ppargcla, failed to normalize in the absence of NgBR.[000277] Pathway enrichment analysis of AdipoRon-treated livers showed that littermate control mice downregulate pathways associated with gluconeogenesis, pyruvate metabolism, NF-KB signaling, fatty acid degradation, and PPAR signaling, reflecting coordinated normalization of hepatic metabolism (FIG. 7E). In contrast, NgBR HepKO livers failed to suppress these pathways, indicating a loss of adiponectin-driven transcriptional regulation. Quantitative PCR validation confirmed these trends: NgBR HepKO mice showed the elevated expression of G6pc, Pckl, Fbpl, Pcx, and Ppargcla gluconeogenic genes in post adiporon treatment (FIG. 7F). Consistently, in primary human hepatocytes, siRNA-mediated NgBR knockdown abolished the suppressive effects of AdipoRon on G6PC and PCK1, demonstrating that the requirement for NgBR in mediating adiponectin signaling is cell-autonomous and conserved across species (FIG. 7G).[000278] After treatment with Adiporon, NgBR HepKO mice showed no suppression of enzymatic activity and maintained elevated glucose production (FIG. 7H). Histological analyses further supported these observations: AdipoRon improved hepatic morphology in NgBR fl / fl mice, reducing ballooning and lipid accumulation, while NgBR HepKO livers remained steatotic and displayed high G6PC and PCK1 staining despite treatment (FIG. 71).Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026 Immunoblotting further confirmed that AdipoRon suppressed PCK1 and G6PC protein levels only in NgBR fl / fl mice, with no detectable response in NgBR HepKO livers (FIG. 7J).[000279] Assessment of proximal adiponectin pathway components revealed that the failure of AdipoRon responsiveness in NgBR HepKO liver reflects a primary loss of adiponectin receptor competence. While AdipoRon treatment did not change AdipoRl or AdipoR2 expression in NgBR fl / fl mice, the expression of both receptors was markedly reduced in NgBR HepKO livers, as determined by RNA-seq and qPCR analyses (FIG. 7L, FIG. 7M). AdipoRl / R2 receptor deficiency was accompanied by reduced KAT7 expression. Importantly, Insr expression remained largely preserved, arguing against global transcriptional suppression. Functionally, this receptor-level collapse translated into a signaling blockade: AdipoRon robustly activated AMPK phosphorylation in NgBR fl / fl livers but failed to activate AMPK in NgBR HepKO mice despite equivalent drug exposure (FIG. 7N). Pathway visualization using the KEGG Adipocytokine Signaling Pathway revealed that, even after AdipoRon treatment, G6PC and PEPCK remain strongly upregulated in NgBR-deficient livers, underscoring persistent activation of the gluconeogenic program (FIG. 19). Although adiponectin receptor signaling normally suppresses these genes via downstream AMPK activity, pathway mapping showed that this regulatory cascade is disrupted in NgBR HepKO mice, with gluconeogenesis-associated elements remaining active and metabolic suppression nodes failing to engage. These findings further indicate that NgBR loss impairs the proper propagation of adiponectin signaling, reinforcing the transcriptomic and biochemical evidence of adiponectin resistance in the NgBR-deficient liver.[000280] Together, these findings demonstrate that NgBR is an essential upstream determinant of hepatic adiponectin responsiveness. In NgBR fl / fl mice, AdipoRon suppresses gluconeogenic gene expression, remodels metabolic pathways, improves hepatic histology, and activates AMPK signaling. In contrast, NgBR-deficient livers fail to mount any of these responses, retaining elevated G6PC and PCK1 expression, persistent steatosis, and absent AMPK activation despite equivalent agonist exposure. This signaling failure reflects a primary collapse of adiponectin receptor competence, marked by reduced AdipoRl / AdipoR2 expression, rather than impaired ligand availability. Thus, NgBR loss enforces an intrinsic hepatic adiponectin-resistant state, rendering adiponectin agonism ineffective at engaging downstream metabolic control.[000281] NgBR regulates adiponectin receptor transcription via KAT7-dependent histone acetylationDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026[000282] Silencing KAT7 profoundly disrupted the adiponectin-NgBR signaling axis and revealed KAT7 as an essential chromatin effector required for suppressing hepatic gluconeogenesis. In primary hepatocytes, AdipoRon stimulation did not affect the expression of AdipoRl, AdipoR2, or KAT7 (FIG. 8A and FIG. 8B). However, KAT7 knockdown markedly reduced AdipoRl and AdipoR2 expression at both transcriptional and translational levels, whereas Insr expression remained unchanged (FIG. 8A and FIG. 8B). These findings positioned KAT7 upstream of the adiponectin receptor module and indicate that KAT7-mediated histone acetylation is required to maintain adiponectin receptor accessibility.[000283] Consistent with this, NgBR HepKO livers displayed a global reduction in histone acetylation marks regulated by KAT7. Multiple activating histone modifications, including H3K14ac, H3K18ac, and H3K9ac, were significantly reduced in NgBR-deficient hepatocytes, while total H3 remained unchanged (FIG. 8C). Parallel reductions in H4K5ac further supported a broad chromatin remodeling defect in the absence of NgBR (FIG. 8D).These defects were recapitulated in si-KAT7 hepatocytes, which displayed a similar loss of H3 and H4 acetylation marks (FIG. 8E-F), indicating that NgBR deficiency phenocopies KAT7 loss. Together, these data place NgBR as an upstream regulator of KAT7-mediated histone acetylation. Chromatin engagement analyses substantiated a regulatory link between NgBR and adiponectin receptor transcription. Targeted ChlP-qPCR demonstrated enrichment of H3K14ac and H3K18ac at defined regulatory regions within the AdipoRl and AdipoR2 promoters. NgBR deficiency significantly reduced H3K14ac and H3K18ac occupancy at the AdipoRl (-1972 to -1806) and AdipoR2 (-534 to -422) loci, mirroring the effect observed following KAT7 silencing (FIG. 8G-H). In contrast, broader ChIP mapping across the AdipoRl (-2983 to +323) and AdipoR2 (-1250 to +347) promoter regions revealed comparable overall H3 and KAT7 occupancy between groups, as shown in the supplementary datasets. These data indicate that NgBR does not globally alter promoter chromatin loading, but rather modulates site-specific histone acetylation at key regulatory elements. Collectively, the findings support a model in which NgBR influences adiponectin receptor expression through selective regulation of KAT7-associated histone acetylation (FIG. 20).[000284] Loss of KAT7 also directly impaired adiponectin's ability to suppress gluconeogenic genes. KAT7 knockdown results in the induction of G6PC and PCK1 in hepatocytes (FIG. 81 and FIG. 8J) and impairs the AdipoRon-stimulated phosphorylation of AMPK (FIG. 8J). These data demonstrate the critical role of KAT7 in suppressing gluconeogenesis in response to adiponectin. To determine whether restoring KAT7 expression can rescue NgBR deficiency, NgBR HepKO HepG2 cells were transduced with KAT7-Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026 expressing vectors. KAT7 overexpression restored mRNA and protein levels of AdipoRl and AdipoR2 by altering acetylation of histone proteins (FIG. 8L-M). Importantly, KAT7 overexpression reinstated adiponectin-stimulated AMPK phosphorylation and restored the suppression of PCK1 and G6PC, following AdipoRon treatment (FIG. 8N and FIG. 80).These findings were recapitulated in HepG2 cells. Genetic deletion of NgBR attenuated the adiponectin-induced upregulation of AdipoRl, AdipoR2, KAT7, and INSR, and prevented the suppression of the gluconeogenic genes G6PC and PCK1 (FIG.20A-D). Consistently, NgBR deficiency markedly reduced AMPK phosphorylation in response to AdipoRon or recombinant Nogo-B (FIG. 20E-F). Dose-response analyses further demonstrated that escalating concentrations of AdipoRon failed to repress G6PC and PCK1 expression in si-NgBR cells (FIG. 20G), indicating that NgBR is required for effective adiponectin signaling in this context.[000285] Collectively, these results demonstrate that KAT7 functions as a critical chromatin effector linking NgBR to adiponectin receptor expression and to adiponectin-dependent suppression of hepatic gluconeogenesis. Loss of NgBR or KAT7 disrupts histone acetylation, downregulates adiponectin receptors, prevents AMPK activation, and leads to unregulated expression of the gluconeogenic genes G6PC and PCK1. KAT7 restoration rescues this signaling defect in NgBR-deficient hepatocytes, identifying a mechanistic NgBR-KAT7-Adiponectin axis that governs hepatic gluconeogenesis.[000286] Hepatic NgBR Is Required for Adiponectin-Driven Ceramide Clearance and Protection Against Ceramide-Induced Gluconeogenesis[000287] Ceramide accumulation is a hallmark of metabolic dysfunction and has been implicated in adiponectin resistance and excessive hepatic glucose production. Given that adiponectin stimulates ceramide catabolism via AMPK signaling and that NgBR is required for effective adiponectin-AMPK activation, we tested whether loss of hepatic NgBR disrupts ceramide remodeling after AdipoRon treatment. To address this, we integrated human lipidomics, mouse hepatic lipidomics, AdipoRon intervention, gene expression, ceramide-driven activation assays, and rescue experiments using ceramide and PP2A modulation.[000288] Analysis of >2,000 individuals from the All of Us cohort showed significantly higher plasma ceramide 16:0 and ceramide 22:0 levels in individuals with T2D than in metabolically healthy controls (FIG. 9A). These data establish a clinical foundation linking ceramide accumulation to diabetes and justify probing how ceramide biology is altered in states of impaired adiponectin sensitivity.Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026[000289] To interrogate the impact of impaired adiponectin sensitivity on hepatic ceramide metabolism, we performed mass spectrometry-based lipidomic analysis of AdipoRon-treated liver samples of NgBR fl / fl and NgBR hepKO mice under high-fat diet conditions (FIG.9B). Untargeted lipidomic profiling revealed broad alterations in sphingolipid composition in NgBR HepKO livers compared with NgBR fl / fl controls. The heatmap showed enrichment of multiple ceramide and sphingomyelin subclasses in NgBR HepKO mice, including SM(dl8: 1 / 17:0), HexCer(t22:2 / 15:l(2OH)), and Cer(d29:2 / 30:2(2OH)) (FIG. 9C-D). As shown in the volcano plot, 93 lipid species were reduced and 31 were increased in NgBR HepKO livers relative to controls (FIG. 9E).[000290] Following AdipoRon treatment, NgBR fl / fl mice exhibited lipid remodeling, characterized by coordinated reductions across multiple ceramide subclasses (including Cer-AS, Cer-NP, and Cer-NS), as well as hexosylceramides and sphingomyelins, as shown in the heatmap (FIG. 9F). In contrast, NgBR HepKO mice failed to show comparable lipid suppression after AdipoRon exposure. Heatmap patterns revealed persistent or increased abundance of ceramide and sphingolipid species (FIG. 9G), and the volcano plot showed a predominance of lipid species that were increased rather than decreased, with 248 lipid species significantly elevated and only 141 reduced in NgBR HepKO mice compared with AdipoRon-treated NgBR fl / fl controls (FIG. 9H). A focused heatmap of long-chain ceramides (C16:0, Cl 8:0, C20:0, C22:0, C24:0) demonstrated that AdipoRon significantly reduced these species in NgBR fl / fl livers but had no effect — and in some cases worsened accumulation — in NgBR HepKO mice (FIG. 91). This aligns with the metabolic phenotype of adiponectin resistance. Together, these data indicate that loss of hepatic NgBR blunts the lipidomic response to adiponectin receptor activation, resulting in sustained ceramide accumulation despite AdipoRon treatment.[000291] To comprehensively define the contribution of hepatic NgBR to adiponectin-driven lipid remodeling, we performed untargeted lipidomic profiling of livers from NgBR fl / fl and NgBR HepKO mice treated with AdipoRon. Hierarchical clustering and Z-score-normalized heatmap analysis revealed robust and coordinated lipid reprogramming in NgBR fl / fl livers following AdipoRon administration (FIG. 23A-B). AdipoRon treatment induced widespread reductions across multiple sphingolipid subclasses, including ceramide species (Cer-AP, Cer-AS, Cer-NP, Cer-NS) and complex sphingolipids such as hexosylceramides and sphingomyelins, accompanied by broader shifts in fatty acids, glycerolipids, and glycerophospholipids. This global suppression pattern was consistent across biological replicates, indicating structured remodeling rather than stochastic lipid variation.Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026[000292] Volcano plot analysis further quantified the magnitude of this response. In NgBR fl / fl livers, AdipoRon treatment significantly decreased 579 lipid species while increasing 216 species relative to untreated controls (FIG. 23C). The predominance of downregulated lipid species underscores a coordinated suppression and redistribution of hepatic lipid pools, such as within ceramide-enriched classes, consistent with adiponectin-mediated lipid clearance and improved metabolic homeostasis. In contrast, hepatic NgBR deficiency markedly blunted the lipidomic response to AdipoRon. Heatmap clustering in NgBR HepKO mice revealed persistent enrichment of sphingolipids and ceramide subclasses despite treatment (FIG. 23D-E), with attenuated suppression across multiple lipid categories. Instead of coordinated downregulation, several ceramide and complex sphingolipid species remained elevated or exhibited incomplete normalization. Consistently, volcano plot analysis demonstrated an altered remodeling signature in NgBR HepKO livers. Compared with AdipoRon-treated NgBR fl / fl mice, NgBR HepKO mice exhibited 442 lipid species significantly increased and only 307 decreased (FIG. 23F), reflecting a shift toward lipid accumulation rather than suppression. This imbalance indicates failure of adiponectin-driven lipid repression in the absence of hepatic NgBR.[000293] To determine whether elevated ceramides contribute to the metabolic phenotype, we treated hepatocytes with C2-ceramide, a membrane-permeable ceramide analog. NgBR HepKO HepG2 cells showed markedly exaggerated induction of G6PC and PCK1 compared with NgBR fl / fl cells (FIG. 9J-K). This heightened responsiveness mirrors the in vivo transcriptional pattern and indicates that NgBR-deficient hepatocytes are hypersensitive to ceramide. Because ceramides activate gluconeogenesis partly through PP2A-mediated suppression of AMPK, we tested whether the PP2A inhibitor LB- 100 can blunt the excessive ceramide response. In NgBR fl / fl hepatocytes, C2 + LB- 100 completely suppressed G6PC and PCK1 induction. In NgBR HepKO hepatocytes, LB- 100 significantly reduced — but did not normalize — ceramide-stimulated G6PC and PCK1 expression (FIG. 9J-K).[000294] Immunoblotting confirmed that ceramide impaired AMPK phosphorylation in NgBR HepKO cells, and that LB- 100 partially restored AMPK activation while reducing PCK1 / G6PC protein abundance (FIG. 9L). These findings demonstrate that NgBR regulates the ceramide-PP2A-AMPK axis and that NgBR loss creates a state in which ceramide-PP2A signaling becomes dominant. To exclude cytotoxic effects of pharmacologic interventions used in complementary mechanistic studies, cell viability assays were performed with C2 and LB 100 (FIG.23G-H). C2 treatment reduced cell viability in a dose-dependent manner in both NgBR fl / fl and NgBR HepKO cells, whereas LB 100 also decreased viability at higherDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 concentrations. These data establish appropriate dosing parameters for mechanistic experiments while confirming that the observed lipid remodeling phenotypes are not attributable to nonspecific toxicity under the experimental conditions used.[000295] These findings identify NgBR as a critical determinant of hepatic ceramide homeostasis and adiponectin responsiveness. In the presence of NgBR, adiponectin agonism reduces pathogenic ceramide species, activates AMPK, and suppresses gluconeogenesis. In contrast, NgBR-deficient livers fail to clear ceramides, resulting in elevated lipotoxic sphingolipids, impaired suppression of gluconeogenesis, and an adiponectin-resistant state. Together, these data place the NgBR-ceramide-PP2A-AMPK axis at the center of hepatic metabolic resilience in obesity-related diabetes.[000296] AA V8-mediated hepatic NgBR overexpression reinstates adiponectin sensitivity and glucose homeostasis in NgBR-deficient mice[000297] AAV-mediated re-expression of NgBR in hepatocytes fully restored hepatic and systemic metabolic abnormalities in NgBR HepKO mice. Under both control and high-fat diets, NgBR HepKO mice receiving AAV-NUS 1 showed a progressive decline in fasting blood glucose, whereas AAV-Control-treated knockout mice remained persistently hyperglycemic despite equivalent AdipoRon exposure (FIG. 10B, FIG. 101). qPCR analysis confirmed robust NgBR re-expression and restored key adiponectin pathway components, including KAT7, AdipoRl, and AdipoR2, to levels comparable to physiological controls (FIG. 10C, FIG. 10 J), indicating reconstitution of adiponectin signaling competence.[000298] Dynamic metabolic testing revealed complete functional rescue. On a control diet, AAV-NUS 1 restored physiological glucose excursions during GTT, ITT, PTT, and ATT, reversing the severe glucose intolerance, impaired insulin sensitivity, and exaggerated substrate-driven gluconeogenesis characteristic of NgBR HepKO mice (FIG. 10D). These improvements were even more striking during high-fat feeding, when AAV-NUS 1 corrected profound hyperglycemia and restored near-normal responsiveness to glucose, insulin, pyruvate, and alanine (FIG. 10K). Quantitative metabolic indices confirmed this recovery: HbAlc, fasting insulin, and C-peptide concentrations were significantly reduced, HOMA-IR normalized, and the QUICKI index increased markedly demonstrating restored insulin sensitivity (FIG. 10E, FIG. 10L).[000299] Hormonal metabolic regulators that were dysregulated in NgBR HepKO mice also normalized after AAV-NUS 1 treatment. Circulating adiponectin increased appropriately, glucagon levels decreased, leptin levels stabilized, and hepatic glycogen stores increased significantly, confirming correction of the defective nutrient and hormonal signaling pathwaysDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 (FIG. 10E-G, FIG. 10L O) However, there were no changes in serum soluble NogoB levels under either dietary condition. Enzymatic assays directly demonstrated that AAV-NUS1 restored suppression of G6PC and PCK1 activity in response to AdipoRon, reversing the persistently elevated gluconeogenic enzyme activity observed in untreated NgBR HepKO mice (FIG. 10F, FIG. 10M)[000300] At the protein level, NgBR restoration reinstated the hepatic signaling axis required for adiponectin action. Immunoblots showed that AdipoRon failed to activate AMPK in NgBR HepKO mice, whereas AAV-NUS1 fully restored AMPK phosphorylation despite identical drug exposure (FIG. 10P). PCK1 and G6PC protein levels, which remained elevated in untreated knockouts, were markedly reduced after NgBR re-expression, and KAT7 — whose expression depends on NgBR — was also restored. AdipoRl and AdipoR2 protein levels normalized as well, indicating that NgBR is required to maintain both receptor abundance and downstream signaling capacity.[000301] AAV-NUS1 also improved multiple extrahepatic metabolic parameters. Kidney function tests showed reduced serum creatinine, increased albumin, and decreased BUN after NgBR restoration (FIG. 24B, FIG. 24G). Liver injury markers (ALT, AST, bilirubin) improved significantly under both diets (FIG. 24D, FIG. 241), and pancreatic enzyme abnormalities (amylase, lipase) fully normalized (FIG.24E, FIG.24J). Lipid homeostasis was also corrected: AAV-NUS1 significantly reduced hepatic and circulating triglycerides, total cholesterol, and FFAs (FIG. 24C, FIG. 24H), consistent with restored AMPK signaling and suppression of lipotoxic pathways.[000302] Body composition analyses showed that AAV-mediated NgBR rescue improved several parameters without altering caloric intake. On a control diet, NgBR HepKO mice receiving AAV-NUS1 showed modest but consistent improvements in sample area, bone area, and lean mass (FIG. 25A). On a high-fat diet, AAV-NUS1 increased sample area, bone area, BMD, and overall body weight — changes aligned with metabolic recovery rather than obesity promotion (FIG.25B). Importantly, food intake and total energy expenditure remained unchanged between groups (FIG. 26), confirming that metabolic improvements were driven by intrinsic restoration of hepatocellular signaling, not behavioral or energetic confounders.[000303] Together, these findings demonstrate that hepatic NgBR restoration is sufficient to reverse the metabolic defects observed in NgBR HepKO mice, restoring adiponectin responsiveness, normalizing AMPK signaling, suppressing excessive hepatic gluconeogenesis, and correcting systemic glycemic and hormonal abnormalities. These results position hepatic NgBR as a critical determinant of adiponectin responsiveness in vivo.Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026[000304] Discussion[000305] Adiponectin has long been viewed as a promising therapeutic target in obesity and type 2 diabetes because of its broad metabolic benefits, including suppression of hepatic glucose production and improved lipid handling. Yet despite compelling experimental data, adiponectin-based therapies have yielded inconsistent clinical benefit, indicating unrecognized constraints on adiponectin responsiveness. The present study identifies hepatic NgBR (NUS1) as a key determinant of whether adiponectin signaling can be productively engaged in the liver and provides a mechanistic framework for hepatic adiponectin resistance. Across human cohorts, non-human primates, and multiple mouse models, NUSl / NgBR expression is selectively reduced in the diabetic liver, whereas expression of its ligand Nogo-B is largely unchanged. In mice, hepatocyte-specific NgBR loss produces a phenotype that recapitulates central features of adiponectin resistance — including fasting and postprandial hyperglycemia, elevated HbAlc, dyslipidemia, and multi organ biochemical injury — despite unchanged body weight, body composition, and whole-body energy expenditure. These findings argue that declining hepatic NgBR is not merely a secondary consequence of obesity but a biologically meaningful lesion that predisposes the liver to impaired adiponectin action and dysregulated glucose output. The association of NUS1 variants with type 2 diabetes risk further supports the clinical relevance of this pathway.[000306] A major conclusion of this work is that hepatic NgBR constrains gluconeogenesis and preserves metabolic flexibility by maintaining the liver’s responsiveness to adiponectin. Transcriptomic analyses of NgBR-deficient liver reveal a consistent induction of canonical gluconeogenic drivers (G6pc, Pckl, Fbpl, Pcx, Foxol) and broad reprogramming of pathways that coordinate nutrient sensing and metabolic suppression, including AMPK and adipocytokine signaling networks. These signatures are mirrored in primate liver and in human hepatocytes following NgBR perturbation, indicating that the NgBR-gluconeogenesis relationship is evolutionarily conserved and hepatocyte-intrinsic. Functionally, NgBRHepKO mice display exaggerated glucose production during pyruvate and alanine challenges and reduced hepatic glycogen stores under both control and obesogenic feeding, consistent with loss of adiponectin’ s hepatic restraint on glucose output. The emergence of this phenotype in the absence of measurable changes in locomotor activity or energy balance supports a primary hepatic mechanism.[000307] The most direct evidence that NgBR governs hepatic adiponectin responsiveness comes from pharmacologic interrogation with the adiponectin receptor agonist AdipoRon. In NgBR fl / fl mice, AdipoRon lowers fasting glucose and HbAlc, improvesDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 glucose and gluconeogenic substrate tolerance, preserves hepatic glycogen, and normalizes lipid and liver injury markers. Strikingly, these benefits are absent in NgBR HepKO mice despite comparable drug exposure and paradoxically elevated circulating adiponectin. This dissociation between ligand abundance and tissue response recapitulates the clinical syndrome of adiponectin resistance and indicates that NgBR establishes a permissive hepatocellular state in which adiponectin receptor activation can be coupled to downstream metabolic control. These results indicate that reduced hepatic NgBR can contribute to heterogeneous responses in trials of adiponectin-mimetic therapies and that restoring NgBR function can be required to convert an adiponectin-resistant liver into an adiponectin-responsive one.[000308] Mechanistically, our data identify an epigenetic regulator as a proximal cause of adiponectin resistance in NgBR-deficient hepatocytes. We show that NgBR maintains a chromatin module centered on the histone acetyltransferase KAT7 that is necessary for adiponectin receptor competence. Loss of NgBR produces a broad reduction in activating histone acetylation marks on H3 and H4 and diminishes the binding of acetylated histone proteins at the promoters of AdipoRl and AdipoR2, accompanied by reduced receptor expression and failure to propagate AMPK signaling. KAT7 silencing phenocopies NgBR loss by preventing AdipoRon-induced AMPK activation and abolishing suppression of G6PC and PCK1, whereas KAT7 restoration in NgBR-deficient hepatocytes rescues AdipoRl / R2 expression, reinstates AMPK activation, and restores adiponectin-mediated repression of gluconeogenesis. Together, these findings extend prior observations that NgBR stabilizes KAT7-dependent acetylation and reveal a mechanism by which hepatic adiponectin resistance can be encoded at the level of receptor transcriptional competence rather than solely by postreceptor signaling defects.[000309] This epigenetic model refines prevailing views of adiponectin resistance in obesity and type 2 diabetes. Much of the field has emphasized impaired AMPK phosphorylation, altered ceramidase activity, or downstream inflammatory signals as primary explanations for diminished adiponectin efficacy. Our data indicate that receptor deficiency and reduced promoter acetylation precede these defects, creating a state in which adiponectin agonism cannot engage AMPK even under pharmacologic stimulation. This framework also provides a coherent explanation for the paradoxically elevated adiponectin levels observed in metabolic disease: increased ligand abundance can reflect compensatory secretion but remains ineffective when the hepatocyte lacks the chromatin and receptor architecture required for signaling competence.Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026[000310] The link between NgBR and ceramide metabolism provides a second mechanistic layer connecting adiponectin resistance to lipotoxic reinforcement of gluconeogenesis. In a large human cohort, long-chain ceramides are elevated in type 2 diabetes, consistent with their role as cardiometabolic risk biomarkers. In mice, AdipoRon reduces multiple ceramide and sphingolipid subclasses in NgBR fl / fl liver but fails to reduce these lipids in NgBR HepKO animals, which retain or further increase pathogenic ceramide species. Functionally, NgBR-deficient hepatocytes show exaggerated induction of G6PC and PCK1 in response to ceramide challenge and heightened sensitivity to ceramide-associated stress. Partial reversal by PP2A inhibition indicates that ceramide-PP2A antagonism of AMPK becomes dominant when NgBR is absent. These findings indicate that NgBR allows for adiponectin-AMPK signaling to counterbalance ceramide-driven phosphatase activity; without NgBR, ceramide accumulation and PP2A activity reinforce failure of AMPK activation, thereby stabilizing a gluconeogenic, adiponectin-resistant state.[000311] A critical strength of this study is demonstrating that the NgBR defect is reversible and that restoring NgBR in hepatocytes is sufficient to re-establish adiponectin responsiveness in vivo. AAV8-mediated hepatic NgBR re-expression restores KAT7 and AdipoRl / R2 abundance, reinstates AMPK phosphorylation in response to AdipoRon, suppresses G6PC and PCK1 activity, and normalizes fasting glycemia and HbAlc. This intervention also improves dyslipidemia and ameliorates biochemical markers of liver, kidney, and pancreatic injury without altering food intake or whole-body energy expenditure, indicating that correcting hepatocellular signaling competence is sufficient to drive systemic metabolic recovery. Although gene therapy is not yet routine for metabolic disease, these data motivate strategies to stabilize NgBR, enhance NgBR-KAT7 function, or restore histone acetylation at adiponectin receptor loci as enabling approaches to unlock the therapeutic potential of adiponectin agonism.[000312] In summary, this work identifies hepatic NgBR as a conserved regulator that determines adiponectin signaling competence, thereby governing hepatic glucose output and lipid remodeling in metabolic disease. By stabilizing a KAT7-dependent acetylation program at the AdipoRl / R2 loci and enabling adiponectin-driven AMPK activation to counteract ceramide-PP2A signaling, NgBR preserves hepatic adiponectin sensitivity. Loss of NgBR dismantles this network, resulting in intrinsic adiponectin resistance marked by persistent ceramide accumulation, unchecked gluconeogenesis, and systemic metabolic deterioration. Restoring NgBR reverses these defects and reinstates adiponectin responsiveness, highlightingDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 the NgBR-KAT7-Adiponectin axis as a target for precision therapies in obesity-associated diabetes.[000313] Conclusion[000314] Loss of NgBR-KAT7 in the livers of obese patients is responsible for adiponectin resistance, characterized by impaired histone acetylation and reduced expression of AdipoRl and AdipoR2. Our findings identified an opportunity for epigenetic intervention to restore adiponectin function and suppress gluconeogenesis.[000315] Materials availability: Unique reagents and materials generated in this study are available from the corresponding author upon reasonable request and completion of a materials transfer agreement (MTA), where applicable. The hepatocyte-specific NgBR knockout (NgBR HepKO) mouse model (NgBR fl / fl crossed with Albumin-Cre) and AAV8-TBG-NgBR-HA constructs generated for this study are available upon request. AdipoRon and other commercially available reagents were obtained from the sources specified in the Key Resources Table.[000316] Human liver tissue microarrays were purchased from Sekisui Xenotech. Publicly available transcriptomic datasets analyzed in this study are accessible through the Gene Expression Omnibus (GEO) under accession numbers GSE15653 and GSE188418. Additional human plasma lipidomic data were obtained from the All of Us Research Program under approved data use agreements.[000317] RNA-seq raw and processed data generated in this study have been deposited in a public repository and are available under the accession number provided in the Data and Code Availability section. No new proprietary software or custom algorithms were generated in this study.[000318] Data and code availability[000319] This study utilized a range of open-source tools for data analysis; however, no new algorithms or tools were developed. Detailed information about the tools and their respective versions can be found herein. The codes used in this study are available upon request.[000320] Materials Availability[000321] All unique biological materials generated in this study, including hepatocytespecific NgBR knockout mice, AAV8-TBG-NgBR-HA vectors, and plasmids are available upon reasonable request and completion of a material transfer agreement.[000322] Data and Code AvailabilityDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026[000323] RNA sequencing data generated in this study will be deposited in the Gene Expression Omnibus (GEO) and made publicly available upon publication. Accession numbers are listed in the Key Resources Table. Previously published datasets analyzed in this study include human liver transcriptomic data (GEO: GSE156563) and cynomolgus monkey liver RNA-seq data (GEO: GSE188418). Bioinformatic analyses were conducted using publicly available software; no custom code was generated.[000324] Experimental Model and Subject Details[000325] Human Liver Samples[000326] Human liver tissue microarrays (formalin-fixed, paraffin-embedded) were purchased from Sekisui Xenotech and included samples from lean individuals (n = 6), obese individuals without type 2 diabetes (n = 15), and obese individuals with type 2 diabetes (n = 30). Samples were provided as de-identified specimens without direct identifiers. Available clinical metadata, including BMI and diabetes status, were supplied by the vendor. Use of these commercially available, de-identified specimens was considered not human subjects research and was therefore exempt from institutional review board oversight.[000327] Immunohistochemical staining for NgBR was performed on the tissue microarrays, and staining intensity was quantified using a semi-quantitative H-score approach. Image acquisition and scoring were performed in a blinded manner with respect to donor group assignment.[000328] Animals[000329] All animal experiments were conducted in accordance with NIH guidelines for the care and use of laboratory animals.[000330] Mice were housed in a pathogen-free facility under standard laboratory conditions, including a 12-hour light / 12-hour dark cycle (lights on at 7:00 a.m.), a temperature-controlled environment (22-23 °C), and ad libitum access to food and water unless otherwise specified. Animals were acclimated to handling for at least one week prior to metabolic testing.[000331] C57BL / 6J wild-type mice (JAX:000664) and db / db mice (JAX:000697) were obtained from The Jackson Laboratory. Hepatocyte-specific NgBR knockout mice (NgBR HepKO) were generated by crossing NgBR floxed mice with Albumin-Cre transgenic mice (JAX:003574) as described in our previous publication.56 Littermate NgBR floxed mice lacking Cre recombinase were used as controls (NgBR fl / fl).[000332] Only male mice were used for experiments to minimize variability due to sexdependent differences in metabolic phenotypes. Unless otherwise indicated, mice were 12 weeks of age at the start of dietary interventions. Animals were fed a control diet (CD;Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026 D12450J, 10% kcal from fat) or a high-fat diet (HFD; D12492, 60% kcal from fat; Research Diets) for up to 16 weeks.[000333] METHOD DETAILS[000334] Study Design and Randomization[000335] Mice were randomly assigned to experimental groups based on genotype and diet using simple randomization, with littermates distributed across groups whenever possible. Investigators were blinded to genotype during metabolic phenotyping, biochemical measurements, histological analyses, and data quantification, and blinding was maintained until completion of data analysis.[000336] Sample sizes were determined based on prior experience with metabolic phenotyping studies and were sufficient to detect biologically meaningful differences in glucose homeostasis. Humane endpoints were defined in advance, and mice were euthanized at study completion by CO2 inhalation followed by cervical dislocation, in accordance with institutional guidelines. No animals were excluded from analysis unless predefined technical failure occurred.[000337] AdipoRon Administration[000338] AdipoRon was prepared fresh on the day of injection and administered intraperitoneally (i.p.) at a dose of 50 mg / kg / day. Treatment was initiated after 10 weeks of control diet (CD) or high-fat diet (HFD) feeding and continued once daily for 4 consecutive weeks. Vehicle-treated mice received intraperitoneal injections on the same schedule. In AAV rescue experiments, AdipoRon treatment was initiated after hepatic viral expression had stabilized. Metabolic phenotyping was performed after completion of the AdipoRon treatment period.[000339] AA V-Mediated Hepatic NgBR Rescue[000340] Recombinant AAV8 vectors expressing HA-tagged NgBR under the hepatocyte-specific thyroxine-binding globulin (TBG) promoter (AAV8-TBG-NgBR-HA) or empty control vectors were used. Adult mice received a single tail vein injection of AAV at a dose of 0.5 x 1011genome copies (gc) per mouse following 8 weeks of control diet or high-fat diet feeding. Viral expression was allowed to proceed for 6 weeks prior to metabolic phenotyping.[000341] Hepatic specificity and expression efficiency were verified by quantitative PCR and immunoblotting of liver tissue.[000342] Longitudinal Metabolic MonitoringDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026[000343] Body weight, food intake, and fasting blood glucose levels were measured biweekly throughout the experimental period. Fasting blood glucose was assessed after a 12-hour overnight fast using tail vein sampling and a handheld glucometer.[000344] Metabolic Tolerance Tests[000345] All metabolic tolerance tests were conducted after a 12-hour overnight fast (food removed at 7:00 p.m.; testing performed the following morning). Mice were allowed free access to water during fasting.[000346] Glucose Tolerance Test (GTT)[000347] Following a 12-hour overnight fast, D-glucose was dissolved in sterile saline and administered intraperitoneally at a dose of 2 g / kg body weight. Blood glucose was measured from the tail vein at 0, 15, 30, 60, 90, and 120-minutes post-injection.[000348] Insulin Tolerance Test (ITT)[000349] Following a 12-hour overnight fast, recombinant human insulin was administered intraperitoneally at a dose of 0.75 U / kg body weight. Blood glucose was measured from the tail vein at 0, 15, 30, 60,90, and 120-minutes minutes post-injection.[000350] Pyruvate Tolerance Test (PTT)[000351] Following a 12-hour overnight fast, sodium pyruvate was administered intraperitoneally at a dose of 2 g / kg body weight. Blood glucose was measured from the tail vein at 0, 15, 30, 60, 90, and 120 minutes post-injection.[000352] Alanine Tolerance Test (ATT)[000353] Following a 12-hour overnight fast, L-alanine was administered intraperitoneally at a dose of 1.5 g / kg body weight. Blood glucose was measured from the tail vein at 0, 15, 30, 60, 90, and 120 minutes post-injection.[000354] For tolerance tests, area under the curve (AUC) was calculated using the trapezoidal method.[000355] DEXA Body Composition Analysis[000356] Whole-body composition was assessed by dual-energy X-ray absorptiometry (DEXA). Body composition and metabolic measurements were performed at ambient room temperature (23 °C). Mice were anesthetized and maintained under isoflurane inhalation anesthesia throughout the scanning procedure to minimize movement. Anesthetized mice were positioned prone on the specimen tray and scanned for approximately 4-5 min per animal. The head region was excluded from analysis. Parameters assessed included total body weight, fat mass, lean mass, percent body fat, bone mineral density (BMD), and bone mineral contentDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 (BMC). Animals were returned to their home cages and monitored during recovery from anesthesia.[000357] CLAMS Metabolic Cage Analysis[000358] Locomotor activity, oxygen consumption, and carbon dioxide production were monitored using a Comprehensive Lab Animal Monitoring System (Oxymax®-CLAMS, Columbus Instruments, Columbus, OH). Mice were singly housed in metabolic cages and acclimated for 48 hours prior to data acquisition to allow adaptation to the cages and drinking system. Data collected during the initial acclimation period were excluded from analysis.[000359] Following acclimation, energy expenditure, food intake, locomotor activity, oxygen consumption (VO2), carbon dioxide production (VCO2), and respiratory exchange ratio (RER) were continuously recorded. Measurements were analyzed over total 24-hour periods as well as separately for light and dark cycles.[000360] Blood Biochemistry and Hormone Measurements[000361] Blood samples were collected from fasted mice in the morning and centrifuged at 8,000 x g for 5 minutes to obtain serum. Serum samples were analyzed for HbAlc, insulin, C-peptide, adiponectin, glucagon, leptin, free fatty acids, triglycerides, cholesterol, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total bilirubin, albumin, blood urea nitrogen (BUN), creatinine, amylase, and lipase using commercially available ELISA or colorimetric assay kits according to the manufacturers’ instructions. Kit details are described herein.[000362] Insulin resistance and insulin sensitivity were estimated using the homeostatic model assessment of insulin resistance (HOMA-IR) and the quantitative insulin sensitivity check index (QUICKI), calculated from fasting glucose and insulin values.[000363] Primary Hepatocyte Isolation[000364] Mice were anesthetized and euthanized by cervical dislocation in accordance with institutional guidelines. The inferior vena cava was cannulated using a 24 G butterfly needle connected to a peristaltic pump. A small incision was made in the portal vein to allow outflow, and the liver was perfused in situ with 35 mL phosphate-buffered saline (PBS) containing 1% penicillin / streptomycin to remove blood.[000365] The liver was subsequently perfused with 35 mL liver perfusion medium (Gibco, #17701038) supplemented with 1% penicillin / streptomycin, followed by 35 mL liver digestion medium (Gibco, #17703034) containing 0.25% collagenase II (Thermo Fisher Scientific, #17101015). Following perfusion, the liver was excised, minced in digestion medium, and incubated on a rotor at 37 °C until complete tissue dissociation was achieved.Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026[000366] An equal volume of hepatocyte culture medium (Gibco, #17705-021) containing 10% fetal bovine serum (FBS) was added to terminate collagenase activity. The cell suspension was centrifuged at 300 × g for 10 minutes, and the resulting pellet was washed with hepatocyte wash buffer and centrifuged again at 300 x g for 10 minutes. The pellet was resuspended in hepatocyte culture medium and filtered through a 100 pm sterile cell strainer (Fisher Scientific, #431752). The filtrate was centrifuged at 300 x g for 10 minutes, and the final hepatocyte pellet was resuspended in hepatocyte culture medium and seeded onto collagen-coated six- well plates (Corning, #356400).[000367] Hepatic Glucose Production Assay[000368] Primary hepatocytes were incubated in glucose-free DMEM supplemented with lactate (20 mM) and pyruvate (2 mM. Cells were maintained under serum-free conditions for the indicated incubation period. At the end of the incubation, culture supernatants were collected, and glucose concentrations were quantified using an enzymatic glucose assay according to the manufacturer’s instructions. Glucose production was normalized to total cellular protein content, determined from parallel cell lysates.[000369] si-RNA-Mediated Knockdown in HepG2 Cells[000370] HepG2 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum and penicillin / streptomycin and maintained at 37 °C in a humidified incubator with 5% CO2. Cells were seeded one day prior to transfection to achieve approximately 50-70% confluence at the time of siRNA delivery.[000371] For siRNA-mediated gene silencing, HepG2 cells were transfected using Lipofectamine according to the manufacturer’s instructions. siRNA duplexes were used at a final concentration of 20 nM. siRNA-Lipofectamine complexes were prepared by diluting siRNA and Lipofectamine separately in Opti-MEM, combining the solutions, and incubating for 20 minutes at room temperature prior to addition to cells. Complexes were added dropwise to cells maintained in serum-containing medium, and plates were gently rocked to ensure even distribution.[000372] Control conditions included non-targeting siRNA and transfection reagent-only (mock) controls. Culture medium was replaced with fresh complete medium 6-8 hours posttransfection or the following day if signs of cytotoxicity were observed.[000373] Gene silencing efficiency was assessed at the mRNA level 24 hours posttransfection by quantitative real-time PCR and at the protein level 48 hours post-transfection by immunoblotting. Functional assays were performed at time points corresponding to maximal knockdown, as indicated in the figure legends.Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026[000374] si-RNA-Mediated Knockdown in Human Hepatocyte[000375] Cryopreserved human hepatocytes were thawed and plated according to the manufacturer’s instructions in hepatocyte medium and maintained at 37 °C in a humidified incubator with 5% CO2. Cells were seeded onto poly-L-lysine-coated culture plates at the recommended density and allowed to attach for 16-24 hours prior to transfection. Medium was refreshed the following day to remove residual DMSO and unattached cells.[000376] For gene silencing, hepatocytes were transfected with gene-specific siRNA duplexes at a final concentration of 20 nM using Lipofectamine RNAiMAX according to the manufacturer’s protocol optimized for primary cells. Briefly, siRNA and Lipofectamine RNAiMAX were diluted separately in Opti-MEM, combined, and incubated for 15-20 minutes at room temperature to allow complex formation. The siRNA-lipid complexes were added dropwise to cells maintained in serum-containing medium.[000377] Non-targeting siRNA was used as a negative control. Culture medium was replaced with fresh hepatocyte medium 6-8 hours after transfection to minimize cytotoxicity. Knockdown efficiency was assessed at the mRNA level 24 hours post-transfection by quantitative real-time PCR and at the protein level 48 hours post-transfection by immunoblotting. Functional assays were performed at time points corresponding to maximal gene suppression, as indicated in the figure legends.[000378] Lentiviral Overexpression[000379] Lentiviral vectors expressing KAT7 or a control lentivirus lacking a transgene were generated using a second-generation lentiviral packaging system. Lentiviral expression plasmids were co-transfected with the packaging plasmid psPAX2 and the envelope plasmid pVSVG into Lenti-X 293T cells using Lipofectamine 3000, according to the manufacturer’s instructions.[000380] Twelve hours after transfection, the culture medium was replaced with high-fetal bovine serum (FBS)-containing medium without antibiotics. Lentiviral supernatants were collected at 24- and 48-hours post-transfection, centrifuged at 12,000 rpm for 5 minutes to remove cellular debris, and filtered through 0.45-pm filters. Filtered viral supernatants were concentrated using the Lenti-X Concentrator according to the manufacturer’s protocol.[000381] HepG2 cells were infected with the concentrated lentiviral preparations. Twenty-four hours after infection, cells were selected with puromycin (1 pg / mL) for 3-4 days. Successfully transduced cell populations were subsequently expanded and allowed to recover to confluency prior to downstream analyses.[000382] Western BlottingDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026[000383] Cellular protein was extracted using radioimmunoprecipitation assay (RIP A) lysis buffer (Thermo Scientific) supplemented with protease and phosphatase inhibitor tablets (Pierce-Thermo Scientific). Lysates were cleared by centrifugation, and protein concentrations were determined using a detergent-compatible colorimetric protein assay (Bio-Rad, CA).[000384] Equal amounts of protein were mixed with Laemmli sample buffer supplemented with 10% P-mercaptoethanol, denatured by heating at 65 °C for 10 minutes, and resolved on 8-12% or 10% SDS-PAGE gels as indicated. Proteins were transferred onto nitrocellulose membranes using a Bio-Rad Trans-Blot® Turbo™ Transfer System for 30 minutes.[000385] Membranes were blocked in Tris-buffered saline (TBS) containing 1% (wt / vol) casein buffer (Bio-Rad) and incubated with primary antibodies overnight at 4 °C. Membranes were washed with TBS containing 0.1% Tween-20 (TBST) prior to incubation with secondary antibodies.[000386] Primary antibodies were detected using highly cross-adsorbed IRDye-conjugated secondary antibodies. Details are available in key resources table.[000387] Blots were imaged wet using the Odyssey CLx Imaging System (LLCOR Biosciences) with detection in the 680-nm and 780-nm channels. Densitometric analysis was performed using Image Studio software (LLCOR Biosciences).[000388] Quantitative Real-Time PCR[000389] Total RNA was isolated from cells or tissues using TRIzol reagent or the RNeasy Mini Kit (QIAGEN, Hilden, Germany), according to the manufacturers’ instructions. RNA concentration and purity were assessed spectrophotometrically. One microgram of total RNA was reverse-transcribed into complementary DNA (cDNA) using the i Script cDNA Synthesis Kit (Bio-Rad, Los Angeles, CA).[000390] Quantitative real-time PCR (qPCR) was performed on a Bio-Rad CFX Real-Time PCR Detection System using iTaq Universal SYBR Green Supermix (Bio-Rad, Los Angeles, CA). Reactions were run under standard cycling conditions as recommended by the manufacturer.[000391] Relative messenger RNA (mRNA) expression levels were calculated using the ΔΔCt method and normalized to the housekeeping gene GAPDH. Primer sequences used for qPCR are provided herein.[000392] Chromatin Immunoprecipitation— qPCR (ChlP—qPCR) Assay[000393] Chromatin immunoprecipitation (ChIP) assays were performed in HepG2 cells under the indicated treatment conditions using the SimpleChIP® Plus Enzymatic ChromatinDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 IP Kits (Cell Signaling Technology, #9004 and #9005), according to the manufacturer’s instructions. Briefly, cells were cross-linked with formaldehyde, quenched with glycine, and nuclei were isolated. Chromatin was digested enzymatically and sheared to an average fragment size suitable for qPCR analysis.[000394] Immunoprecipitation was carried out using antibodies specific to the indicated targets, as listed herein. An anti-histone H3 antibody was used as a positive control, and a normal IgG antibody was used as a negative control. Following immunoprecipitation, crosslinks were reversed, and DNA was purified according to the kit protocol.[000395] Recovered DNA was analyzed by quantitative PCR (qPCR) using gene promoter-specific primers, which are listed herein. ChlP-qPCR data were calculated as percent input or fold enrichment relative to IgG controls, as indicated in the figure legends.[000396] Histology, Immunohistochemistry[000397] Liver tissues were fixed in 10% neutral -buffered formalin, embedded in paraffin, and sectioned at 5 pm thickness. Sections were stained with hematoxylin and eosin (H& E) following standard histological procedures.[000398] For immunohistochemistry (IHC) paraffin sections were deparaffinized, rehydrated, and subjected to heat-induced antigen retrieval. Endogenous peroxidase activity was quenched for IHC analyses, and nonspecific binding was blocked prior to antibody incubation. Sections were incubated with validated primary antibodies against NgBR, G6PC, PCK1 overnight at 4 °C, followed by appropriate secondary antibodies for chromogenic detection (IHC).[000399] Images were acquired using a fluorescence or bright-field microscope under identical exposure settings. Quantification, where applicable, was performed in a blinded manner using standardized image analysis criteria.[000400] RNA sequencing and Library preparation[000401] The amount and quality of the total isolated RNA from the liver tissue were evaluated. To guarantee high-quality RNA for sequencing, RNA integrity numbers (RIN) were calculated. After that, the mRNA was separated from the total RNA using magnetic beads coupled to poly-T oligos, and it was broken up into tiny fragments using divalent cations at a high temperature.[000402] Reverse transcriptase and random hexamer primers were used for first-strand cDNA synthesis, whereas DNA Polymerase I and RNase H were used for second-strand cDNA synthesis. In order to maintain strand orientation for directional libraries, dUTP was added to the second-strand synthesis. After that, the cDNA was subjected to adapter ligation, A-tailing,Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026 and end repair. To choose cDNA fragments of the ideal lengths for sequencing, size selection was used.[000403] A Qubit Fluorometer and an Agilent Bioanalyzer were used to assess the quality of the prepared libraries. Real-time PCR was used to quantify the libraries, and the Bioanalyzer was used to verify their size distribution. Libraries were pooled based on their effective concentration and data amount, and sequenced on an Illumina platform using a paired-end 150 bp (PEI 50) strategy (Parkhomchuk et al. 2009). These procedures were carried out by Novogene in Sacramento, CA.[000404] Data Processing[000405] Raw sequencing reads were initially processed to eliminate adapters, poly-N sequences, and low-quality reads using Trimmomatic v0.36, applying the default parameters57. Subsequently, each sample’s quality was evaluated with standard parameters implemented in FastQC program. The paired-end alignment of pre-processed reads to the reference mouse genome (mm10) was conducted using the HISAT2 v.2.1.0 splice-mapping technique with default parameters58. Furthermore, FeatureCounts v1.5.0-p3 was used to determine the number of reads mapped to each gene59. Each gene's FPKM (Fragments Per Kilobase of Transcript Sequence per Million Base Pairs) was determined using the gene's length and the read count mapped to it. The most often used variables for estimating gene expression levels are read count and FPKM.[000406] Differential expression analysis[000407] Differential expression analysis of any two groups with three biological replicates per group was performed using DESeq2 (v.1.37.4) implemented in Bioconductor, R package (v.4.2.1). DESeq2 examines the dependence of variance on mean counts in the count data from two sample groups and tests for differential gene expression using the negative binomial distribution.60It computes statistical metrics such as False Discovery Rate (FDR), log2 fold change, and p-value following Benjamini and Hochberg's technique. Genes having an adjusted p-value (padj) less than 0.05 were considered significantly expressed. The differentially expressed genes (DEGs) were visualized through complex heat maps and volcano plots.[000408] KEGG Pathway analysis[000409] The KEGG (Kyoto Encyclopedia of Gene and Genome) is a database for higher-level of metabolic functions of biological systems and their annotations based on large-scale molecular datasets generated by high-throughput sequencing.61KEGG pathway enrichment analysis of differentially expressed genes was conducted using clusterProfiler (v. 4.5.1)Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026 implemented in Bioconductor, R package, with the p-value (< 0.05) is considered as a significant62.[000410] Lipidomics Analysis[000411] Hepatic lipidomic profiling was performed by MetWareBio (8 A Henshaw Street, Woburn, MA 01801). Fresh-frozen liver tissues were submitted directly to MetWareBio, where subsequent procedures — including lipid extraction, mass spectrometrybased lipidomics acquisition, lipid identification, and primary quantification — were conducted by the service provider using their standardized platforms. Lipid species were annotated and grouped into major lipid classes, including fatty acids, glycerolipids, glycerophospholipids, sphingolipids, prenol lipids, and sterol lipids. The processed lipidomics datasets provided by MetWareBio were subsequently analyzed in our laboratory. Quantitative data were normalized to tissue weight prior to downstream analysis. Differential lipid abundance between experimental groups was determined based on log2 fold-change thresholds with statistical significance assessed using adjusted p-values to control for multiple testing.[000412] Quantification and Statistical Analysis[000413] Data are presented as mean ± SD as indicated. Statistical analyses were performed using unpaired two-tailed Student’s t-tests or one-way or two-way ANOVA with appropriate post hoc tests using GraphPad Prism version 10. A p value < 0.05 was considered statistically significant.[000414][000415] KEY RESOURCES TABLEDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026[000416] Experimental Models: Cell Lines[000417] Biological Samples[000418] Chemicals, Peptides, and Recombinant Proteins[000419] Viral VectorsDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026[000420] Recombinant DNA[000421] Oligonucleotides[000422] DietsDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026[000423] Software and Algorithms[000424] Critical Commercial AssaysDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026[000425] Cell Culture & Molecular Reagents[000426] AntibodiesDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026[000427][000428] qPCR Primers Used in This Study [000429] MouseDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026[000430] HumanDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026Adipo-R2 qPCR primer setTargetregion Forward Primer (5'— >3') Reverse Primer (5'— >3') -1250—1160 CCACTCCTTGGAGGAAATTAGTTCC GCCCACTCATTTAAGCTTGAAAGAG -1184—1031 CTCTTTCAAGCTTAAATGAGTGGGC GCTGGAGTCGGATATATGACGA -1052—949 TCGTCATATATCCGACTCCAGC GCCCACGGCTTACTGTCCTTA -969—854 TAAGGACAGTAAGCCGTGGGC GGGGAATTTATCACATTCTTAAGGCG -879—756 CGCCTTAAGAATGTGATAAATTCCCC GAAGCCAAGAACAGATTTGGTTACG -780—674 CGTAACCAAATCTGTTCTTGGCTTC GCACTAAATACCTGCGTCCATTTAC -698—514 GTAAATGGACGCAGGTATTTAGTGC CCCAGAGCAATAGTGTTTGCC -534—422 GGCAAACACTATTGCTCTGGG TGGATCGTGTGTCTCTGCCAA -442—349 TTGGCAGAGACACACGATCCA CGGATGCTTTTCGCAGTCTCTAT -371—256 ATAGAGACTGCGAAAAGCATCCG CTCCTTAGGCGCTCACACAADocket No.: 2969825-000009-W01Date of Filing: May 08, 2026-275—164 TTGTGTGAGCGCCTAAGGAG CGCTCTAAAACCTGGGTGC -182—82 GCACCCAGGTTTTAGAGCG CATCGCACGAGGCGGTTC-99-+14 GAACCGCCTCGTGCGATG GCGATGCCGCTTCTGGAATC-6-+114 GATTCCAGAAGCGGCATCGC TCGGACTTCTTGGGAGCCA+96-+219 TGGCTCGCAAGAAGTCCGA AGCTCTCACCTCCTCCC+203-+347 GGATGGAGGTGAGAGCT GGCTCCAGGTCCTCACAC[000431][000432] Example 3[000433] Project Description[000434] We identified a target for improving hepatic insulin sensitivity and the effectiveness of GLP-1 receptor agonists (GLP-lRAs). The loss of this target in the livers of obese patients leads to an inadequate response. Developing drugs to restore target expression is essential for enhancing the efficacy of GLP-lRAs.[000435] Abstract[000436] The function of GLP-1 receptor (GLP1R) agonists is to promote insulin secretion from the pancreas. However, if patients lose functional beta cells due to prolonged diabetes or have severe insulin resistance, where insulin fails to suppress glucose production in the liver, GLP1R agonists cannot achieve a sufficient reduction in blood glucose levels. The advantage of our innovation is its ability to restore insulin sensitivity, thereby reducing the demand for excessive insulin production. New features include: 1) Identifying a new target, Nogo-B receptor (NgBR), for restoring insulin sensitivity. 2) Revealing that the loss of NgBR in the obese liver significantly undermines the efficacy of GLP-1R agonists. 3) Demonstrating the feasibility of enhancing the efficacy of GLP-1R agonists through an AAV-mediated gene delivery approach. 4) Restoring NgBR expression can lower the required dosage of GLP-1R agonists to achieve comparable glycemic control, which is crucial for type 1 diabetes patients and others with beta cell failure. In addition, we found that GLP-1R agonists induced the NgBR expression in the mouse livers, which can contribute to the beneficial effects of GLP-1 R agonists in glycemia control.[000437] Background[000438] Blood glucose homeostasis is regulated by three essential biological functions: insulin-dependent suppression of glucose production in the liver, insulin secretion from the pancreas, and glucose uptake by skeletal muscle. GLP-1 receptor (GLP-1R) agonists are theDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 most commonly prescribed medications for diabetes because they stimulate insulin secretion from the pancreas. However, if patients lose functional beta cells due to a prolonged duration of diabetes or experience severe insulin resistance, insulin cannot adequately suppress glucose production in the liver. Therefore, GLP-1R agonists may not sufficiently lower blood glucose levels in some diabetes patients. Moreover, they can produce adverse effects, such as muscle loss and gastrointestinal discomfort, leading to discontinuation of the medication. Consequently, enhancing the efficacy of GLP-1R agonists while reducing their dosage is a key focus of current research. Strategies being explored include developing dual glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptor agonists, optimizing drug delivery mechanisms to extend half-life, modulating receptor trafficking to amplify signaling, and investigating combinations with other therapeutic agents, such as sodium-glucose cotransporter 2 (SGLT2) inhibitors, to synergistically improve metabolic effects. These approaches still focus on modifying GLP-1R agonists and overlook the intrinsic insulin sensitivity regulated by the liver, which is the sole tissue responsible for glucose production.[000439] Nogo-B receptor (NgBR) is a cell surface receptor critical for the biological functions of adiponectin and insulin in suppressing glucose production in the liver. NgBR levels are reduced in the livers of patients with obesity-induced diabetes (OID). The absence of NgBR leads to insulin resistance, the primary cause of type 2 diabetes. Accordingly, without wishing to be bound by theory, the insulin resistance in OID patients hinders their response to insulin, which is enhanced by GLP-1R agonists. This explains why some diabetes patients cannot achieve the reduction in blood glucose levels. After being fed a high-fat diet for 10-12 weeks, the blood glucose levels in mice reach diabetic levels, accompanied by increased body weight. GLP-1R agonist (semaglutide) injections significantly lower blood glucose levels and body weight. However, these injections do not produce a similar reduction in blood glucose levels in NgBR hepatic knockout (hepKO) mice, which are genetically modified to lack NgBR in liver cells, although body weight is reduced. Following the cessation of GLP-1R agonist injections, blood glucose levels increased markedly. Resuming GLP-1 R agonist injections decreased both body weight and blood glucose levels in littermate control mice (NgBR fl / fl), but blood glucose levels in NgBR knockout mice continued to rise. When we employed an adeno-associated virus (AAV)-mediated gene delivery approach to restore NgBR expression in liver cells, the blood glucose levels of NgBR hepKO mice significantly decreased to normal levels, and insulin sensitivity improved. GLP-1R agonists do not elicit a complete response in glycemic control in type 1 diabetes mouse models (STZ-injected littermate control mice). However, AAV-mediated overexpression of the NgBR significantly enhances the response toDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 GLP-1R agonists in terms of glycemic control. Our findings indicate that NgBR expression is essential for maintaining the insulin sensitivity required for the pharmacological function of GLP-1R agonists. This indicates that restoring NgBR expression, which is diminished in the livers of patients with obesity-induced diabetes, can be an alternative approach to increasing sensitivity to GLP-1R agonists and reducing necessary dosages, thus helping to avoid medication complications such as muscle loss and gastrointestinal adverse events.[000440] A major challenge with GLP-1 agonists is the potential for gastrointestinal side effects, such as nausea and vomiting. Reducing dosage while improving GLP-1R agonist efficacy is one of the current research directions. The strategies explored include developing dual GIP / GLP-1 receptor agonists, optimizing drug delivery mechanisms to prolong half-life, modulating receptor trafficking to enhance signaling, and investigating combinations with other therapeutic agents, such as SGLT2 inhibitors, which can synergistically enhance metabolic effects. These approaches still focus on modifying GLP-1R agonists and overlook the intrinsic insulin sensitivity regulated by the liver, the exclusive tissue responsible for glucose production.[000441] The advantage of our innovation lies in its ability to restore insulin sensitivity, thereby decreasing the demand for large amounts of insulin production driven by GLP-1R agonists. The new features of this innovation include: 1) the identification of a new target for restoring insulin sensitivity; 2) the revelation that the loss of NgBR in the obese liver is the primary factor compromising the efficacy of GLP-1R agonists; 3) the demonstration of the feasibility of enhancing the efficacy of GLP-1R agonists through an AAV-mediated gene delivery approach; and 4) the restoration of hepatic NgBR expression, which can lessen the dosage of GLP-1R agonists needed to achieve equivalent glycemic control. This is critical for patients with type 1 diabetes and others experiencing beta cell failure.[000442] GLP1R agonists have the largest market share of diabetes medication, but because of new diabetes drugs, there are not sufficient studies on their long-term side effects. Newly identified drugs that improve the efficiency of GLP1R agonist treatment in poor response patients and increase treatment duration by reducing side effects can have high translational value, which can attract collaboration with pharmaceutical companies.[000443] Results[000444] Hepatic NgBR restoration is required for sustained GLP-1— mediated glycemic control under metabolic stress[000445] Mice were placed on a high-fat diet (HFD; -60% kcal from fat) starting at 12 weeks to induce metabolic dysfunction. At approximately 20 weeks of age, mice received aDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 single intravenous tail-vein inj ection of an adeno-associated virus vector encoding NgBR under a liver-specific promoter (AAV8-TBG-NgBR) or a control vector. At approximately 28 weeks of age, a GLP-1 receptor agonist (semaglutide) was initiated at a dose of approximately 70 pg / kg and administered for -14 weeks. GLP-1 treatment was discontinued at approximately 42 weeks of age, followed by continued metabolic monitoring. Body weight and blood glucose levels were measured bi-weekly throughout the study period (12-58 weeks of age). Glucose tolerance tests (GTT; 2 g / kg glucose following overnight fasting) and insulin tolerance tests (ITT; 0.75 U / kg insulin following short-term fasting) were performed at approximately 46 weeks of age. Data are presented as mean ± SD, with group sizes ranging from n = 6-10 mice per group. Statistical comparisons between groups were performed using analysis of variance (ANOVA) with appropriate post hoc testing. No significant difference in body weight was observed among the groups. However, NgBR hepKO mice with NgBR AAV rescue (restoring hepatic NgBR) showed significantly decreased blood glucose levels. The littermate control (NgBR fl / fl) group maintained lower blood glucose levels, whereas NgBR hepKO mice exhibited persistently high blood glucose levels despite the GLP-1RA treatment. These results indicate that the absence of NgBR in hepatocytes impairs the efficacy of GLP-lRAs, and that restoration of NgBR enhances their efficacy in blood glucose control.[000446] Hepatic NgBR is essential for GLP-1RA— mediated improvement of insulin sensitivity and glucose tolerance[000447] Male mice comprising NgBR fl / fl controls, hepatocyte-specific NgBR knockout (NgBR HepKO), and NgBR HepKO mice with AAV-mediated NgBR restoration were subjected to high-fat diet-induced metabolic dysfunction and treated with a GLP-1 receptor agonist (e.g., semaglutide at ~70 pg / kg) for approximately 14 weeks before metabolic assessment. Insulin tolerance testing (ITT) was performed following a 4-6 hour fast by intraperitoneal administration of insulin (-0.75 U / kg body weight), with blood glucose measured at multiple time points (0-120 minutes). NgBR hepKO mice exhibited elevated blood glucose levels throughout the ITT time course compared to NgBR fl / fl controls, indicating reduced insulin sensitivity. In contrast, NgBR HepKO mice receiving AAV-mediated NgBR restoration showed improved glucose lowering, comparable to control mice. Quantitative analysis of the area under the curve (AUC) confirmed a significant impairment in insulin responsiveness in NgBR-deficient mice, which was corrected by NgBR re-expression. In a subsequent experiment conducted after an appropriate recovery period (approximately one week), glucose tolerance testing (GTT) was performed following an overnight fast (-12 hours) using intraperitoneal glucose administration (-2 g / kg body weight). NgBR HepKO miceDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 exhibited significantly elevated blood glucose levels at multiple time points (15-120 minutes) compared with both the control and NgBR-rescued groups, indicating impaired glucose clearance. Restoration of NgBR expression normalized glucose tolerance, as reflected by reduced glucose excursion and AUC. Collectively, these results demonstrate that loss of NgBR in hepatocytes diminishes the metabolic efficacy of GLP-1 receptor agonist treatment, leading to impaired insulin sensitivity and glucose tolerance, whereas restoration of NgBR reverses these defects.[000448] NgBR restoration is essential for GLP-1RA to control blood glucose in type 1 diabetic mice[000449] Twelve-week-old male mice were used for the experiments. A single intraperitoneal injection of streptozotocin (STZ) at a dosage of 200 mg / kg body weight was administered to induce type 1 diabetes, which was confirmed after two weeks. GLP-1RA (semaglutide) treatment began immediately after the STZ injection at a dose of 70 pg / kg body weight and continued for 2 weeks. No significant differences in body weight were noted among the groups. The NgBR hepKO mice showed persistently elevated glucose levels despite GLP- 1RA treatment. However, NgBR hepKO mice with NgBR AAV rescue (restoring hepatic NgBR) exhibited a significant reduction in blood glucose levels. These findings indicate that the expression of NgBR in hepatocytes is critical for the glucose-lowering efficacy of GLP- 1RA in the setting of type 1 diabetes.[000450] GLP-1 receptor agonists coordinate NgBR induction and a Adipose-derived Nogo-B signaling to establish a functional metabolic axis[000451] Male mice were maintained under control diet (CD) or high-fat diet (HFD) conditions to establish baseline and metabolically impaired states. A subset of HFD-fed mice received treatment with a GLP-1 receptor agonist (GLP-1RA). At the experimental endpoint, serum, liver, and white adipose tissue (WAT) were collected for molecular and biochemical analyses.[000452] As shown in FIG.27, gene expression of NgBR (NUS1) was assessed in tissue samples using quantitative PCR following RNA isolation and normalization to housekeeping genes. Circulating soluble Nogo-B levels were measured in serum using immunoassay-based methods. Expression of Nogo-B (RTN4) in WAT was quantified by quantitative PCR. GLP- 1RA treatment resulted in a significant increase in NgBR expression relative to control conditions, indicating that GLP-1 signaling promotes upregulation of the Nogo-B receptor in target tissues (p ~ 0.0121). In parallel, circulating levels of soluble Nogo-B were significantlyDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 elevated in GLP-l-treated mice compared with both the control diet and untreated HFD groups (p ~ 0.0145-0.0159), indicating increased systemic availability of the ligand.[000453] Consistent with these findings, Nogo-B mRNA expression in WAT was markedly increased in GLP- IRA-treated mice relative to control groups (p ~ 0.0003-0.0004), indicating that adipose tissue is a source of GLP-l-induced Nogo-B production. Collectively, these results demonstrate that GLP-1 receptor agonist treatment induces coordinated upregulation of both NgBR and its ligand Nogo-B across multiple tissues, including increased receptor expression and enhanced adipose-derived ligand production. These changes establish a functional signaling axis that can contribute to improved systemic glucose homeostasis and enhanced metabolic responsiveness.[000454] Pharmacologic Activation of PPARy Induces NgBR Expression in Hepatocytes in a Dose-Dependent Manner[000455] Human hepatocyte-derived HepG2 cells were cultured under standard conditions and treated with the PPARy agonist pioglitazone at concentrations of 5 pM and 10 pM for approximately 24 hours. Untreated cells served as controls. Following treatment, total RNA was isolated, and quantitative PCR (qPCR) was performed to assess NUS1 (NgBR) expression. Gene expression levels were normalized to housekeeping genes and expressed as fold change relative to untreated controls.[000456] As shown in FIG.28, treatment with pioglitazone resulted in a dose-dependent increase in NgBR (NUS1) expression. Specifically, cells treated with 5 pM pioglitazone exhibited a significant increase in NgBR mRNA compared to control conditions (p < 0.0001). A further increase in NgBR expression was observed at 10 pM, indicating a dose-responsive effect (p < 0.0001 versus control and lower dose).[000457] These findings demonstrate that activation of PPARy signaling induces NgBR expression in hepatocytes in a concentration-dependent manner. The data support the conclusion that NgBR is a pharmacologically inducible target and that small-molecule PPAR agonists can be used to enhance NgBR expression, thereby providing a mechanistic basis for combination therapies aimed at improving metabolic function and responsiveness to GLP-1 receptor agonists.[000458] Conclusion: Hepatic NgBR is essential for sustaining insulin sensitivity and improving the efficacy of GLP-lRAs. Induction of NgBR in the liver and Nogo-B in adipose tissue can contribute to the beneficial effects of GLP-lRAs.[000459] Methods:[000460] AnimalsDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026[000461] All animal experiments conducted in accordance with NIH guidelines for the care and use of laboratory animals.[000462] Mice were housed in a pathogen-free facility under standard laboratory conditions, including a 12-hour light / 12-hour dark cycle (lights on at 7:00 a.m.), a temperature-controlled environment (22-23 °C), and ad libitum access to food and water unless otherwise specified. Animals were acclimated to handling for at least one week prior to metabolic testing.[000463] C57BL / 6J wild-type mice (JAX:000664) and db / db mice (JAX:000697) were obtained from The Jackson Laboratory. Hepatocyte-specific NgBR knockout mice (NgBR HepKO) were generated by crossing NgBR floxed mice with Albumin-Cre transgenic mice (JAX:003574) as described in our previous publication. Littermate NgBR floxed mice lacking Cre recombinase were used as controls (NgBR fl / fl).[000464] Only male mice were used for experiments to minimize variability due to sexdependent differences in metabolic phenotypes. Unless otherwise indicated, mice were 12 weeks of age at the start of dietary interventions. Animals were fed a control diet (CD; D12450J, 10% kcal from fat) or a high-fat diet (HFD; D12492, 60% kcal from fat; Research Diets) for up to 16 weeks.[000465] AA V-Mediated Hepatic NgBR Rescue[000466] Recombinant AAV8 vectors expressing HA-tagged NgBR under the hepatocyte-specific thyroxine-binding globulin (TBG) promoter (AAV8-TBG-NgBR-HA) or empty control vectors were used. Adult mice received a single tail vein injection of AAV at a dose of 0.5 x 1011genome copies (gc) per mouse following 8 weeks of control diet or high-fat diet feeding. Viral expression was allowed to proceed for 6 weeks prior to metabolic phenotyping.[000467] Hepatic specificity and expression efficiency were verified by quantitative PCR and immunoblotting of liver tissue.[000468] Longitudinal Metabolic Monitoring[000469] Body weight, food intake, and fasting blood glucose levels were measured biweekly throughout the experimental period. Fasting blood glucose was assessed after a 12-hour overnight fast using tail vein sampling and a handheld glucometer.[000470] Metabolic Tolerance Tests[000471] All metabolic tolerance tests were conducted after a 12-hour overnight fast (food removed at 7:00 p.m.; testing performed the following morning). Mice were allowed free access to water during fasting.[000472] Glucose Tolerance Test (GTT)Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026[000473] Following a 12-hour overnight fast, D-glucose was dissolved in sterile saline and administered intraperitoneally at a dose of 2 g / kg body weight. Blood glucose was measured from the tail vein at 0, 15, 30, 60, 90, and 120-minutes post-injection.[000474] Insulin Tolerance Test (ITT)[000475] Following a 12-hour overnight fast, recombinant human insulin was administered intraperitoneally at a dose of 0.75 U / kg body weight. Blood glucose was measured from the tail vein at 0, 15, 30, 60,90, and 120-minutes post-injection.[000476] For tolerance tests, area under the curve (AUC) was calculated using the trapezoidal method.[000477] Blood Biochemistry and Hormone Measurements[000478] Blood samples were collected from fasted mice in the morning and centrifuged at 8,000 x g for 5 minutes to obtain serum. Serum samples were analyzed for HbAlc, insulin, C-peptide, using commercially available ELISA or colorimetric assay kits according to the manufacturers’ instructions.[000479] Insulin resistance and insulin sensitivity were estimated using the homeostatic model assessment of insulin resistance (HOMA-IR) and the quantitative insulin sensitivity check index (QUICKI), calculated from fasting glucose and insulin values.[000480] Quantitative Real-Time PCR[000481] Total RNA was isolated from cells or tissues using TRIzol reagent or the RNeasy Mini Kit (QIAGEN, Hilden, Germany), according to the manufacturers’ instructions. RNA concentration and purity were assessed spectrophotometrically. One microgram of total RNA was reverse-transcribed into complementary DNA (cDNA) using the i Script cDNA Synthesis Kit (Bio-Rad, Los Angeles, CA).[000482] Quantitative real-time PCR (qPCR) was performed on a Bio-Rad CFX Real-Time PCR Detection System using iTaq Universal SYBR Green Supermix (Bio-Rad, Los Angeles, CA). Reactions were run under standard cycling conditions as recommended by the manufacturer.[000483] Relative messenger RNA (mRNA) expression levels were calculated using the ΔΔCt method and normalized to the housekeeping gene GAPDH.[000484] Quantification and Statistical Analysis[000485] Data are presented as mean ± SD as indicated. Statistical analyses were performed using unpaired two-tailed Student’s t-tests or one-way or two-way ANOVA with appropriate post hoc tests using GraphPad Prism version 10. A p value < 0.05 was considered statistically significant.Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026[000486][000487] Example 4[000488] The pharmacological approach to enhance the efficacy of GLP1R agonists in glycemic control by restoring hepatic insulin sensitivity[000489] We identified a target for improving hepatic insulin sensitivity and the effectiveness of GLP-1 receptor agonists (GLP-lRAs). The loss of this target in the livers of obese patients leads to an inadequate response. Developing drugs to restore target expression is essential for enhancing the efficacy of GLP-lRAs.[000490] Abstract[000491] The function of GLP-1 receptor (GLP1R) agonists is to promote insulin secretion from the pancreas. However, if patients lose functional beta cells due to prolonged diabetes or have severe insulin resistance, where insulin fails to suppress glucose production in the liver, GLP1R agonists cannot achieve a sufficient reduction in blood glucose levels. The advantage of our innovation is its ability to restore insulin sensitivity, thereby reducing the demand for excessive insulin production. The new features include: 1) Identifying a new target, Nogo-B receptor (NgBR), for restoring insulin sensitivity. 2) Revealing that the loss of NgBR in the obese liver significantly undermines the efficacy of GLP-1R agonists. 3) Demonstrating the feasibility of enhancing the efficacy of GLP-1R agonists through an AAV-mediated gene delivery approach. 4) Restoring NgBR expression can lower the required dosage of GLP-1R agonists to achieve comparable glycemic control, which is crucial for type 1 diabetes patients and others with beta cell failure. The goal of this proposal is to screen small-molecule drugs that can restore NgBR expression in obese livers and evaluate the efficacy of the identified drugs in improving the effectiveness of GLP1R agonists in established diabetic animal models.[000492] Background[000493] Blood glucose homeostasis is regulated by three essential biological functions: insulin-dependent suppression of glucose production in the liver, insulin secretion from the pancreas, and glucose uptake by skeletal muscle. GLP-1 receptor (GLP-1R) agonists are prescribed medications for diabetes because they stimulate insulin secretion from the pancreas. However, if patients lose functional beta cells due to a prolonged duration of diabetes or experience severe insulin resistance, insulin cannot adequately suppress glucose production in the liver. Therefore, GLP-1R agonists may not sufficiently lower blood glucose levels in some diabetes patients. Moreover, they can produce adverse effects, such as muscle loss and gastrointestinal discomfort, leading to discontinuation of the medication. Consequently, enhancing the efficacy of GLP-1R agonists while reducing their dosage is a key focus of currentDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 research. Strategies being explored include developing dual glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptor agonists, optimizing drug delivery mechanisms to extend half-life, modulating receptor trafficking to amplify signaling, and investigating combinations with other therapeutic agents, such as sodium-glucose cotransporter 2 (SGLT2) inhibitors, to synergistically improve metabolic effects. These approaches still focus on modifying GLP-1R agonists and overlook the intrinsic insulin sensitivity regulated by the liver, which is the sole tissue responsible for glucose production. Nogo- B receptor (NgBR) is a cell surface receptor critical for the biological functions of adiponectin and insulin in suppressing glucose production in the liver. NgBR levels are reduced in the livers of patients with obesity- induced diabetes (OID). The absence of NgBR leads to insulin resistance, the primary cause of type 2 diabetes. Without wishing to be bound by theory, insulin resistance in OID patients hinders their response to insulin, which is enhanced by GLP-1R agonists. This explains why some diabetes patients cannot achieve the reduction in blood glucose levels. After being fed a high-fat diet for 10-12 weeks, the blood glucose levels in mice reach diabetic levels, accompanied by increased body weight. GLP-1R agonist (semaglutide) injections significantly lower blood glucose levels and body weight. However, these injections do not produce a similar reduction in blood glucose levels in NgBR hepatic knockout (hepKO) mice, which are genetically modified to lack NgBR in liver cells, although body weight is reduced. Following the cessation of GLP-1R agonist injections, blood glucose levels increased markedly. Resuming GLP-1 R agonist injections decreased both body weight and blood glucose levels in littermate control mice (NgBR fl / fl), but blood glucose levels in NgBR knockout mice continued to rise. When we employed an adeno-associated virus (AAV)-mediated gene delivery approach to restore NgBR expression in liver cells, the blood glucose levels of NgBR hepKO mice significantly decreased to normal levels, and insulin sensitivity improved. GLP-1R agonists do not elicit a complete response in glycemic control in type 1 diabetes mouse models (STZ-injected littermate control mice). However, AAV-mediated overexpression of the NgBR significantly enhances the response to GLP-1R agonists in terms of glycemic control. Our findings indicate that NgBR expression is essential for maintaining the insulin sensitivity required for the pharmacological function of GLP-1R agonists. This indicates that restoring NgBR expression, which is diminished in the livers of patients with obesity-induced diabetes, can be an alternative approach to increasing sensitivity to GLP-1R agonists and reducing necessary dosages, and thus helping to avoid medication complications such as muscle loss and gastrointestinal adverse events.Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026[000494] A major challenge with GLP-1 agonists is the potential for gastrointestinal side effects, such as nausea and vomiting. Reducing dosage while improving GLP-1R agonist efficacy is one of the current research directions. The strategies explored include developing dual GIP / GLP-1 receptor agonists, optimizing drug delivery mechanisms to prolong half-life, modulating receptor trafficking to enhance signaling, and investigating combinations with other therapeutic agents, such as SGLT2 inhibitors, which can synergistically enhance metabolic effects. These approaches still focus on modifying GLP-1R agonists and overlook the intrinsic insulin sensitivity regulated by the liver, the exclusive tissue responsible for glucose production. The advantage of our innovation lies in its ability to restore insulin sensitivity, thereby decreasing the demand for large amounts of insulin production driven by GLP-1R agonists. The new features of this innovation include: 1) the identification of a new target for restoring insulin sensitivity; 2) the revelation that the loss of NgBR in the obese liver is the primary factor compromising the efficacy of GLP-1R agonists; 3) the demonstration of the feasibility of enhancing the efficacy of GLP-1R agonists through an AAV-mediated gene delivery approach; and 4) the restoration of hepatic NgBR expression, which can lessen the dosage of GLP-1R agonists needed to achieve equivalent glycemic control. This is critical for patients with type 1 diabetes and others experiencing beta cell failure.[000495] Goals[000496] 1. Identify small-molecule drugs that can restore the expression of NgBR in hepatocytes by drug screening.[000497] 2. Evaluate how effectively candidate drugs restore NgBR expression in obese livers and enhance the efficacy of GLP1R agonists for glycemic control in diabetic mouse models.[000498] Research Strategy[000499] 1. To validate small-molecule drugs that can restore the expression of NgBR in hepatocytes, we will establish an in vitro cell culture system (reporting cells) for drug screening in my laboratory. We will clone the human NgBR promoter into the luciferase reporting vector and test its sensitivity using known agonists, including clinically approved PPARa agonists like Fenofibrate and Pemafibrate. Our recent publication showed that the NgBR promoter region contains the PPAR response element (PPRE). Based on the single-nuclei RNA-seq data (GSE189600), PPARa is the predominant isoform in hepatocytes and is significantly downregulated in the nonalcoholic steatohepatitis (NASH) liver. As one of the PPAR-targeted genes, NgBR is only significantly expressed in PPARa-positive hepatocytes. The knockdown of PPARa downregulated the transcription of NgBR in hepatocytes, while PPARa agonistDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 stimulation increased NgBR expression in hepatocytes. Based on current agonists (Fenofibrate and Pemafibrate), we will select an appropriate chemical library and conduct in vitro drug screening.[000500] 2. To assess the efficacy of candidate drugs in restoring NgBR expression in obese livers and enhancing the effectiveness of GLP-1R, we will first validate the performance of these candidate drugs in palmitic acid-treated human and mouse hepatocytes, as palmitic acid decreases the expression of NgBR. Additionally, we will validate the ability of the candidate drugs to enhance the effects of GLP-1R agonists in established diabetes mouse models, including obesity-induced type 2 diabetes and streptozotocin (STZ)-induced type 1 diabetes, characterized by beta cell dysfunction. Treatment outcomes will be evaluated by monitoring improvements in fasting blood glucose, hemoglobin Ale (HbAlC), insulin sensitivity tests, body weight, and body composition. Potential drug toxicity will also be assessed by measuring changes in liver function (AST / ALT) and indicators of pancreatitis (S-Amylase and lipase activities) as well as kidney function tests (Creatinine levels, estimated Glomerular filtration rate (eGFR), Urine Albumin-Creatinine ratio (UACR), Blood Urea Nitrogen (BUN)).[000501] Milestones and deliverables[000502] 1. Identify drugs that restore NgBR expression with low cytotoxicity in vitro and in vivo.[000503] 2. Evaluate the preclinical efficacy of enhancing GLP-1R agonists in established diabetes mouse models.[000504] GLP1R agonists have the largest market share of diabetes medication, but because of new diabetes drugs, there are not sufficient studies on their long-term side effects. Newly identified drugs that improve the efficiency of GLP1R agonist treatment in poor response patients and increase treatment duration by reducing side effects can have high translational value, which can attract collaboration with pharmaceutical companies.[000505][000506] Example 5[000507] NgBR Restoration[000508] Referring to FIG. 29, GLP-1RA (Semaglutide, 10 nmol / kg, every other day) treatment increases the expression levels of PPARy and NgBR in the liver of littermate control mice fed with a high-fat diet for 10 weeks.[000509][000510] Example 6Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026[000511] Liver tissues were collected and H& E staining was performed to assess morphology. As shown in the FIG.30, FIG.30A shows the liver of littermate control mice on a high-fat diet, with fatty liver. GLP1-RA injection (FIG. 30B) mitigated the fatty liver. FIG.30C shows that NgBR hepatocyte knockout (hepKO) mice have a severe fatty liver compared to FIG. 30A. GLP-1RA cannot achieve the reduction effects in NgBR hepKO mice (FIG.30D) However, AAV-mediated overexpression of NgBR (FIG. 30E) in the hepatocyte restores the beneficial effects of GLP1-RA on reducing fatty liver to a healthy condition. The results indicate that NgBR is also essential for GLP-lRAs to reduce fatty liver.[000512] The disclosed method and compositions are not limited to the particular methodology, protocols, and reagents described as these can vary. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present invention, which will be limited only by the appended claims.[000513] Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, many equivalents to the specific embodiments of the method and compositions described herein. Such equivalents are intended to be encompassed by the following claims.
Claims
Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026 CLAIMSWe claim:
1. A method of preventing one or more symptoms associated with diabetes in a subject, comprising administering to the subject, an effective amount of an NgBR activator and a glucagon-like peptide-1 receptor agonists (GLP-1RA).
2. The method of claim 1, wherein the NgBR activator comprises a nucleic acid encoding the NgBR in an expression vector.
3. The method of claim 2, wherein the expression vector is an adeno-associated vector (AAV).
4. The method of any one of claims 1-3, wherein the GLP-1RA is selected from the group consisting of exenatide, lixisenatide, liraglutide, albiglutide, dulaglutide, semaglutide, orfoglipron, retatrutide, CagriSema (semaglutide with cagrilintide), tirzepatide, and mazdutide.
5. The method of claim 4, wherein the GLP-1RA is semaglutide.
6. The method of any one of claims 1-5, wherein the subject is a type I diabetic.
7. The method of any one of claims 1-5, wherein the subject is a type II diabetic, wherein the subject has beta cell dysfunction.
8. The method of any one of claims 1, 4-7, wherein the NgBR activator is a small molecule activator.
9. The method of claim 8, wherein the small molecule activator is caffeine, a statin, or a PPAR agonist.
10. The method of clam 9, wherein the statin is selected from the group consisting of Atorvastatin (Lipitor), Rosuvastatin (Crestor), Simvastatin (Zocor), Lovastatin (Altoprev), Pravastatin (Pravachol), Fluvastatin (Lescol), and Pitavastatin (Livalo).
11. The method of clam 9, wherein the PPAR agonist is selected from the group consisting of Fibrates (Fenofibrate, Benzafibrate, Gemfibrozil), Thiazolidinediones (Pioglitazone, Rosiglitazone), GW501516, Lanifibranor (pan-PPAR agonists).
12. The method of claim 10, wherein the subject does (a) have high cholesterol (LDL above 190 mg / dL); (b) have an LDL above 160 mg / dL, a family history of early coronary artery disease and are 20 to 39 years old; (c) have a history of a stroke, heart attack or peripheral artery disease (PAD); (d) have diabetes and an LDL of at least 70 mg / dL and are 40 to 75 years old; or (e) Have an LDL of at least 70 mg / dL and a high risk of getting heart disease and are 40-75 years old.
13. The method of any one of claims 1-12, wherein the composition is administered for atDocket No.: 2969825-000009-W01Date of Filing: May 08, 2026 least 10 days, and up to one month, optionally, daily.
14. The method of claim 13, wherein the composition is administered at a first effective dose for at least two weeks, followed by administration of a second effective dose (the maintenance dose), wherein the maintenance dose is at least half, a third or a quarter of the first effective dose.
15. The method of any one of claims 1-14, wherein the NgBR activator and GLP-1RA are administered for at least one month.
16. The method of any one of claims 1-15, wherein the NgBR activator comprises a nucleic acid encoding the NgBR in a viral or non-viral carrier, wherein the carrier comprises a hepatocyte targeting moiety.
17. The method of any one of claims 1-15, wherein the blood glucose levels and optionally, the subject’s daily body weight, reduces following administration of the NgBR activator and GLP-1RA relative to untreated control.
18. A construct comprising or consisting of a therapeutic nucleic acid sequence encoding NgBR (gene alias NUS1), wherein the therapeutic nucleic acid encodes a polypeptide comprising an amino acid sequence according to SEQ ID NO: 2, or a sequence at least 90% identical thereto.
19. The construct of claim 18, wherein the therapeutic nucleic acid sequence comprises a sequence according to SEQ ID NO: 1, or a sequence at least 80% identical thereto.
20. A recombinant expression vector comprising the construct of claim 18.
21. The recombinant expression vector of claim 20, wherein the recombinant expression vector is a viral vector or a non-viral vector.
22. The recombinant expression vector of claim 21, wherein the viral vector comprises an adeno-associated virus (AAV).
23. A cell comprising the construct of any one of claims 18-19, or the recombinant expression vector of any one of claims 20-22.
24. A pharmaceutical composition comprising the construct of any one of claims 18-19 or the recombinant expression vector of any one of claims 20-22, and an acceptable carrier or excipient.
25. The pharmaceutical composition of claim 24, wherein the pharmaceutical composition further comprises glucagon-like peptide- 1 receptor agonist (GLP-1RA).
26. The pharmaceutical composition of claim 25, wherein the GLP-1RA is selected from the group consisting of exenatide, lixisenatide, liraglutide, albiglutide, dulaglutide,Docket No.: 2969825-000009-W01Date of Filing: May 08, 2026 semaglutide, orfoglipron, retatrutide, CagriSema (semaglutide with cagrilintide), tirzepatide, and mazdutide.
27. A method of treating, ameliorating, or preventing one or more symptoms associated with diabetes in a subject, comprising administering to the subject, an effective amount of the construct of any one of claims 18-19, the recombinant expression vector of any one of claims 20-22, the cell of claim 23, or the pharmaceutical composition of any one of claims 24-26.
28. The method of claim 27, further comprising administering to the subject a glucagon-like peptide-1 receptor agonist (GLP-1RA).
29. The method of claim 28, wherein the GLP-1RA is selected from the group consisting of exenatide, lixisenatide, liraglutide, albiglutide, dulaglutide, semaglutide, orfoglipron, retatrutide, CagriSema (semaglutide with cagrilintide), tirzepatide, and mazdutide.
30. The method of claim 29, wherein the GLP-1RA is semaglutide.
31. A method of treating, ameliorating, or preventing one or more symptoms associated with fatty liver disease in a subject, comprising administering to the subject, an effective amount of the construct of any one of claims 18-19, the recombinant expression vector of any one of claims 20-22, the cell of claim 23, or the pharmaceutical composition of any one of claims 24-26.
32. The method of claim 31, further comprising administering to the subject a glucagon-like peptide-1 receptor agonist (GLP-1RA).
33. The method of claim 32, wherein the GLP-1RA is selected from the group consisting of exenatide, lixisenatide, liraglutide, albiglutide, dulaglutide, semaglutide, orfoglipron, retatrutide, CagriSema (semaglutide with cagrilintide), tirzepatide, and mazdutide.
34. The method of claim 33, wherein the GLP-1RA is semaglutide.
